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The emergence of antibiotic resistance has been a serious concern for the last few 
decades. It hinders the treatment of infectious diseases, raising mortality and morbidity 
rates, as well as increasing the cost of healthcare. To investigate the problem of antibiotic 
resistant E. coli, 50 E. coli bacteraemia clinical isolates (Kent collection) were collected 
from East Kent Hospitals University NHS Foundation and phenotypically/genotypically 
characterized for antibiotic resistance, virulence factors, and the presence of putative 
plasmids. High levels of resistance were detected for amoxicillin and trimethoprim, and 
14% of the isolates showed a multidrug-resistant phenotype. ST73 isolates exhibited the 
highest virulence potential while ST131 exhibited the highest levels of antibiotic 
resistance, although no correlation was detected between the two variables. In accordance 
with previous observations, co-carriage of CTX-M-15 and aac(3)-IIa, aac(6')Ib-cr, and 
blaOXA was observed in the collection, providing a possible explanation on why ESBL-
producing isolates are often multidrug resistant. 
The production of nitric oxide (NO) by the mammalian immune system and its 
well-known anti-bacterial properties has prompted the investigation exogenously 
administered NO as an alternative to antibiotics. While combinatorial treatments of NO 
and antibiotics have proved to be successful against bacterial biofilms, this strategy has 
not been investigated in planktonic bacterial cells. Moreover, recent studies have shown 
that the generation of reactive oxygen species (ROS) resulting from hyperactivation of 
the aerobic respiratory chain of E. coli occurs in response to treatment with bactericidal 
antibiotics. This secondary effect of antibiotics is an important part of the as part of the 
lethality of bactericidal antibiotics under aerobic conditions. Given that NO is a well-
known respiratory inhibitor, it was hypothesised this would diminish the toxic effects of 
antibiotics. To test this hypothesis, the effect of NO upon the lethality of a bactericidal 
antibiotic (gentamicin) was tested on a multidrug resistant E. coli. Pre-exposure to the 
NO-donor GSNO or NOC-12 prior to gentamicin treatment was found to increase 
bacterial tolerance to the antibiotic in planktonic cells: the presence of NO elicits a 10-
fold increase in IC50 for gentamicin lethality against an E. coli clinical isolate. Further 
investigation showed that cytochrome bd-I, a NO-tolerant respiratory oxidase expressed 
maximally under microaerobic conditions in E. coli, is largely responsible for the 
sensitization of E. coli to gentamicin during NO exposure. 
The work herein reports that NO elicits a dramatic increase in the tolerance of E. 
coli to antibiotics. Hence, this work has revealed a huge void in knowledge related to 
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antibiotic potency during conditions relevant to infection (i.e. in the presence of NO). 
Furthermore, this work reveals that the cytochrome bd-I respiratory oxidase sensitises E. 
coli to antibiotics in the presence of NO.  These findings shed light on how NO 
encountered during infection could impair the function of antibiotics and will prompt 
future research into how controlling levels of respiratory inhibition during infection may 
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1.1. The Antibiotic Paradox 
 
1.1.1. A brief history of antibiotics 
Ever since the discovery of penicillin by Sir Alexander Fleming (Fleming, 1929) 
in 1928, antibiotics have undoubtedly become one of medicines greatest achievements. 
Their use drastically improved the treatment of infectious diseases, patient outcome, and 
transformed the face of medicine: invasive surgeries became common practice, immune-
compromising therapies were introduced to fight cancer, organ transplant procedures 
helped save the lives of millions of people. The combined result was the improvement in 
quality of life and increase in life expectancy. Fleming’s discovery might have 
revolutionized medicine, but antibiotics have been around for much longer. In 1980, 
tetracycline-stained human Nubian bones from a civilization that pre-dates the modern 
antibiotic era were discovered (Bassett et al., 1980); the medical properties of mould have 
been known since ancient times (Aminov, 2010), and most antibiotics are natural products 
or derived from natural products (Harvey, 2000). 
In the four decades following the discovery of penicillin, also known as the 
‘golden era of antibiotic discovery’, ten new classes of antibiotics were discovered 
(Figure 1.1), but in the 1960s the discovery of new antibiotic classes halted. Alternatively, 
the chemical modification of the natural scaffolds of existing antibiotics was successfully 
implemented during this period, but the limited number of effective iterations soon also 
placed this strategy in hiatus. Only two synthetic classes of antibiotics (fluoroquinolones 
– e.g. ciprofloxacin; and oxazolidinones - e.g. linezolid) were discovered during the 
golden era. Despite the technological advances and efforts, mainly driven by the 
pharmaceutical industry, no new synthetic drug has emerged  in the last 20 years 
(Aminov, 2010; Lewis, 2013) with similar efficacy to conventional antibiotics (Brown 
and Wright, 2016). One of the biggest obstacles of synthetic compounds is the bacterial 
membrane, as fully synthetic compounds do not have the benefit of evolution to facilitate 
membrane transit (Lewis, 2013; Brown and Wright, 2016). The difficulty of producing 
compounds with a broad spectrum of activity combined with avoiding toxic and possible 
life-threatening side effects, and the low profit margins compared to other drugs has 









1.1.2. Antibiotic Resistance 
1.1.2.1. Causes, consequences, and prevention 
 Antibiotics were a turning point in human history and have saved many lives. 
Nevertheless, public health is now compromised due to the emergence of antibiotic-
resistant bacteria. Shortly after the discovery of penicillin, strains of staphylococci 
resistant to this antibiotic were found (Barber, 1947), a trend that has now been observed 
over several decades for many other bacterial species and antibiotics (Figure 1.1), with 
some bacteria developing resistance to two or more classes of antibiotics making the 
treatment of infections very problematic, sometimes even impossible. 
 The Centre for Disease Control (CDC) has estimated that over two million people 
every year are afflicted with an antibiotic-resistant infection in the United States, with 
23,000 dying as a result (CDC, 2013). In Europe, the number of deaths per year resulting 
from antibiotic-resistant infections is 25,000 (ECDC/EMEA Joint Working Group, 2009). 
If no measures and policies are put in place in an effort to counteract this problem, these 
numbers will only get worse: a recent British study claimed that by the year 2050, 10 
million people could die every year due to infections cause by antibiotic-resistant 
microorganisms (Review on Antimicrobial Resistance, 2016). 
 To successfully tackle the problem of antibiotic resistance, it is important to 
understand the causes. Paradoxically, the main driver of antibiotic resistance is the use of 
antibiotics. Ever since their discovery, millions of tons of antibiotics have been produced, 
used, and discarded into the environment creating a selective pressure that facilitates the 
Figure 1.1 – Timeline of antibiotic discovery and appearance of resistance. The golden era of 
antibiotic discovery started in the 1930s. After four decades, antibiotic discovery decreased 
significantly, aggravating the problem posed by the emergence of antibiotic resistant bacteria. 
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survival of bacteria carrying the resistance determinant. Antibiotics are often incorrectly 
prescribed to treat viral infections, against which antibiotics are ineffective. Increases in 
human-life expectancy and the advance of medicine has led to the survival of severely ill 
patients and elderly patients, both of which are at higher risk for infection. One prime 
example are cystic fibrosis patients which are known to be at higher risk for pulmonary 
infections and thus frequently require administration of antibiotics. In fact, Pseudomonas 
aeruginosa , an opportunistic Gram-negative bacterium, is known to cause chronic 
infections in cystic fibrosis patients and is currently listed as a “Serious Threats” by the 
CDC (CDC, 2013). Antibiotics are also used in agriculture to promote the growth of 
livestock, and although this practice has been banned in the European Union, it continues 
in other countries, such as the United States, providing an excellent reservoir for 
antibiotic-resistant bacterial populations and a means to later colonize humans. It was 
estimated that antibiotic consumption in livestock increased by 30% in the last decade 
and it is projected to increase by another 37% by 2030 (Van Boeckel et al., 2015).  
 The consequences of antibiotic resistance are two-fold: increase in the cost of 
healthcare and increase in mortality. Infections caused by antibiotic-resistant bacteria, and 
especially multidrug-resistant bacteria, are difficult to treat and lead to an increase in the 
duration of hospital stay, thus increasing healthcare expenses. Moreover, the therapy may 
be unsuccessful, thus increasing the mortality rate associate with infectious diseases. The 
CDC estimated a loss of $20 billion US dollars per year in healthcare expenditures due 
to antibiotic resistant infections, with indirect costs due to loss of members of the work 
force estimated to be $35 billion US dollars (CDC, 2013). In Europe, the total cost was 
estimated to be €1.5 billion per year (ECDC/EMEA Joint Working Group, 2009). 
Additionally, antibiotic resistance has an impact on the world economy. Low-income 
countries could experience an increase of up to 25% per year in healthcare costs by 2050, 
compared to the 15% and 6% estimated for middle and high-income countries, 
respectively, increasing the economic rift between high- and low-income countries and 
sending millions of people into extreme poverty (Adeyi et al., 2017). 
 Irresponsible  use of antibiotics combined with the adaptability of bacteria has led 
to the emergence and alarming dissemination of antibiotic resistance, and has  left us on 
the brink of a post-antibiotic era (World Health Organization (WHO), 2014). Thus, it is 
of the utmost importance to combat antibiotic resistance. Local, national and global 
surveillance systems need to be put in place to monitor antibiotic resistance and facilitate 
the choice of treatment and implementation of policies to help control resistance. 
Moreover, in the face of decrease in antibiotic efficacy, it is imperative to use them wisely 
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and decrease their usage in general. This could be accomplished by decreasing the usage 
of antibiotics in agriculture, development of fast and reliable tests to identify the causative 
agent and its resistance pattern which would allow for a more targeted treatment, and 
public awareness and education on the dangers of antibiotic misuse and overuse (Aminov, 
2010; Davies and Davies, 2010; Michael et al., 2014). More importantly, there is a dire 
need for the development of new safe and efficient drugs and alternative therapies, a 
problem that will require more private and public investment in research (Alanis, 2005). 
  
1.1.2.2. Mechanisms of Antibiotic Resistance 
 Antibiotic resistance is a natural phenomenon. In fact, even before the widespread 
use of penicillin, observations made by Abraham and Chain suggested that bacteria could 
destroy penicillin (Abraham and Chain, 1940). Over the years, the continued selective 
pressure led to the emergence of bacteria exhibiting different resistance mechanisms than 
that initially identified for penicillin but, overall, resistance mechanisms can be divided 
into three categories: 1) Inactivation or modification of the antibiotic molecule; 2) 
Mutation or substitution of the target; and 3) Decreased uptake or efflux of antibiotic 
(Table 1.1).  
The best-known example of antibiotic inactivation are beta-lactamases. This 
group of enzymes is very diverse, varying in physical/chemical properties and spectrum 
of activity (Bush et al., 1995). They are responsible for the inactivation of beta-lactam 
antibiotic classes, which includes penicillins, cephalosporins, monobactams, and 
carbapenems. Bacteria expressing these enzymes export it into the periplasmic space 
where the antibiotic is inactivated through the hydrolysis of the beta-lactam ring. 
Presently, one of the biggest concerns is the emergence of extended-spectrum beta-
lactamases (ESBLs). Initially detected in Klebsiella pneumoniae (K. pneumoniae) 
(Bradford, 2001), these enzymes have since spread to other members of the 
Enterobacteriaceae family, such as Escherichia coli (E. coli), and are currently widely 
disseminated and responsible for many ‘difficult-to-treat’ infections  (Lau et al., 2008; 
Croxall et al., 2011). Alternatively, antibiotic modifications can be achieved by addition 
of an adenylyl, phosphoryl, or acetyl groups to the molecule through the action of 
nucleotidyltransferases, phosphotransferases, and acetyltransferases, respectively 
(Alekshun and Levy, 2007). Many aminoglycosides, such as streptomycin and 
gentamicin, are inactivated through this mechanism. Another example is 
chloramphenicol, which is inactivated by the action of a chloramphenicol 
acetyltransferase that is usually encoded by the cat gene. 
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 Owing to the specificity of the antibiotic:target interaction, subtle structural 
changes in the cellular target can prevent said interaction while still allowing the target to 
maintain normal function. For example, high-level resistance to fluoroquinolones in E. 
coli is mainly attributed to mutations in genes encoding subunit A of DNA gyrase (gyrA) 
(McDermott et al., 2003; Alekshun and Levy, 2007). Structural alterations in bacterial 
lipopolysaccharide (LPS) have also enabled K. pneumoniae to evade the action of 
polymyxins: mutations in mgrB result in increased synthesis of sugar 4-amino-4-deoxy-
L-arabinose (L-ara4N), and its insertion in the lipid A moiety of LPS results in an altered 
target (Cannatelli et al., 2013; Cannatelli et al., 2014; Poirel et al., 2015). Bacteria can 
also evade antibiotic toxicity through expression of alternative forms of the targeted 
enzyme. The prototypical example is a penicillin-binding–protein (PBP) variant in 
methicillin-resistant Staphylococcus aureus (MRSA). This variant is encoded by mecA 
and exhibits low affinity for derivatives of penicillin, and cell wall biosynthesis therefore 
remains unaffected by exposure to these beta-lactam antibiotics (Alekshun and Levy, 
2007). 
With the exception of polymyxins, all antibiotics currently available target 
intracellular bacterial proteins. As such, efficacy is dependent on whether the antibiotic 
reaches the target in sufficient quantity. Bacteria can prevent intracellular accumulation 
of the antibiotic by changing membrane permeability or through the export of the 
antibiotic by efflux pumps. The latter can be specific to an antibiotic or antibiotic class, 
or can be promiscuous and capable of exporting a wide array of antibiotics resulting in a 
multidrug-resistant phenotype (McDermott et al., 200γ; Džidić et al., 2008). 
Interestingly, recent studies have shown a synergy between efflux pumps and mutations 
in intracellular drug targets (Fange et al., 2009; Lovmar et al., 2009). Lovmar and 
colleagues (Lovmar et al., 2009) showed that mutations in the L22 protein of the 50S 
subunit of the E. coli ribosome, conferring erythromycin resistance, was only effective in 
a drug efflux pump proficient E. coli strain, whilst in an E. coli strain unable to effectively 
export antibiotic, susceptibility to erythromycin was similar to that observed in the E. coli 
strain without the ribosomal mutation, i.e. sensitive to erythromycin. This shows that drug 
efflux deficiency can “mask” antibiotic resistance arising from drug target mutations. 
Furthermore, it also shows that inhibition of efflux pumps of pathogenic bacteria with 
altered cytoplasmic drug targets, arising due to mutation, could provide an alternative 




Table 1.1 – Targets and common resistance mechanism for different antibiotic 
classes. 
 
Antibiotic class Target Resistance mechanism 
Aminoglycosides (Streptomycin, 
Gentamycin) 




Cell wall synthesis Hydrolysis; Target 
modification/substitution 
Phenicols (Chloramphenicol) Protein synthesis Antibiotic modification 
Fluoroquinolones 
(Ciprofloxacin) 
DNA Replication Target modification 
Glycopeptides (Vancomycin) Cell wall synthesis Target 
modification/substitution 
Polypeptides (Polymyxins) Cell membrane Target 
modification/substitution; 
Efflux 
Pyrimidines (Trimethroprim) Folic acid metabolism Target 
modification/substitution; 
Efflux 
Rifamycins (Rifampin) Transcription Target 
modification/substitution; 
Efflux 
Sulphonamides Folic acid metabolism Target 
modification/substitution; 
Efflux 




1.1.2.3. Genetics of Antibiotic Resistance 
Resistance to antibiotics can be intrinsic (natural) or acquired. In intrinsic 
resistance, the bacterium exhibits the innate ability to resist the activity of specific 
antibiotics mediated by, for example, the bacterial outer membrane or by efflux pumps 
(Henriques Normark and Normark, 2002). However, studies have shown that there are 
many other naturally-occurring genes in different bacterial species that also contribute to 
an antibiotic-resistant phenotype. One such example is the chromosomal-encoded AmpC 
beta-lactamase of E. coli, which confers resistance to many beta-lactam antibiotics 
(Alekshun and Levy, 2007). Interestingly, work by Adam et al. (2008) suggests that 
epigenetic effects occurring during exposure to low concentrations of ampicillin are 
responsible for further activation AmpC expression, usually poorly expressed in E. coli 
and thus unable provide substantial protection to ampicillin, thus resulting in a more 
potent antibiotic resistance. This study by Adam and colleagues further shows the 
complexity of antibiotic resistance.  
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Acquired resistance arises through mutations in chromosomal genes, or horizontal 
gene transfer (HGT), via transduction (transfer of genetic material using a bacteriophage 
as a vector), conjugation (direct transfer between bacterial cells through the pilus 
produced by the donor cell), or transformation (direct uptake of exogenous DNA) 
(McDermott et al., β00γ; Alekshun and Levy, β007; Džidić et al., 2008), During HGT 
resistance genes are carried on mobile genetic elements (plasmids, transposons, and 
integrons) and acquired by the host bacterium from other bacterial species. Plasmid-
mediated transmission of resistance genes is, by far, the most common form of HGT and 
main contributor to antibiotic resistance among clinical isolates (Davies and Davies, 
2010). Plasmids are extra-chromosomal DNA segments that replicate independently of 
the hosts chromosome, can be transferred to other bacteria and often carry genes that 
provide the host with a selective advantage, such as resistance to an antibiotic 
(McDermott et al., 2003) Moreover, plasmids can also provide a vehicle for other mobile 
genetic elements, such as transposons and integrons. Transposons are mobile genetic 
elements which can be incorporated into a plasmid or the hosts chromosome via the action 
of the site-specific transposases encoded within the transposon (Henriques Normark and 
Normark, 2002; McDermott et al., 2003; Alekshun and Levy, 2007). Integrons represent 
an interesting situation and provide a unique, albeit problematic, role to the antibiotic 
resistance problem. Integrons are DNA elements that promote the capture of one or more 
resistance genes to form a cluster that is under the control of a single strong promoter. 
Hence, due to this co-expression, exerting a selective pressure with one antibiotic will 
also select the remaining adjacent genes, resulting in a multidrug resistant phenotype 
(Henriques Normark and Normark, 2002; McDermott et al., β00γ; Džidić et al., 2008; 
Davies and Davies, 2010). Taken together, the existence of different mobile genetic 
elements and modes of transmission, combined with the increasing selective pressure 
caused by the growing use of antibiotics, resulted in the perfect set of conditions that gave 
rise to the alarming emergence and dissemination of antibiotic resistance currently 
observed. 
It is important to note that acquisition and expression of resistance determinants 
genetically encoded is not the only method of antibiotic resistance. Bacteria can also 
develop a tolerant phenotype, i.e. alter their physiology and metabolism in response to 
environmental conditions which result in an antibiotic resistant phenotype (adaptive 
resistance). Persister cells are a prime example of this. Persister cells are a phenotypic 
variant that forms within a bacterial population (Lechner et al., 2012; Lewis, 2013). 
Whilst the mechanism by which they form is still not well understood, their metabolically 
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inactive phenotype allows for persister cells to survive treatment with antibiotics (e.g. 
Fluoroquinolones target DNA synthesis and, thus, are only effective against actively 
dividing cells) (Lewis, 2013). Another mechanism of adaptive resistance is epigenetic 
inheritance (Adam et al., 2008): DNA methylation, resulting in different gene expression 
patterns, and methylation of bacterial ribosomal RNA (rRNA) have both been shown to 
lead to the development of drug resistance (Motta et al., 2015; Manderwad, 2017). 
 
1.2. Nitric Oxide 
 
1.2.1. Physical and chemical properties of nitric oxide 
Nitric oxide (NO), discovered by Joseph Priestly in 1772, is in gaseous form under 
atmospheric conditions and for a long time it was thought that it was merely a product of 
pollution. It wasn’t until the 1980s that the role of NO in biological systems started to 
unravel.  
In mammals, NO is synthesized by nitric oxide synthase (NOS), which converts 
the amino acid L-arginine into NO and citrulline, and is involved in critical roles, such as  
vasoregulation, smooth muscle relaxation, platelet aggregation, and neurotransmission 
(Snyder and Bredt, 1992; Vallance, 2003). 
The reactivity of NO is highly dependent on its physical and chemical properties. 
NO is a small diatomic molecule of lipophilic nature and high diffusivity (Hughes, 2008). 
However, its unpaired electron is the most significant property of NO conferring it its 
radical natural and determining its high reactivity (Hughes, 2008; Lancaster Jr, 2015) and, 
consequently, its short half-life (5-15 seconds) (Kröncke et al., 1997; Lancaster Jr, 1997; 
Hughes, 2008). Due to the presence of the unpaired electron NO displays high chemical 
reactivity towards other free radicals, such as superoxide, giving rise to higher reactive 
species with different biological consequences (Mateo and de Artiñano, 2000; Hughes, 
2008). NO can also react with transition metals, such as iron, copper, and zinc, an 
interaction which results in the formation of a metal-nitrosyl complex which may lead to 
changes in the function of the targeted protein. A prime example is the interaction with 
soluble guanylyl cyclase (sGC), a well-known intracellular receptor of NO in mammals. 
The binding of NO to the haem prosthetic group of sGC results in an increase of cGMP 
levels, which in turn regulates downstream processes involved in smooth muscle 
relaxation, vasodilatation, and neurotransmission (Nisbett and Boon, 2016). NO can also 
react with thiol groups of molecules, forming S-nitrosothiols, compounds which can 
either be an inert form of NO storage but also a S-nitrosating agent, thus capable of 
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altering or inhibiting the function of other target proteins (MacMicking et al., 1997; 
Schindler and Bogdan, 2001).  
Whilst its reactivity, high rate of diffusion, and lipophilic nature provide NO with 
the necessary properties to carry out its important role as a messenger molecule, it is 
important to note that in high concentrations NO is highly toxic. Indeed, NO has been 
implicated in many pathophysiological states including septic shock, hypertension, and 
neurodegenerative diseases (Vallance, 2003; Pacher et al., 2007). As such, its synthesis 
must be tightly regulated to prevent cytotoxicity. However, high levels of NO are known 
to be produced by iNOS, the inducible NOS expressed by cells of the mammalian immune 
system (macrophages and neutrophils) (Schairer et al., 2012; Nisbett and Boon, 2016), in 
response to infection (see section 1.2.2.). 
 
1.2.2. Nitric oxide and immunity 
An important feature of NO, and of particular interest in this antibiotic resistance 
era, is its antimicrobial activity. Immune cells such as macrophages and neutrophils 
express the inducible form of NOS (iNOS) upon activation with proinflammatory 
cytokines (Figure 1.2), which in turn produces NO from L-arginine. The highly reactive 
nature of NO makes the biochemistry and antimicrobial activity of NO very complex. On 
its own, NO can strongly bind to the iron of haem groups and iron-sulphur ([Fe-S]) 
clusters, both important cofactors in a plethora of bacterial proteins (Wink et al., 2011). 
The destruction of [Fe-S] clusters by NO prompts the release of  ferrous iron (Fe2+), which 
in combination with hydrogen peroxide (H2O2) leads to formation of the highly toxic 
hydroxyl radical (Kröncke et al., 1997).  However, it is the ability to react with other free 
radicals and create other nitrogen oxides that makes NO so toxic. Peroxynitrite (ONOO-
) is a reactive nitrogen species (RNS) formed through the fast reaction of NO with 
superoxide (O2-). It rapidly reacts with lipids and proteins, limiting its ability to diffuse 
into target cells but nonetheless has a much greater cytotoxicity than NO and superoxide 
alone. Peroxynitrite can also lead to the formation of other toxic RNS, including 
dinitrogen trioxide (N2O3) and nitrogen dioxide (NO2) (Bogdan, 2001; Pacher et al., 
2007). Additionally, peroxynitrite is more effective at producing highly-toxic hydroxyl 
radicals than the Fenton reaction, which forms hydroxyl radicals through the reaction of 
hydrogen peroxide (H2O2) with  ferrous iron (Fe2+) (Pacher et al., 2007). NO can also 
react with glutathione (GSH) to form S-nitrosoglutathione (GSNO), a S-nitrosating agent 
involved in signalling and NO storage in mammalian cells, but also toxic to bacteria due 
to its ability to nitrosylate cysteines. Hence, NO is capable of directly and indirectly 
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damaging or inhibiting important cellular functions, such as damaging DNA, inhibiting 
protein synthesis, inhibiting protein function through S-nitrosylation or disruption of [Fe-
S] clusters and haem groups, and disruption of cellular membrane through lipid 
peroxidation. Although the toxic effects of NO contribute to the host defence against 
invading pathogens, they are also toxic to mammalian cells in high concentrations. 
Protection from the toxic effects of NO and related RNS in mammalian cells occurs 
through formation of inert NO-storage/transport compounds, which also allow for a more 
efficient and far-reaching NO signalling, since the reactivity of NO towards a plethora of 
cellular components and radicals limits its diffusion (Kröncke et al., 1997; MacMicking 
et al., 1997; Mateo and de Artiñano, 2000; Villanueva and Giulivi, 2011), and through 
compartmentalization (e.g. acidic compartments such as lysosomes), which restricts the 
toxic effects of NO and its RNS derivatives to a small sub-cellular location (Villanueva 





Figure 1.2 – Chemistry of nitric oxide. In the mammalian immune system, NO is produced by 
iNOS and rapidly reacts with superoxide (O2-) to form peroxynitrite. (ONOO-), a highly toxic 
RNS capable of forming other RNS through reaction with carbon dioxide (CO2) and hydroxyl 
radicals (.OH). NO also reacts with glutathione (GSH) to form S-nitrosoglutathione (GSNO), a 
S-nitrosating agent. All these species combined can lead to DNA damage, protein damage and 
peroxidation of membrane lipids, and are an effective means of combating bacterial infections. 
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It is important to note that the role of NO in immunity extends beyond its 
antimicrobial properties: NO synthesized by iNOS also exerts a regulatory function, most 
notably a role in the maturation and regulation of the activity of Natural Killer (NK) cells 
(Coleman, 2001; Wink et al., 2011), required for a robust immune response. 
 
1.2.3. Nitrosative stress in E. coli 
 Bacteria encounter NO in a wide range of environments: during infection, 
neutrophils and activated macrophages are a source of NO which is used to combat 
invading pathogens; NO can also be produced at low concentrations as a by-product of 
bacterial anaerobic respiration (Bender and Conrad, 1994) or by bacterial homologues of 
the mammalian NOS (Crane, 2008; Sudhamsu and Crane, 2009; Crane et al., 2010). 
 
Figure 1.3 – NO resistance mechanisms of E. coli. A) Periplasmic cytochrome c nitrite 
reductase (NrfA, the catalytic subunit of the Nrf complex) reduces nitrite to ammonium, releasing 
NO in the process, which in turn can be also converted to ammonium by NrfA; B) Cytochrome 
bd-I is a NO-tolerant respiratory oxidase that facilitates aerobic respiration; C) Flavohaemoglobin 
Hmp converts NO to nitrate or to nitrous oxide in the presence or absence of oxygen respectively; 
D) The hybrid cluster protein, Hcp, and its partner reductase, Hcr, convert NO to nitrous oxide 
under anoxic conditions; E) Flavorubredoxin, NorV, and its partner reductase, Flavorubredoxin 
reductase NorW, converts NO to nitrous oxide under anaerobic conditions; F) YtfE, a di-iron 
protein, repairs iron-sulphur clusters damaged by nitrosative stress. 
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Like many other bacteria, E. coli has a remarkable capacity to respond to 
environmental stresses through a series of well-coordinated mechanisms. Thus, the 
existence of mechanisms in E. coli that helps to circumvent the toxic effects of NO and 
its derivatives is unsurprising (Figure 1.3). Studies have shown that bacterial NO 
detoxification increases in response to NO or NO-releasing molecules such as GSNO 
(Hausladen et al., 1998; Flatley et al., 2005; Jarboe et al., 2008). E. coli possesses various 
NO-detoxifying enzymes, including the periplasmic cytochrome c nitrite reductase 
(NrfA), the cytoplasmic flavohaemoglobin (Hmp), flavorubredoxin (NorV), and hybrid-
cluster protein (Hcp). Alongside them there are mechanisms that repair the damage 
caused by NO, such as via the action of YtfE which repairs [Fe-S] clusters. Furthermore, 
the NO-tolerannt cytochrome bd-I respiratory oxidase facilitates aerobic respiration in the 
presence of NO. These mechanisms are discussed in more detail below. 
 
1.2.3.1. Flavohaemoglobin Hmp 
 Flavohaemoglobins are widely distributed microbial proteins comprising two 
domains: a N-terminal globin-like domain containing haem b, and a C-terminal 
ferredoxin-NADP+ reductase (FNR)-like domain with binding sites for FAD and 
NAD(P)H. As the best studied microbial flavohaemoglobin, the role of E. coli Hmp 
during nitrosative stress has been intensely studied. Encoded by the hmp gene in E. coli, 
microarray studies have shown that Hmp expression is up-regulated after cells are 
exposed to NO (Justino et al., 2005), GSNO (Mukhopadhyay et al., 2004; Flatley et al., 
2005), and NO-releasing compounds (NOC) (Pullan et al., 2007), both aerobically and 
anaerobically. In the presence of oxygen this cytoplasmic protein catalyses a NO 
dioxygenation reaction by binding O2 at the ferrous haem giving rise to a ferrous (Fe2+) 
haem:superoxide intermediate that rapidly reacts with NO and produces nitrate. The FAD 
cofactor at the C-terminal catalyses the reduction of the now ferric (Fe3+) haem to its 
original ferrous form through a sequential electron transfer from NADH to the bound 
haem in the globin-like domain (Figure 1.4). A hmp mutant was shown to be unable to 
catalyse NO consumption (Hausladen et al., 1998) and exhibited a more pronounced 
growth inhibition compared to wild-type cells when in presence NO or S-nitrosothiols 
(Gardner et al., 1998; Hausladen et al., 1998). NO consumption by Hmp was inhibited 
by cyanide, indicating that the NO reaction occurs at the oxyhaem, and possibly arises 
due to interference of cyanide in the reduction of ferric haem to ferrous haem (Hausladen 
et al., 1998). Additionally, Hmp was found to have higher affinity for NADH rather than 
NADPH, with Km for NADPH being 10-fold higher than that of NADH (Anjum et al., 
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1998). In addition, Wu et al. (2004) and Membrillo-Hernández et al. (1996) demonstrated 
formation of superoxide by Hmp during aerobic NO turnover in vitro and in vivo, the 
latter accomplished by monitoring the transcription of sodA (superoxide dismutase), 
which is up-regulated in the presence of superoxide. Under anoxic conditions, Hmp 
catalyses the NADH-dependent reduction of NO to nitrous oxide (N2O) with formation 
of a nitrosyl intermediate complex (Hausladen et al., 1998; Kim et al., 1999). Taken 




NO inhibits the function of many bacterial proteins by binding to their cofactors, 
such as haem and [Fe-S] clusters. This includes the haem-binding respiratory oxidase 
complexes involved in  aerobic respiration, which have been shown to be inhibited in E. 
coli by NO in an O2-dependent manner, i.e. respiratory inhibition is more profound at 
lower oxygen
 
tensions (Yu et al., 1997). Hmp is able to protect aerobic respiration 
catalysed by cytochrome bo’  or cytochrome bd from NO-mediated inhibition (Stevanin 
et al., 2000). Respiration rates in cells lacking either cytochrome bd or cytochrome bo’ 
was measured following the addition of NO gas and it was shown that inhibition of 
respiration catalysed by either cytochrome was more profound in a hmp mutant, thus 
establishing the importance of a functional Hmp in alleviating NO-mediated respiratory 
inhibition (Stevanin et al., 2000). Hmp has also been shown to protect the activity of 
aconitase, an important enzyme of the citric acid cycle with a [4Fe-4S]  cofactor, from 
NO-mediated inhibition  (Gardner and Gardner, 2002). 
Figure 1.4 – NO detoxification by Hmp. Electrons are transferred from NADH to FAD and then 
to the haem group where under aerobic conditions (left) O2 is reduced to form superoxide, which 
in turn reacts with NO (oxygenation reaction) yielding nitrate. Under anaerobic conditions (right), 
ferrous heam reacts with NO giving rise to a nitrosyl species. Further reaction yields nitrous oxide 
as the final product. 
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The protection against NO that is conferred by Hmp make it a valuable virulence 
factor during infection. In Salmonella , the virulence of different mutant strains was 
investigated in a mouse infection model, which showed that compared to the parental 
strain, the hmp mutant exhibited an almost complete loss of virulence, which was restored 
after addition of an iNOS inhibitor, hence suggesting that loss of virulence was due to 
inability of mutant to cope with RNS produced by the host during infection (Bang et al., 
2006). In E. coli, survival of a hmp mutant is significantly reduced in both murine 
macrophages and human neutrophils (Shepherd et al., 2016). In addition to NO tolerance, 
the generation of reactive ROS by Hmp (Membrillo-Hernández et al., 1996; Mills et al., 
2001; Wu et al., 2004) leads to intracellular oxidative stress and, as such, some systems 
involved in the response to oxidative stress are activated (Membrillo-Hernandez et al., 
1999). This shows that not only is the presence of a functional Hmp important during 
infection for protection of bacterial cells against host-derived RNS, but it is also important 
for the expression of other important virulence factors and induction of a more robust 
SOS response. 
 Overexpression of Hmp has been shown to exacerbate oxidative stress in both 
Salmonella (Bang et al., 2006; McLean et al., 2010) and E. coli (Membrillo-Hernández 
et al., 1996; Mills et al., 2001; Wu et al., 2004). Thus, Hmp expression needs to be tightly 
regulated to prevent intracellular oxidative stress (Figure 1.5). Fumarate nitrate reduction 
(FNR) regulator is a member of the cyclic-AMP receptor family of transcriptional 
regulators and a repressor of Hmp expression (Poole et al., 1996). The [4Fe-4S] cluster 
of FNR is sensitive to both O2 and NO, with both inhibiting DNA-binding activity of FNR 
and allowing de-repression of genes involved in anaerobic metabolism and respiration, 
including hmp (Green et al., 2014). FNR is able to detect NO levels as low as 5 µM, 
making it a relevant NO-sensor in vivo (Cruz-Ramos et al., 2002). MetR is a 
transcriptional regulator involved in the control of genes encoding proteins that 
participate in methionine biosynthesis, and has also been implicated in the induction of 
the hmp gene by GSNO and sodium nitroprusside (SNP) (Membrillo-Hernández et al., 
1998). Interestingly, microarray studies by Pullan et al. (2007) using NOC compounds to 
induce nitrosative stress revealed no upregulation of the met genes, which was attributed 
to GSNO and NOC compounds behaving differently with respect to homocycteine (Hcy), 
the cofactor of MetR: GSNO reacts with Hcy forming S-nitroso-Hcy and depleting the 
Hcy intracellular pool; in the absence of Hcy, MetR binds to the promoter of hmp and 
activates transcription (Membrillo-Hernández et al., 1998; Pullan et al., 2007). However, 





NsrR (Nitrite-sensitive repressor) is a NO-sensor with a [2Fe-2S] cluster that is 
nitrosylated by NO, which results in the formation of a cysteine-bound dinitrosyl iron 
complex that abolishes the DNA-binding activity of NsrR, resulting in de-repression of 
hmp transcription (Figure 1.5) (Filenko et al., 2007; Tucker et al., 2008). 
 
1.2.3.2. Flavorubredoxin NorV and partner reductase NorW 
Flavorubredoxin (FIRd) is encoded by the norV gene in E. coli and the NorV 
protein possesses three distinct domains: a N-terminal metallo-beta-lactamase domain 
containing a non-haem di-iron centre, a flavodoxin-like domain containing one FMN 
element, and a C-terminal rubredoxin (Rd)-like domain (Gomes et al., 2000; Gomes et 
al., 2002; Vicente et al., 2007). FIRd is associated with FIRd-reductase, a member of the 
NAD(P)H:rubredoxin oxireductase family of proteins encoded by the norW gene in E. 
coli. FIRd-reductase catalyses the transport of electrons from NADH to the Rd domain 
of FIRd, which then proceed to the FMN moiety followed by transfer to the di-iron site 
where they become available to efficiently reduce NO to nitrous oxide (Gomes et al., 
2000; Gomes et al., 2002; Vicente et al., 2007) (Figure 1.6). 
Figure 1.5 – Regulation of Hmp expression. FNR and NsrR are both negative regulators of hmp 
transcription. NO interacts with the [Fe-S] clusters of these transcriptional factors and prevents 
DNA-binding, leading to de-repression of hmp. MetR-dependent transcriptional activation of hmp 
was shown to occur only in the presence of nitrosating compounds, such as GSNO, which depletes 





Total RNA transcriptomics showed an increase in mRNA levels for norV and 
norW in response to GSNO (Mukhopadhyay et al., 2004; Flatley et al., 2005), NO 
(Justino et al., 2005), and NOC compounds (Pullan et al., 2007), in both aerobic and 
anaerobic conditions.  Interestingly, studies using norV-lacZ and norW-lacZ fusions have 
shown that induction of norV and norW was significantly inhibited in fully aerated 
conditions (200- and 20-fold less for norV and norW, respectively, compared to anoxic 
conditions), and other studies have also revealed NorVW has higher NO-metabolizing 
activity under anaerobic conditions (Gardner et al., 2002). Combined with the observation 
by Gardner and Gardner (2002) that NO consumption in cells expressing high levels of 
Hmp is higher in the presence of oxygen, and only in the presence of oxygen was Hmp 
capable of protecting aconitase activity from NO-dependent inactivation, it was 
hypothesized that under anaerobic conditions NorVW plays a more predominant role in 
NO detoxification than Hmp. Conversely, Hmp was proposed to be more important in the 
presence of oxygen. This hypothesis was supported by studies that monitored Hmp and 
NorVW protein levels following exposure to NO in an anoxic environment: expression 
of NorV occurred immediately after NO-exposure and remained constant throughout the 
experiment, while Hmp expression reached maximal expression much later (Justino et 
al., 2005). Interestingly, deletion of both norV and hmp results in a severe impairment of 
growth in the presence of nitrosative stress under anoxic conditions, more so than in hmp 
or norV single mutants suggesting that despite the predominant role of NorVW in NO-
detoxification in anaerobic conditions, Hmp still plays an important, albeit minor, role 
(Justino et al., 2005). 
Figure 1.6 – NO reduction by NorVW. FIRd-reductase catalyses the electron transfer from 
NADH to FIRd, which in turn reduce NO to nitrous oxide. Sourced from Vicente et al. (2007). 
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The NO-sensing transcription factor NorR, encoded by the norR gene in E. coli 
that is divergently transcribed from norVW, is responsible for NO-mediated regulation of 
the norVW operon (Figure 1.7). NorR has three domains: a N-terminal GAF domain 
containing a mononuclear non-haem iron which reversibly binds NO and is responsible 
for signal sensing (Gardner et al., β00γ; D’Autréaux et al., 2005); a central AAA domain 
with ATPase activity; and a C-terminal DNA-binding domain (D’Autréaux et al., 2005; 
Spiro, 2007). Binding of NO stimulates the ATPase activity of the central AAA domain 
and initiates transcription of the norVW operon (D’Autréaux et al., 2005; Spiro, 2007). 
 
 
1.2.3.3. Hybrid-cluster protein system: Hcp-Hcr 
The hybrid cluster protein (Hcp), encoded by hcp in E. coli, is a cytoplasmic 
protein of approximately 60 kDa with unique [Fe-S] cluster properties: it contains one 
conventional [2Fe-2S] cluster and a hybrid [4Fe-2S-2O] cluster (van den Berg et al., 
2000; Aragão et al., 2008). Downstream the hcp gene, the gene hcr encodes a NAD(P)H 
oxidoreductase of approximately 34.6 kDa that binds a FAD cofactor and a [2Fe-2S] 
cluster (van den Berg et al., 2000). Hcr catalyses the reduction of Hcp in vitro in the 
presence of the electron donor NADH, to which Hcr demonstrates relatively high affinity 
(Km=10 µM for NADH while Km for NADPH is approximately 0.3 mM). Electrons are 
transferred from NADH to the hybrid [4Fe-2S-2O] cluster of Hcp via the [2Fe-2S] 
clusters of Hcr and Hcp, which are used in the subsequent reduction of NO to nitrous 
oxide (van den Berg et al., 2000). 
Induction of Hcp-Hcr was shown to occur in both aerobic and anaerobic cultures 
exposed to either GSNO (Flatley et al., 2005) or NOC compounds (Pullan et al., 2007), 
however the rate of NO reduction by Hcp in cells grown aerobically was low, suggesting 
oxygen inactivates Hcp activity in vivo (Wang et al., 2016). In anoxic conditions, deletion 
Figure 1.7 – NorRVW transcriptional unit. In the presence of NO, NorR is activated and 
initiates transcription of the norVW operon. Activated NorR is capable of self-regulation. 
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of hcp resulted in a NO-mediated growth impairment and loss of activity of aconitase and 
fumarase, two enzymes involved in central carbon metabolism that are dependent on 
functional [Fe-S] clusters (Wang et al., 2016). Despite the role in NO detoxification, Hcp 
inactivation is triggered by NO concentrations above 200 nM. Thus, it was suggested that 
Hcp-Hcr provides protection against nitrosative stress under anaerobic conditions only 
when NO concentrations are low and unable to cause substrate-mediated inactivation of 
Hcp (Karlinsey et al., 2012; Wang et al., 2016).  
The hcp-hcr genes are regulated by FNR and NsrR. In an E. coli fnr  mutant, 
exposure to NO-donor spermine NONOate is unable to induce transcription of hcp to 
wild-type levels, suggesting that FNR is responsible for the activation of hcp-hcr operon 
transcription under anaerobic conditions (Filenko et al., 2007; Wang et al., 2016). 
Furthermore, gel-shift assays showed binding of FNR to hcp promoter in vitro, further 
supporting the role of FNR in transcriptional regulation of hcp-hcr regulon (Filenko et 
al., 2007). In Salmonella , the putative consensus binding site of NsrR is present in the 
predicted promoter region of hcp-hcr operon, and microarray and qRT-PCR data showed 
it was a part of the NsrR regulon in this Gram-negative bacterium (Karlinsey et al., 2012). 
Moreover, a Salmonella nsrR mutant displayed a 678.1-fold induction of the hcp-hcr  
operon compared to wild-type (Karlinsey et al., 2012), with similar results obtained for a 
E. coli nsrR mutant (Filenko et al., 2007). In an assay involving a multi-copy plasmid 
containing the promoter of a known NsrR target, thus relieving NsrR-mediated repression 
of the target genes through titration of NsrR, a strong induction of hcp-hcr was observed  




Figure 1.8 – Transcriptional regulation of the hcp-hcr operon. In the presence of NO, NsrR-
mediated repression is lifted; FNR acts as a transcriptional activator under anaerobic conditions. 
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1.2.3.4. Detoxification of NO by NrfA 
The periplasmic cytochrome c nitrite reductase of E. coli, NrfA, is a homodimeric 
protein containing five c-type haems per monomer. Expressed under microaerobic and 
anaerobic conditions in the presence of nitrate or nitrite (Wang and Gunsalus, 2000), NrfA 
catalyses the reduction of nitrite to ammonium (Darwin et al., 1993) via a NO 
intermediate (Figure 1.3). NO consumption by NrfA was observed by Poock et al. (2002) 
using an E. coli strain with a nirA- background to better assess the contribution of NrfA 
towards NO consumption. NirA is a cytoplasmic nitrite reductase expressed under 
microaerobic or anoxic conditions, and thus could mask the effect of NrfA on NO 
metabolism. Under aerobic conditions, the nirA- nrfA+  strain reduced NO at a maximal 
rate 300 nmol of NO (mg of protein-1 min-1), whilst NO consumption was abolished in a 
nirA- nrfA- strain under aerobic condition, consistent with the absence of  NrfA expression 
in these conditions (Poock et al., 2002). Furthermore, anaerobic growth of nrfA- strains 
has been shown to be more sensitive to NO than the parental strain, further suggesting a 
role for NrfA in NO tolerance (Poock et al., 2002; Pittman et al., 2007; van Wonderen et 
al., 2008). The periplasmic location of NrfA is well-suited for NO detoxification in vivo, 
metabolizing NO before it enters the cell. Interestingly, NrfA has also been implicated in 
NO production as a consequence of its anaerobic nitrite reductase activity (Corker and 
Poole, 2003). Nevertheless, the low NO levels produced by NrfA during anaerobic 
respiration of nitrite can be easily dealt with by Hmp and NorVW, preventing inactivation 
of FNR, an important transcriptional regulator of various important genes, including NrfA 
(Corker and Poole, 2003). 
The gene encoding NrfA is positively regulated by FNR (Spiro, 2006). However, 
due to sensitivity of its [Fe-S] cluster, FNR is prone to NO-mediated inactivation resulting 
in NrfA down-regulation (Pullan et al., 2007), a result that is not consistent with its 
proposed protective role during nitrosative stress. A possible explanation for this 
phenomenon arose from studying the role of NrfA in Salmonella . Mills et al. (2008) 
showed that under NrfA-inducing conditions (i.e. anaerobic growth in minimal medium 
with glycerol as a carbon source and nitrate and fumarate as respiratory electron 
acceptors), NrfA is unable to protect Salmonella from NO in the absence of NorV and 
Hmp, suggesting that NrfA is not a vital component of the immediate response to NO 
under these conditions. Hence, whereas the NO-reductase activity of NrfA provides an 
advantage under conditions in which NrfA is already being expressed, its absence due to 
inactivation of FNR by NO does not affect cellular viability in response to nitrosative 
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stress. A microarray study has shown that nrfA transcription increases 2.2-fold in a nsrR 
mutant, suggesting that nrfA is a member of the NsrR regulon (Filenko et al., 2007).  
  
1.2.3.5. Iron-sulphur cluster repair: YtfE 
[Fe-S] clusters are prosthetic groups that are present in a variety of important 
bacterial proteins. Since NO is well-known to nitrosylate [Fe-S] clusters, it is unsurprising 
that bacteria possess systems capable of repairing the damage inflicted to these cofactors 
during nitrosative stress. In E. coli, YtfE is a member of the Repair of Iron Centres (RIC) 
family of proteins with a di-iron centre and aids in the tolerance of E. coli to nitrosative 
stress by repairing [Fe-S] clusters (Justino et al., 2006; Justino et al., 2007). Several 
microarray studies of total RNA have shown an increase in ytfE transcription in response 
to NO (Justino et al., 2005), GSNO (Mukhopadhyay et al., 2004; Flatley et al., 2005), 
and NOC compounds (Pullan et al., 2007), suggesting a protective role for YtfE during 
nitrosative stress. This hypothesis was further corroborated by Justino et al. (2005) when 
a ytfE E. coli mutant showed higher sensitivity than parental strain to 50 µM NO. 
Furthermore, activity of the [Fe-S] cluster containing enzymes aconitase and fumarase 
was diminished following exposure to NO in cells lacking ytfE (Justino et al., 2007). 
Importantly, activity of aconitase and fumarase was restored in the parental strain after a 
period of time, but cells lacking ytfE were unable to do so, suggesting that NO caused 
damage that was irreversible due to lack of a functional repair system (Justino et al., 2006; 
Justino et al., 2007). Deletion of ytfE in E. coli has also been shown to exhibit increased 
sensitivity to killing by human neutrophils and decreased survival in murine macrophages 
(Shepherd et al., 2016).  
In E. coli, the ytfE gene has been shown to be a part of both the FNR and NsrR 
regulons (Figure 1.9). Filenko et al. (2007) showed ytfE to be one of the most up-regulated 
genes in response to NsrR titration, strongly implicating NsrR as a transcriptional 
repressor of ytfE. This was also inferred for Salmonella , as ytfE exhibits a 314.5-fold 
induction in the absence of nsrR (Karlinsey et al., 2012). In a fnr strain of E. coli, ytfE 
mRNA levels are elevated (Justino et al., 2006), although no FNR binding site motif was 
found in the putative promoter of ytfE, suggesting the possibility of an indirect mechanism 





1.2.3.6. Cytochrome bd-I and NO tolerance 
One key target of NO are respiratory oxidases such as cytochrome bo' and 
cytochrome bd-I, the latter containing three haem cofactors: b558, b595, and d. (Goldman 
et al., 1996). Both cytochromes are expressed in the presence of oxygen, with cytochrome 
bo’ exhibiting maximal expression under aerobic conditions and cytochrome bd-I 
achieving maximal expression in microaerobic environments (Cotter et al., 1990; Fu et 
al., 1991; Cotter et al., 1997). This differential expression allows for the best suited 
cytochrome to be expressed in different conditions, with cytochrome bd-I being more 
suitable under microaerobic conditions due to its high affinity for oxygen, with a Km of 
3-8 nM (D’mello et al., 1996) compared to a Km of 0.016-0.085 µM for cytochrome bo’ 
(D’Mello et al., 1995). This fine-tuned expression of cytochrome bd-I, encoded by the 
genes cydABX in E. coli, is achieved through the combined effects of FNR and the 
oxidative-sensing two-component system ArcAB (aerobic respiration control proteins) 
(Figure 1.10). In oxygen rich environments, neither FNR nor ArcAB are active. However, 
when oxygen levels drop, ArcB phosphorylates ArcA which binds to the promoter of the 
cydABX operon, initiating transcription. When oxygen is absent, FNR is activated and 
mediates cydABX repression. The antagonistic effects of ArcA and FNR on cydABX were 
demonstrated by Tseng et al. (1996) by determining expression of a cyd-lacZ fusion in a 
range of different oxygen concentrations in both fnr and arcA single mutants. To date, 
induction of cydABX expression in response to nitrosative stress has only been shown to 
occur under anoxic conditions (Pullan et al., 2007) and it is in agreement with the current 
model for cydABX regulation: FNR inactivation by NO will impede repression of the 
operon under anaerobic conditions.  
Figure 1.9 – FNR- and NsrR-dependent transcription of ytfE. Both transcription factors FNR 




The correct assembly of cytochrome bd-I is dependent on the cydDC operon 
(Georgiou et al., 1987; Poole et al., 1994; Goldman et al., 1996), which encodes a 
heterodimeric ABC transporter (Cook et al., 2002) important for the maintenance of the 
periplasmic redox balance through export of the low molecular weight thiols glutathione 
and cysteine (Pittman et al., 2002; Pittman et al., 2005). Deletion of the cydC gene in E. 
coli results in a non-functional cytochrome bd-I due to absence of haem incorporation 
(Georgiou et al., 1987). Predictably, a cydDC mutant strain exhibits many of the same 
phenotypic traits as a cydAB mutant, namely temperature sensitivity, hypersensitivity to 
hydrogen peroxide, and loss of viability in stationary phase under aerobic conditions 
(Poole et al., 1994; Goldman et al., 1996; Siegele et al., 1996). All of these phenotypes 
were shown to be corrected by overexpression of cydAB from a plasmid (Goldman et al., 
1996), suggesting the phenotypes can be solely attributed to loss of a functional 
cytochrome bd-I in a cydDC mutant.    
Cytochrome bd-I was first thought to be involved in NO tolerance after a 
transcriptomic study revealed cydA and cydB to be upregulated after exposure to a NOC 
compound under anoxic conditions (Pullan et al., 2007). Growth and respiratory rates of 
E. coli strains lacking either cytochrome bo’ (cyo- cyd+) or cytochrome bd-I (cyo+  cyd-) 
in response to NO were assessed, with data revealing a significant growth inhibition of 
cyo+  cyd- compared to wild-type (Mason et al., 2009; Shepherd et al., 2016). IC50 values 
for NO were greater in cyo- cyd+  cells, meaning cytochrome bd-I has higher tolerance for 
NO than cytochrome bo’ (Mason et al., 2009). Moreover, a faster respiratory recovery 
was observed in cytochrome bd-I, with NO dissociating faster from cytochrome bd-I 
resulting in weaker binding of NO to cytochrome bd-I (NO off rate (koff) = 0.163 s-1) 
compared to cytochrome bo’ (NO off rate (koff) = 0.03 s-1) (Mason et al., 2009). In E. coli, 
a cydAB mutant exhibited increased susceptibility to killing by human neutrophils and 
murine macrophages and showed impaired virulence in a mouse urinary tract infection 
model (Shepherd et al., 2016), revealing its importance during infection. The contribution 
of CydDC towards cytochrome bd-I-mediated NO tolerance has also been investigated. 
Interestingly, deletion of cydDC resulted in a more profound NO-sensitive phenotype 
than the one exhibited by the cytochrome bd-I mutant, and it was suggested the low 
molecular weight thiols exported by CydDC to the periplasm interact with NO in the 
periplasm and restrict the flow of NO into the cytoplasm (Holyoake et al., 2016). Taken 
together, these results show that cytochrome bd-I and the ABC transporter CydDC both 





1.2.3.7. Secondary NO sensors: Fur, OxyR, and SoxR 
Transcriptomic analysis of the bacterial response to nitrosative stress 
(Mukhopadhyay et al., 2004; Justino et al., 2005; Pullan et al., 2007) revealed up-
regulation of genes from specific regulons controlled by transcriptional regulators with 
primary functions unrelated to nitrosative stress: these were therefore described as 
secondary NO sensors. A prototypal example of such a sensor is FNR, which primarily 
senses oxygen. However, due to its involvement in the regulation of many of the NO-
tolerant mechanisms described so far, FNR will not be described in this section. 
The ferric uptake regulator (Fur) is an iron-dependent transcriptional repressor 
responsible for sensing iron limitation: in an iron-limited environment Fur is inactivated 
due to lack of a ferrous iron cofactor (Fe2+), allowing de-repression of genes involved in 
iron acquisition (Andrews et al., 2003). A possible role in responding to  nitrosative stress 
was suggested for Fur after transcriptomic studies revealed de-repression of Fur-targeted 
genes in response to GSNO (Mukhopadhyay et al., 2004) and NO (Justino et al., 2005): 
notable examples include genes of the suf operon, which encode the machinery necessary 
for assembly of [Fe-S] clusters. This contrasts with the data obtained for defined media 
transcriptomic studies, which indicated that Fur was not involved in the response to 
GSNO (Flatley et al., 2005) or NOC compounds (Pullan et al., 2007). It was suggested 
the results observed in the work of Justino et al. (2005) and Mukhopadhyay et al. (2004) 
are an artefact due to poor bioavailability of iron (Flatley et al., 2005). In vitro studies 
revealed inactivation of Fur by NO (D’Autreaux et al., β00β; D’Autréaux et al., 2004) 
Figure 1.10 – Transcriptional regulation of cydABX. Under aerobic conditions, neither FNR 
nor ArcAB are active and expression of cydABX is kept at very low basal levels. As the oxygen 
in the environment decreases, ArcB phosphorylates ArcA which binds to the promoter and 
induces transcription of the cydABX operon. In an anaerobic environment, FNR is activated and 
represses expression of cydABX. In the presence of NO, FNR is inactivated, resulting in an 
abolishment of FNR-mediated repression of cydABX transcription under anaerobic conditions. 
38 
 
providing further insight into the possible role of Fur during nitrosative stress. However, 
whether Fur has a more prominent role in NO tolerance or if the Fur-mediated effects 
during nitrosative stress are a consequence of Fur being a target of NO are still to be 
determined. 
OxyR (oxidative stress regulator) is a thiol-containing transcriptional regulator 
responsible for primarily coordinating bacterial response to hydrogen peroxide. However 
studies have shown OxyR can be activated by S-nitrosylation (Hausladen et al., 1996). 
Furthermore, S-nitrosylated but not S-oxidized OxyR stimulated in vitro transcription at 
the hcp promoter (Seth et al., 2012). Hence it was proposed that S-oxidised and S-
nitrosylated OxyR control different regulons, with exposure to nitrosative stress resulting 
in a different regulatory output than the one caused by oxidative stress (Seth et al., 2012; 
Green et al., 2014) (Figure 1.11). This hypothesis could explain why transcriptomic 
studies so far have not shown significant induction of members of the OxyR oxidative 
stress regulon. 
The superoxide response protein (SoxR) controls the expression of many genes in 
response to superoxide (Green et al., 2014). Expression of soxS-lacZ, controlled by SoxR, 
was found to be up-regulated in response to NO gas with an even greater induction 
observed under anoxic conditions, suggesting that NO itself and not a downstream 
product is responsible for this increase in SoxS expression (Nunoshiba et al., 1993). Both 
in vivo and in vitro data reveal that both oxidation or nitrosylation of the two [2Fe-2S] 
clusters of SoxR are equally capable of activating this protein (Ding and Demple, 2000; 
Vasil’eva et al., 2001). Interestingly, while expression of soxS was observed in three 
different transcriptomic studies (Mukhopadhyay et al., 2004; Justino et al., 2005; Pullan 
et al., 2007), little to no change was observed in the remaining members of the SoxRS 
regulon, possibly because the levels of SoxS are insufficient to trigger induction of the 
remaining genes (Pullan et al., 2007).  
 It is important to note that in spite of the different mechanisms of NO-
detoxification present in E. coli, these are not redundant systems but in fact provide E. 





1.2.4. Nitric oxide role in bacterial pathogenicity 
Nitric oxide is involved in many important biological processes in mammals. In 
bacteria, NO was initially thought to be only an intermediate product of anaerobic 
respiration, but the intrinsic role of NO as a bacterial signalling molecule capable of 
affecting bacterial metabolism and gene expression soon became obvious.  This is 
exemplified by the NO sensors NsrR and NorR regulating the expression of different 
genes involved in the protection against nitrosative stress (discussed at length in section 
1.2.1.). However, in this section the roles of NO in bacterial pathogenesis, beyond the 
nitrosative stress response, will be discussed. 
  
1.2.4.1. Bacterial biofilms 
Bacterial biofilms are complex multicellular structures that allow bacterial 
communities to withstand adverse environmental conditions such as osmotic pressure, 
extreme pH and temperature changes, and oxidative stress (Laverty et al., 2014). The 
formation of biofilms is initiated by environmental stresses sensed by planktonic bacterial 
cells that then attach to a surface, a process dependent on the expression of adhesion 
structures such as type I fimbriae encoded by the fim operon in E. coli, type IV pili 
encoded by the bfp operon in E. coli and necessary for attachment and twitching and 
swarming motility, and P pili encoded by the pap operon in E. coli (Laverty et al., 2014). 
Figure 1.11 – Activation of OxyR. OxyR contains thiols which are oxidised in the presence of 
hydrogen peroxide, activating the expression of genes involved in the SOS response to oxidative 
stress. During nitrosative stress, the thiols are nitrosylated and a different set of genes is activated. 
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This is followed by a maturation stage where the bacteria grow and attach more firmly to 
the surface, increasing the production of an extracellular polymeric substance which acts 
as a protective layer and stabilizer of the biofilm structure (Kostakioti et al., 2013; Laverty 
et al., 2014). The life cycle is complete with the dispersal stage, wherein some cells detach 
from the three-dimensional structure returning to their planktonic form and thus allowing 
colonization of new surfaces (Kostakioti et al., 2013). The primary reason for biofilm 
formation is to facilitate bacterial survival in harsh environments, which interestingly 
includes resistance to most antibiotics: bacterial cells can exhibit extreme sensitivity to 
an antibiotic when in planktonic form yet biofilms of the same organism can be up to 
1000 times more resistant to that same antibiotic (Mah and O’Toole, β001). Increased 
resistance to antibiotics in a biofilm has been attributed to low permeability of the biofilm, 
decreased metabolic rate of the biofilm-contained cells, and heterogeneity of the structure 
(i.e. biofilms can often contain different bacterial species or cells in different metabolic 
states (Mah and O’Toole, β001; Stewart and William Costerton, β001; de la Fuente-
Núñez, Reffuveille, Fernández, et al., 2013)).  
Bacterial biofilms have had a serious impact upon the treatment of infections and 
are implicated in 65% of infections (de la Fuente-Núñez, Reffuveille, Fernández, et al., 
2013), most occurring in cases where a medical device (e.g.: catheter or surgical implant) 
has been used. Biofilm-related infections are very difficult to treat and very often lead to 
relapse or chronic infection, as it is the case of cystic fibrosis patients. This contributes to 
the spread of antibiotic resistance, especially since biofilms can also facilitate transfer of 
plasmids and other genetic material (Ong et al., 2009) that encode antibiotic resistance 
determinants. Strategies have been designed to combat biofilm-mediated infection, 
ranging from hindering initial adhesion to the development of drugs capable of 
penetrating the biofilm. Another possible therapeutic approach is the dispersal of the 
biofilm followed by antibiotic treatment, since planktonic cells are more susceptible to 
antimicrobials. 
Detection of nitrosative stress inside P. aeruginosa  and S. aureus biofilms 
(Barraud et al., 2006; Miranda et al., 2011) prompted the investigation of the role of NO 
in biofilm formation. Exposure of P. aeruginosa  biofilms to 500 nM of the NO-donor 
SNP led to a 80% decrease in biofilm biomass, with similar results observed when 1 µM 
GSNO was used instead of SNP (Barraud et al., 2006). In contrast, high concentrations 
of SNP resulted in an increase of biofilm biomass (Barraud et al., 2006). Furthermore, a 
nitrite reductase-deficient strain of P. aeruginosa (i.e. unable to endogenously produce 
NO) exhibited impaired swarming motility, a feature important for biofilm formation (de 
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la Fuente-Núñez, Reffuveille, Fairfull-Smith, et al., 2013), and low levels of SNP are 
shown to increase swimming and swarming motility in P. aeruginosa  planktonic cells by 
25% and 77%, respectively (Barraud et al., 2006). This data suggests that NO plays an 
important role in biofilm biogenesis and dispersal. Importantly, pre-exposure to SNP 
potentiated the effect of various antimicrobial agents (Barraud et al., 2006), and similar 
results were obtained when P. aeruginosa and E. coli biofilms were treated with the 
nitroxide Carboxy-TEMPO (a compound with NO mimetic properties) in combination 
with the antibiotic ciprofloxacin (Reffuveille et al., 2015).  
 
1.2.4.2. Bacterial nitric oxide synthases 
In mammals, NO can be synthesized by nitric oxide synthase (NOS) enzymes that 
concomitantly convert L-arginine to citrulline. Mammalian NOS enzymes are 
homodimers with a haem oxygenase domain and a reductase domain (Figure 1.12) 
(Crane, 2008; Crane et al., 2010). Analysis of various bacterial genomes led to the 
discovery that some Gram-positive bacteria, such as B. subtilis, B. anthracis, and S. 
aureus encode proteins similar to the oxidase domain of mammalian NOS. Bacterial NOS 
(bNOS) proteins are also homodimer, bind haem cofactors and catalyse the same 
conversion of arginine to produce NO (Crane, 2008). However, one striking difference is 
the lack of a reductase domain in bNOS (Figure 1.12) (Crane, 2008; Gusarov et al., 2008; 
Crane et al., 2010). In B. subtillis, bNOS was shown to be a somewhat promiscuous 
enzyme with different bacterial flavodoxins shown to be capable of supporting the bNOS-
catalysed reaction in vitro (Wang et al., 2007).  
 
 
In B. subtillis and B. anthracis, bNOS-derived NO production has been implicated 
in the protection against oxidative stress (Gusarov and Nudler, 2005; Shatalin et al., 
Figure 1.12 – Domain arrangement of mammalian and bacterial nitric oxide synthases. The 
haem-binding oxygenase domain is present in both NOS enzymes. However, bNOS does not have 
a reductase domain. 
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2008). Endogenously-produced NO prevents the reduction of cysteine, an abundant thiol 
in Bacillus species that is responsible for maintaining redox balance. This in turn 
consequently interferes with the recycling of ferrous iron in the cell and ROS production 
via Fenton chemistry (Figure 1.13). Furthermore, NO stimulates the activity of KatA, a 
catalase enzyme that detoxifies hydrogen peroxide (Park and Imlay, 2003; Gusarov and 
Nudler, 2005; Shatalin et al., 2008).  S. aureus also exhibited increased oxidative stress 
sensitivity when the nos gene was deleted (Van Sorge et al., 2013), further demonstrating 
the importance of bNOS in cytoprotection. The ability of bNOS-derived NO to rapidly 
activate antioxidant protective systems provides an advantage during the oxidative stress 
burst that often occurs during host infection (Shatalin et al., 2008). Furthermore, 
endogenously-produced NO also provides protection against antibiotics that mediate their 
toxic effects via the production of ROS (Gusarov et al., 2009; Van Sorge et al., 2013; 












Figure 1.13 – Cysteine oxidation drives Fenton chemistry in Bacillus species. In species of 
Bacillus, cysteine reduces ferric iron to ferrous iron. The reaction between hydrogen peroxide 
and ferrous iron results in the formation of hydroxyl radicals, which causes DNA damage. The 
NO synthesized by bNOS transiently inhibits the reduction of cysteine to cystine, stopping the 
Fenton reaction from proceeding. 
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1.3.  Project Aims 
 
As antibiotic resistance becomes more and more common, the treatment of 
infections becomes more problematic, often relying on drugs that cause severe side-
effects. Hence, the development of new strategies is of the utmost importance. The natural 
occurrence of nitric oxide in the mammalian immune system and its documented 
antimicrobial activity against bacterial pathogens make it a tempting candidate to use as 
an alternative therapy or even in combination with conventional antibiotics as a means to 
potentiate their action. 
The overarching goal of this project was to determine the antimicrobial effects of 
NO in pathogenic E. coli and determine its suitability as a stand-alone therapy or in 
combination with conventional antibiotics. A collection of 50 E. coli clinical isolates 
(herein referred to as the Kent collection) was characterized for their antibiotic resistance, 
virulence gene carriage, plasmid content, and GSNO-susceptibility. Moreover, the effect 
of GSNO and NOC-compound in the survival of a pathogenic E. coli strain when 
combined with an antibiotic was tested, in both planktonic and biofilm-growing cells. 
 Another important aim of this project was to engineer an E. coli NO-producing E. 
coli strain that was also resistant to NO, and ultimately to determine if this strain could 
















































2.1. Bacteriological Methods 
 
2.1.1. Bacterial strains and plasmids 
All bacterial strains and plasmids are listed in Table 2.1 and Table 2.2, 
respectively. All bacterial strains are E. coli, unless otherwise stated. The 50 E. coli blood 
culture isolates were collected from East Kent Hospitals University NHS Foundation 
Trust with approval from the Research Ethics Council in (ref: 12/SC/0673). 
 




Strain Characteristics Reference 
MS1 CFT073; Uropathogenic strain (UPEC) belonging to 
clonal group ST73 Welch et al., 2002 
MS2 MG1655; E. coli K-12 strain Bachmann, 1996 
MS3 MG1655 harbouring pKD46 Prof. Mark Schembri 
MS10 EC958; UPEC strain belonging to clonal group ST131 Totsika et al., 2011 
MS11 EC958 harbouring pKOBEG Prof. Mark Schembri 
MS16 EC958 cydAB::Cm Prof. Mark Schembri; Shepherd et al., 2016 
MS52 
BW25113 F-, ∆(araD-araB)597, 
∆lacZ4787(del)::rrnB-3, LAM-, rph-1, ∆(rhaD-
rhaB)568, hdR514 
Baba et al., 2006 
MS92 EC958 hmp::Cm harbouring pSU2718-G-hmp Prof. Mark Schembri; Shepherd et al., 2016 
MS188 to 
MS237 
Collection of 50 E. coli blood isolates from Kent 
belonging to different sequence types (Appendix A-1) This work 
MS343 83972; Asymptomatic bacteriuria strain Prof. Mark Schembri; Klemm et al., 2006 
MS344 83972 harbouring pKD46 Prof. Mark Schembri 
MS345 BW25141 harbouring pKD3 Datsenko and Wanner, 2000 
MS388 EC958 cydDC::Cm 
Prof. Mark Schembri; 
Shepherd et al., 2016 
MS389 EC958 ytfE::Cm 
MS390 EC958 hmp::Cm 
MS391 EC958 norVW::Cm 
MS392 EC958 nrfA::Cm 
MS403 EC958 cydAB::Cm pSU2718-G-cydABX 
MS436 MG1655 Phmp::Pbla-Cm This work 
MS472 BW25113 pSU2718-bNOS This work 
MS486 RKP2176 Phmp-lacZ 
Same as RKP2178 
from Membrillo-
Hernández et al., 1996 
MS491 RKP2176 Phmp-lacZ harbouring pSU2718-bNOS This work 
MS505 EC958 harbouring pSU2718-bNOS This work 
MS506 EC958 cyoA::Cm (Appendix G.1) This work  
MS546 RKP2176 Phmp-lacZ harbouring pSU2718 This work 
MS547 EC958 harbouring pSU2718 This work 
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Table 2.2 – List of plasmids 
 
2.1.2. Oligonucleotides 
All oligonucleotides used during this work are listed in Table 2.3. 
Oligonucleotides were designed using Vector NTI Advance 10. Each pair of primers were 
designed with less than 5°C difference in melting temperature (Tm) and less than a 5% 
difference in their GC content. Oligonucleotides were synthesized by Eurofins MWG. 
 
2.1.3. Chemicals and water 
All chemicals were purchased from Sigma unless otherwise stated. Nutrient agar, 
tryptone, and yeast extract were purchased from Oxoid. Distilled-deionized water was 
used throughout this work. Mili-Q water was used whenever a high degree of purity was 
required. Solutions were sterilised by autoclaving at 121°C, 15 psi (pound force per 
square inch) for 15 min, or by filtering using Millipore filters with a pore size of 0.22 µm. 
 
2.1.4. Media and buffer solutions 
2.1.4.1. Luria-Bertani medium 
Luria-Bertani (LB) medium contained 10 g tryptone, 5 g yeast extract, and 5 g 
NaCl per litre. pH was adjusted to 7.0. 
 
2.1.4.2. Iso-Sensitest Broth and Iso-Sensitest Agar 
Both media were purchased from Oxoid and prepared according to manufacturer 
instructions. 
Plasmid Characteristics Antibiotic Reference  
pKD46 λ-red recombinase, Temperature 
sensitive (Ts) replicon Amp
R
 Datsenko and 
Wanner, 2000 pKD3 Chloramphenicol resistance cassette flanked by FRT sites Cm
R
 
pKOBEG λ-red recombinase; Temperature 
sensitive (Ts) replicon Gent
R
 




Complementation plasmid for hmp 
knockout Gent
R
 Prof. Mark 
Schembri pSU2718-G-
cydABX 





Empty plasmid control for bacterial 
nitric oxide synthase (bNOS) 
expression 
CmR This work 
pSU2718-bNOS 
Plasmid for IPTG-inducible expression 
of bacterial nitric oxide synthase 
(bNOS) 
CmR This work 
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Table 2.3 – List of oligonucleotides 
 
Name 5'-3' Sequence Use Direction 
pSU2718nssR_seqF AAAAGCACCGCCGGACATCA For screening of bNOS insert into 
pSU2718 vector 
Forward 
pSU2718nssR_seqR CGAATTCGAGCTCGGTACCC Reverse 
hmp_Pbla_F TAAGATGCATTTGAGATACATCAATTAAGATGCAAAAAAAGGAAGACCATCATATGAATATCCTCCTTAG Amplification of CmR cassette 
and Pbla promoter from pKD3 for 
substitution of native promoter of 
hmp 
Forward 
hmp_Pbla_R AGTAAAGGGATGGTGGCTTTTACTGTAGCGATGGTTTGAGCGTCAAGCATACTCTTCCTTTTTCAATATT Reverse 
Hmp_Sc_fw GGCTACGCAAGGCTTTGGAG For screening of Pbla promoter 
insertion upstream hmp gene 
Forward 
Hmp_Sc_rev CTGGCGTAGGCGGCAATAGC Reverse 
SaUSA300_bNOS_Fw CCCTGCGCATATAATTGCATATGCTACAC Amplification of bNOS from S. 
aureus USA300 for pSU2718-
hmp cloning 
Forward 
SabNOS_Rev2 CCCGGATCCTTAACAGGAAACAGCTATGTTATTTAAAGAGGCTCA Reverse 
cyoA_Cm_fw CCGAACATCTTTATTCTTCCTCAACCCCTTTAATGGGCGGATTCCGCGTGGTGTAGGCTGGAGCTGCTTC For cyoA KO in EC958 
background 
Forward 
cyoA_Cm_rev2 CCACACACTTTAAACGCCACCAGATCCCGTGGAATTGAGGTCGTTAAATGCATATGAATATCCTCCTTAG Reverse 
cyoA_Sc_fw GTCAACGGAGGTCAGCCACT 
To screen cyoA KO mutants 
Forward 
cyoA_Sc_rev2 CGCCCTTTTGCAACAGCTTC Reverse 
pSU2718seq_200_F GTCGGGTGATGCTGCCAACT 
For sequencing of pSU2718-
bNOS 
Forward 
pSU2718seq_200_R GCAGCTGGCACGACAGGTTT Reverse 
bNOS_sq150_rev GGTGCTAAAATGGCTTGGCG Reverse 
pSU2718_Fw GGATCCCCGGGTACCGAGCTC For amplification of pSU2718 
backbone 
Forward 
pSU2718_Rev TGCGCAGCCTGAATGGCGAA Reverse 
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2.1.4.3. M9 minimal medium 
5x M9 salts were prepared [80.24 g Na2HPO4.2H2O, 15 g KH2PO4, 2.5 g NaCl, 
and 5 g NH4Cl per litre], autoclaved, and left to cool before use. To prepare 1L of 1X M9 
medium, the following solutions were mixed: 200 mL of 5x M9 salts, 2 mL of a 1 M 
MgSO4 filter sterilized solution, 100 µL of a 1 M CaCl2 filter sterilized solution, 20 mL 
of 20% (w/v) glucose (filter-sterilized), 778 mL of autoclaved water. 
 
2.1.4.4. SOB medium 
 SOB medium contained 20 g tryptone, 5 g yeast extract, 0.584 g NaCl, and 0.186 
g KCl per litre.  
 
2.1.4.5. SOC medium 
 One litre of SOC medium was prepared by addition of 10 mL of 2 M Mg2+ solution 
[20.33 g MgCl2 and 24.65 g MgSO4 per 100 mL. The solution was autoclaved and 
allowed to cool down before use] and 20 mL of a 1 M glucose sterile solution to 970 mL 
of sterile SOB medium. 
 
2.1.4.6. Dulbecco’s Modified Eagle Medium (DMEM) 
 DMEM medium was purchased from Thermo Fisher Scientific. The purchased 
medium is a complex medium containing high levels of glucose, L-glutamine, phenol red, 
sodium pyruvate, whereas the buffer HEPES is absent. 
 
2.1.4.7. Sodium Phosphate Buffer 
 A 50 mM sodium phosphate buffer pH 8.0 was prepared with 94.7 mL 50 mM 
Na2HPO4 and 5.3 mL 50 mM NaH2PO4. The pH was checked prior to filter sterilization. 
The sterile buffer was then aliquoted and stored at 4°C. 
 
2.1.4.8. Tris-Acetate-EDTA (TAE) Buffer 
 A 50x solution of Tris-Acetate-EDTA (TAE) buffer was prepared by adding 242 
g of Tris base, 57.1 mL of acetic acid, and 100 mL of 0.5M EDTA to 900 mL of dH2O. 
The pH was adjusted to 8.5 prior to adjusting the volume to one litre. For a working 
concentration of 1x, 20 mL of the 50x TAE buffer stock was diluted in 980 mL of water. 
 
2.1.4.9. Z- Buffer 
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 Z-buffer contained 60 mM Na2HPO4.7H2O, 40 mM NaH2PO4.H2O, 10 mM KCl, 
1 mM MgSO4.7H2O. Prior to the addition of 50 mM beta-mercaptoethanol, the pH was 
adjusted to 7.0. The buffer was protected from light and stored at 4°C. 
 
2.1.4.10. Phosphate-Buffered Saline (PBS) 
 A 10x concentrated solution of Phosphate-Buffered Saline (PBS) buffer contained 
80 g NaCl, 2 g KCl, 15.4 g Na2HPO4.2H2O, and 2.4 g KH2PO4 per litre. The pH was 
adjusted to 7.4 prior to volume being adjusted to one litre. The buffer solution was 
autoclaved and diluted to a working concentration of 1x by mixing 100 mL of the 10x 
stock solution with 900 mL of sterile milli-Q water. 
 
2.1.5. Media Supplements 
2.1.5.1. Antibiotics 
 Where appropriate, growth media was supplemented with 125 µg/mL of 
ampicillin, 25 µg/mL chloramphenicol, or 20 µg/mL gentamicin. 
 
2.1.5.2. Casamino acids solution 
 A 2% (w/v) casamino acids solution was prepared by adding 2 g of dried casamino 
acids per 100 mL dH2O, after which the solution was autoclaved and allowed to cool 
down before use.  
 
2.1.5.3. Fumarate Solution 
 For anaerobic growth, it was necessary to supplement media with a respiratory 
electron acceptor as an alternative to oxygen. To that end, a 1 M stock solution of fumarate 
was prepared. Briefly, 116.07 g of fumaric acid was added to 500 mL of water. The pH 
was adjusted to 7.0 using NaOH prior to the volume being adjusted to 1L. The solution 
was filter sterilized, aliquoted, and stored at -20°C. 
 
2.1.5.4. Nutrient agar 
15 g of nutrient agar was used per litre of growth medium. Agar plates, unless 
otherwise stated, were inverted and incubated at 37°C. 
 
2.1.6. Culture conditions 
10 mL starter cultures were inoculated from single colonies and grown overnight 
in LB (37°C and 180 rpm). A 1% inoculum of overnight starter culture was used to 
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inoculate fresh media. Liquid cultures were grown in a New Brunswick™ Innova® 3100 
water bath at 37°C and 180 rpm in 50 mL conical flasks containing 10 mL of LB medium, 
unless otherwise stated.  
 
2.1.6.1. Culture optical density 
 The optical density of cultures was measured at 600 nm (OD600nm) using a 
Shimadzu UV-1800 spectrophotometer in cuvettes with a 1 cm path length. 
 
2.1.6.2. Preparation of E. coli glycerol stocks 
Glycerol stocks of E. coli were prepared by mixing 750 µL of sterile 50% (v/v) 
glycerol with 750 µL of an overnight culture in a cryotube. The stocks were stored at -
80°C. 
 
2.1.7. Antibiotic susceptibility assays 
Breakpoint values were obtained from the British Society for Antimicrobial 
Chemotherapy (BSAC) (version 13.0 from June 2014). 
 
2.1.7.1. Antibiotic preparation 
 Antibiotics used to determine antibiotic susceptibility were prepared as shown in 
Table 2.4.  
 
Table 2.4 – List of antibiotics tested 
 
 
2.1.7.2. 0.5 McFarland Standard 
 A stock of 0.5 McFarland solution, corresponding to a cell density of 107-108 
CFU/mL, was prepared by mixing 0.5 mL of 0.048 M BaCl2 and 99.5 mL of 0.18 M 
H2SO4. The cell suspension was then mixed prior to absorbance reading at 625 nm 
Antibiotic Solvent Stock concentration (mg/mL) Disc content (µg) 
Amoxicillin DMSO 2 10 
Cefotaxime Water 6 30 
Chloramphenicol Ethanol 6 30 
Ciprofloxacin Water 0.2 1 
Gentamicin Water 2 10 
Meropenem Water 2 10 
Nitrofurantoin DMSO 50 200 
Trimethoprim DMSO 0.7 2.5 
Polymixin E (Colistin) Water 10 - 
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(A625nm). If the absorbance was between 0.08 and 0.13, the solution was then aliquoted 
into glass vials, protected from light, and stored at room temperature. 
 
2.1.7.3. Preparation of inoculum 
Inocula were prepared according to the British Society for Antimicrobial 
Chemotherapy (BSAC) guidelines (Andrews, 2001b; Howe and Andrews, 2012). Briefly, 
colonies were used to inoculate 5 mL of Iso-Sensitest broth and incubated at 37°C and 
180 rpm until visible turbidity was greater than that of the 0.5 McFarland standard. The 
density of the culture was adjusted to that of the 0.5 McFarland standard with sterile milli-
Q water.  
 
2.1.7.4. Disc diffusion assay 
Iso-Sensitest agar plates were prepared and dried on the day of use. Each plate (90 
mm) contained 20 mL of agar. Cell suspensions prepared as described in section 2.1.7.3 
were diluted 1:100 in sterile milli-Q water. A sterile swab was dipped into the dilution 
and excess liquid was removed by pressing the swab against the side of the falcon tube. 
The inoculum was swabbed over the Iso-Sensitest agar in three different directions to 
obtain an even spread. A 5 mm sterile filter paper disc (Whatman™ No. 1) containing the 
appropriate antibiotic (see Table 2.4) was placed on the agar. Plates were incubated at 
37°C for 16 ± 2 h prior to measuring zones of inhibition. BSAC testing v13.0 was used 
for the zone diameter breakpoint values. 
 
2.1.7.5. Microdilution assay 
 Due to the poor agar diffusion of polymyxin E (colistin), susceptibility to this 
antibiotic was tested using the microdilution assay (Andrews, 2001a). A dilution range 
(two-fold from 0.0625 to 4 mg/L) of polymyxin E was prepared in Iso-Sensitest broth, 
and 75 µL of each dilution was dispensed to a sterile 96-well microtiter plate in duplicate. 
Cell suspensions prepared as described in section 2.1.7.3 were diluted 1:10 in sterile milli-
Q water, and then further diluted 1:100 in Iso-Sensitest broth prior to 75 µL being added 
in duplicate to each antibiotic dilution. Incubation was carried out for 16 ± 2 hs at 37°C. 
BSAC testing v13.0 was used for the MIC breakpoint values. 
 
2.1.8. Biofilm formation assay 
 An overnight starter culture was used to inoculate 5 mL of fresh M9 minimal 
medium supplemented with 0.1% casamino acids. This culture was then incubated at 
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37°C and 180 rpm for 1 h. 150 µL of the growing culture was dispensed into six wells of 
a 96-well microtiter plate, with a negative control consisting of 150 µL of fresh M9 
medium included in each plate. A 24-h static incubation at 37°C was carried out, after 
which the media was completely discarded and 150 µL of a 0.1% (w/v) crystal violet 
solution was dispensed into each well, followed by a 30 min incubation at 4°C. The crystal 
violet solution was discarded and wells were washed until the negative control wells were 
clear. 150 µL of an ethanol/acetone (80:20 ratio) mix was added to each well and the 
microtiter plate was left on a rocker for 1 h at 60 rpm. Absorbance at 595 nm (A595nm) 
was recorded using a SPECTROstar nano microplate reader (BMG Labtech). 
 
2.1.9. Nitric oxide susceptibility  
2.1.9.1. S-Nitrosoglutathione (GSNO) preparation 
 S-nitrosoglutathione (GSNO) was prepared as previously described by Hart 
(1985). Briefly, a solution containing 3.08 g of reduced glutathione, 0.69 g of NaNO2, 
0.83 mL of 12.1 M HCl, and 18 mL of distilled water was stirred for 40 min whilst in an 
ice bath. Following the addition of 20 mL of acetone, the solution was stirred for another 
10 min. The red precipitate was collected by vacuum filtration and washed with five 2 
mL volumes of cold distilled water, three 10 mL volumes of acetone, and three 10 mL 
volumes of ether. The precipitate was then dried overnight in a vacuum desiccator and 
kept at -80°C for no longer than one month. Immediately before use, GSNO was dissolved 
in distilled water, filter sterilized and quantified using a Cary 60 UV-vis 
spectrophotometer (Agilent Technologies) before use (Extinction coefficient (ɛ) at 545nm 
= 15.9 M-1 cm-1). 
 
2.1.9.2. Well-diffusion assay 
 Cultures were prepared in M9 minimal medium supplemented with 0.1% 
casamino acids and incubated at 37°C and 180 rpm until OD600nm was approximately 0.4-
0.5. Cultures were then plated in M9 minimal agar using the pour plate method, i.e. 1 mL 
of culture was mixed with 19 mL of agar and poured into a 90 mm petri dish. Agar was 
allowed to set, at which point six 6 mm wells were cut into the agar and filled with 80 µL 
of an 80 mM solution of GSNO. Plates were incubated in an upright position at 37°C 
under aerobic (for 16 ±2 h), microaerobic (2% oxygen in an InvivO2 300 Hypoxia 
Workstation) (for 32 ± 2 h), or anaerobic (32 ± 2 h) conditions. For the latter, 50 mM 
fumarate was added to the agar and the plates were secured in an anaerobic jar with an 
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oxygen indicator and an anaerobic gas pouch (both purchased from Oxoid). After 
incubation, zones of inhibition were measured.  
 
2.1.9.3. GSNO growth curves under microaerobic conditions 
 An overnight starter culture of strains MS2 and MS436 in M9 minimal medium 
supplemented with 0.1% casamino acids was used to inoculate 10 mL of fresh M9 
minimal medium supplemented with 0.1% casamino acids and 0, 1, or 5 mM of GSNO 
to an initial OD600nm of 0.04. The culture was dispensed into five wells of a 96-well 
microtiter in 200 µL aliquots and incubated at 37°C and 100 rpm in a SPECTROstar nano 
microplate reader (BMG Labtech). OD600nm was followed every 15 min for at least 8 h. 
 
2.1.9.4. GSNO growth curves under anaerobic conditions 
 An overnight starter culture of strains MS2 and MS436 in M9 minimal medium 
supplemented with 0.1% casamino acids was used to inoculate 30 mL of fresh M9 
minimal medium supplemented with 0.1% casamino acids, 50 mM fumarate, and 0, 1, or 
5 mM of GSNO to an initial OD600nm of 0.04. Cultures were grown statically in a sealed 
serum glass bottle at 37°C, and OD600nm was followed every hour for 6 h. 
 
2.1.9.5. NOC-12 preparation 
 Growth curves were carried out using NOC-12 (purchased from Calbiochem), a 
nitric oxide donor with a half-life of 100 min at 37°C, pH 7.4. A 0.1 M stock of NOC-12 
was prepared in 50 mM sodium phosphate buffer (pH 8) (see section 2.1.4.6.) 
immediately before use. To ensure an effect on bacterial growth was observed, a range of 
concentrations between 0.1 mM and 0.75 mM ware tested. 
 
2.1.9.6. NOC-12 growth curves 
 An overnight starter culture in M9 minimal medium supplemented with 0.1% 
casamino acids was used to inoculate 10 mL of fresh M9 minimal medium supplemented 
with 0.1% casamino acids to an initial OD600nm of 0.01. The culture was dispensed into 
five wells of a 96-well microtiter in 200 µL aliquots and incubated at 37°C and 100 rpm 
in a SPECTROstar nano microplate reader (BMG Labtech) until OD600nm was 
approximately 0.04, at which point the NOC-12 compound was added. In control wells, 
50 mM sodium phosphate buffer was added instead of NOC-12 solution. Incubation was 
carried out as before NOC-12 addition, and OD600nm was followed every 15 min for at 
least 8 h.  
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2.1.10. Gentamicin cell survival assay 
2.1.10.1. Exogenous nitric oxide source 
An overnight starter culture in LB of EC958 wild-type (MS10), EC958 
cydAB::Cm (MS16), or EC958 cyoA::Cm (MS506) was used to inoculate 10 mL of fresh 
M9 media supplemented with 0.1% (v/v) casamino acids, and incubated at 37°C and 180 
rpm until OD600nm~0.3 or higher. The culture was diluted to an OD600nm of approximately 
0.125 (1x108 cells/mL) in fresh M9 supplemented with 0.1% casamino acids, and 0 or 15 
mM of GSNO, or 0 or 1 mM of NOC-12, was added, and cultures were incubated at 37°C 
for 30 min. Cells were further incubated at 37°C with different concentrations of 
gentamicin for 90 min. Serial dilutions were performed and 5 µL drops were plated in 
triplicate on LB-agar plates. Plates were incubated at 37°C overnight, and colony counts 
performed to determine CFU/mL. 
For in vitro biofilm assay, all steps were as described above with the following 
exceptions: 200 µL of the 1x108 cell/mL suspension was dispensed onto a 96-microtitre 
and incubated at 37°C statically for 24 h to allow biofilm formation. After the incubation 
biofilms were washed 2x with 1x PBS followed by an incubation at 37°C for 90 min with 
different concentrations of gentamicin and with or without 15 mM GSNO. Subsequently, 
biofilms were washed 2x with 1x PBS and resuspended in 200 µL of 1x PBS with 
vigorous pipetting and vortexing. Serial dilutions were performed and 5 µL drops were 
plated, in triplicate, on LB-agar plates. Plates were incubated at 37°C overnight, and 
colony counts performed to determine CFU/mL. 
 
2.1.10.2. Endogenous nitric oxide source 
All steps were as described in section 2.1.10.1, with the following exceptions: 
strains EC958 pSU2718 and EC958 pSU2718-bNOS were used. After diluting cultures 
to an OD600nm of approximately 0.125 (1x108 cells/mL) in fresh M9 supplemented with 
0.1% casamino acids, 0.4 mM IPTG and 10 mM L-arginine were added followed by an 
incubation at 37°C for 30 min.  
 
2.1.11. Intra-macrophage survival assays 
2.1.11.1. Cell line maintenance 
For this assay, the Raw-Blue™ macrophage cell line (InvivoGen) was used. This 
murine cell line was maintained in complete medium (DMEM medium supplemented 
with 10% (v/v) of foetal bovine serum (FBS; purchased from Gibco®)) supplemented 
55 
 
with 200 units of penicillin, and 200 µg/mL of streptomycin, and incubated at 37°C in 
5% CO2 until approximately 80% confluency was reached. 
 
2.1.11.2. Preparation of bacterial cells for infection 
Approximately 1.8 mL of an overnight culture of EC958 wild-type (MS10) was 
placed in a sterile eppendorf tube and cells were pelleted by centrifugation (1 min at 
16 000 xg). The supernatant was carefully discarded, and the cell pellet washed twice 
with 1 mL of 1x PBS. The cell pellet was re-suspended in 1.5 mL of 1x PBS and further 
diluted 1:5 in 1x PBS. The bacterial suspension was further diluted in 1x PBS until and 
OD600nm of approximately 0.5 was reached (approximately 4x108 cells/mL), at which 
point the appropriate volume of the suspension to achieve 1.5x107 cells/mL was diluted 
in complete medium with or without 2 mM of Nω-Nitro-L-arginine methyl ester (L-
NAME), an inhibitor iNOS. 
 
2.1.11.3. Preparation of macrophage cells for infection 
Macrophage cells were allowed to proliferate in a T-75 flask to approximately 
80% confluency, at which point they were collected with gentle scraping. The cell 
suspension was transferred to a sterile 15 mL falcon tube and centrifuged in an Eppendorf 
centrifuge 5418 for 5 min at 500 xg. The cell pellet was re-suspended in 5 mL of complete 
medium and the number of cells/mL determined using an hemocytometer. Each well on 
a 96-well microtitre was seeded with 1.5x105 cells. For macrophage activation 1 µg/mL 
of lipopolysaccharides (LPS) from Escherichia coli O127:B8 and 10 ng/mL of interferon 
gamma (IFN-Ȗ; purchased from ThermoFisher) were added per well, with or without 2 
mM of L-NAME. Cells were incubated for 18 ± 2 h at 37°C, 5% CO2. 
 
2.1.11.4. Macrophage infection  
Media was carefully removed from each well, as to not disturb the macrophage 
cells, and replaced with 100 µL of the 1.5x107 cells/mL bacterial cell suspension prepared 
in section 2.4.1.2., resulting in a multiplicity of infection (MOI) of approximately 10:1 
(bacteria:macrophage). After a 20 min incubation at 37°C in 5% CO2, the medium was 
removed and the cells washed 2x with complete media supplemented with 200 µg/mL 
gentamicin. After a 20 min incubation in complete medium supplemented with 200 
µg/mL at 37°C in 5% CO2, the media was removed and cells were washed 3x with 
complete media. 100 µL of complete media, with or without 2 mM L-NAME and 
different concentrations of gentamicin (20 or 200 µg/mL) was added to each well and a 
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90 min incubation was carried out at 37°C in 5% CO2. Cells were washed 3x with 1x PBS 
and lysed with a 0.1% (v/v) solution of Triton-X in 1x PBS. The lysate was serial diluted 
in 1x PBS and 5 µL drops were plated on LB-agar in triplicate. Plates were incubated 
overnight at 37°C and colony counts performed to determine CFU/mL. An uptake plate 
to determine the average uptake of bacteria by macrophages per condition was also 
prepared for every assay and used to normalize CFU/well.  
 
2.2. Genetic Methods 
 
2.2.1. Isolation of plasmid DNA 
 Plasmid DNA was isolated using QIAprep Spin Miniprep Kit (QIAGEN) 
according to manufacturers’ instructions. Overnight cultures were pelleted at 7155 xg for 
10 min using a Sigma Laboratory Centrifuge 2k15. Following this step, all centrifugations 
were carried out at 16000 xg in an Eppendorf 5415R micro centrifuge. 
 
2.2.2. Polymerase chain reaction (PCR) 
For colony PCR, each bacterial colony was re-suspended in 50 µL of sterile water, 
and 2 µL were used as template in the PCR reaction. A typical colony PCR reaction would 
contain 400 nM of each primer (forward and reverse), 12.5 µL of 2x PCRBIO Taq Mix 
Red (PCRBiosystems), and sterile water to make up the end volume to 25 µL. PCR tubes 
were then placed in a T3000 thermocycler machine (Biometra®) programmed with the 
following: one cycle at 95°C for 4 min, 35 cycles at 95°C for 15 s, 55°C to 65°C 
(annealing temperature depending on the primers used) for 15 s and 72°C for 15 s per kilo 
base (extension time dependent on the length of the expected PCR product), and finally 
one cycle at 72°C for 2 min. 
 
2.2.3. DNA electrophoresis on agarose gels 
1% (w/v) agarose gels were prepared in 1x TAE buffer (see section 2.1.4.7) and 
electrophoresis was carried out using a gel apparatus at 150 V, 300 mA, for 45 min, in 1x 
TAE buffer. 5 µL samples were mixed with 1 µL of Blue/Orange 6x loading dye 
(Promega) before being loaded onto gel wells. A 1 kb DNA ladder (Promega) was also 
loaded onto the gel in order to determine the size of the DNA present in the sample. Gels 
were stained post-electrophoresis for 30 min at 60 rpm in 100 mL of water containing 0.5 




2.2.4. Cloning bacterial nitric oxide synthase (bNOS) into pSU2718 
2.2.4.1. Preparation of bNOS fragment for cloning 
 A PCR reaction to amplify a bacterial nitric oxide synthase (bNOS) gene 
contained the following:  25 µL Q5 2x Mastermix (NEB), 500 nM SaUSA300_bNOS_Fw 
primer, 500 nM SabNOS_Rev2 primer, 5 µL of a 1:10 dilution of Staphylococcus aureus 
USA300 genomic DNA, and 15 µL of sterile water for a total of 50 µL. The reaction was 
then transferred to a T3000 thermocycler machine (Biometra®) programmed with the 
following: 98°C for 30 s, 35 cycles of 98°C for 10 s, 60°C for 30 s, and 72°C for 1 min, 
and finally 72°C for 2 min. The PCR product was purified using a QIAquick PCR 
purification kit (QIAGEN) and digested with BamHI-HF (NEB) and FspI (NEB) 
restriction enzymes according to manufacturers’ instructions. The digested product was 
again purified using a QIAquick PCR purification kit (QIAGEN), and the DNA 
concentration was quantified with a NanoPhotometer® N50 (Implen) prior to use in a 
ligation reaction with pSU2718 (see section 2.2.4.3). 
 
2.2.4.2. Preparation of pSU2718 for cloning 
 pSU2718-hmp plasmid was isolated from MS18 (see section 2.2.1.) and digested 
with BamHI-HF (NEB) and FspI (NEB) restriction enzymes according to manufacturers’ 
instructions. This restriction digest would result in two DNA fragments, one being the 
desired plasmid backbone (2167 bp) and the other corresponding to the hmp gene (1345 
bp). The restriction digest reaction was loaded onto an agarose gel (see section 2.2.3.) and 
the desired fragment extracted and purified using QIAquick Gel Extraction kit 
(QIAGEN). DNA concentration in the sample was quantified with NanoPhotometer® 
N50 (Implen) prior to use in a ligation reaction with bNOS fragment (see section 2.2.4.3.). 
pSU2718 backbone for re-ligation was amplified by PCR using primers pSU2718_Fw 
and pSU2718_Rev. 
 
2.2.4.3. Ligation reaction 
 Ligation reactions were carried out using T4 DNA ligase (Promega) according to 
manufacturers’ instructions. Briefly, 50 ng of cut pSU2718 plasmid was incubated in 1x 
T4 DNA ligase Reaction Buffer with bNOS fragment in a 1:3 ratio (vector:insert), along 
with 1.5U T4 DNA ligase and sterile water to make up 10 µL. The reaction was incubated 
at 15°C for 16 ± 2 h and used to transform BW25113 competent cells (see sections 2.2.5. 
and 2.2.6.). To obtain the pSU2718 empty plasmid, the PCR-amplified backbone was 
used in a ligation reaction as described above, but bNOS was omitted from the reaction. 
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2.2.5. Preparation of E. coli competent cells 
 An overnight starter culture in LB was used for a 1% (v/v) inoculation of 10 mL 
of fresh LB medium. This culture was incubated at 37°C and 180 rpm until OD600nm was 
approximately 0.5, at which point 1 mL of culture was pelleted at 2300 xg for 5 min. The 
supernatant was discarded and the cell pellet re-suspended in 750 µL of ice-cold 100 mM 
CaCl2, followed by a 1 h incubation on ice. The cells were again pelleted as described 
above, supernatant carefully removed, and cell pellet re-suspended in 100 µL of ice-cold 
100 mM CaCl2. Following another incubation on ice for 1 h the cells were transformed 
with plasmid DNA. 
 
2.2.6. Transformation of E. coli competent cells 
 Plasmid DNA (2-5 µL) or various volumes of ligation reaction were mixed with 
100 µL of competent cells and incubated on ice for 30 min before being heat shocked for 
45 s at 42°C. The transformation mixture was immediately incubated on ice for 2 min 
after the heat shock, and 900 µL of SOC medium was added to aid recovery. An 
incubation at 37°C and 180 rpm was carried out for 1 h, followed by a centrifugation step 
at 2300 xg for 5 min. 900 µL of supernatant was carefully removed, and cells were re-
suspended in the remaining 100 µL prior to being plated onto the appropriate selective 
LB-agar plate. 
 
2.2.7. λ-red mutagenesis 
 The λ-red mutagenesis (Datsenko and Wanner, 2000) approach was used to 
replace the cyoA gene in E. coli EC958 background with a chloramphenicol resistance 
cassette (Figure 2.1), and also to replace the hmp native promoter with a Pbla promoter in 
a E. coli MG1655 background. The phage λ-Red recombinase system is encoded in a 
temperature sensitive plasmid and under the control of an arabinose-induced promoter. 
The recombinase system allows homologous recombination between the PCR product 
and the genome, which results in a knockout mutation. 
 
2.2.7.1. Amplification of PCR fragment for λ-Red mutagenesis 
 For the amplification of the PCR fragment containing the chloramphenicol 
resistance cassette alone (cyoA gene knockout) or the chloramphenicol resistance cassette 
and the Pbla promoter, PCR reactions was prepared as follows: 25 µL 2x PCRBIO Taq 
Mix Red (PCRBiosystems), 400 nM of appropriate forward primer, 400 nM of 
appropriate reverse primer, 0.5 µL pKD3 plasmid, and sterile water was used to top-up 
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the volume to 50 µL. PCR tubes were placed in a T3000 thermocycler machine 
(Biometra®) programmed with the following: 95°C for 1 min, 35 cycles at 95°C for 15 s, 
50°C for 15 s and 72°C for 30 s, and finally one cycle at 72°C for 2 min. Reaction was 
purified using a QIAquick PCR purification kit (QIAGEN), eluted in sterile mili-Q water, 
and used to transform MG1655 pKD46-containing strain (MS3) or EC958 pKOBEG-
containing strain (MS11) (see sections 2.2.7.3 and 2.2.7.4). 
 
 
2.2.7.2. Preparation of electro-competent cells 
 Electro-competent cells were prepared using strains MS3 and MS11, containing 
the temperature sensitive plasmid pKD46 (ApR) and pKOBEG (GmR) respectively. These 
plasmids encode the phage λ-derived Red recombination system and allows the 
homologous recombination between a PCR product and the genome. An overnight starter 
culture in LB grown at 28°C and 180 rpm was used for a 1% inoculation of 50 mL of 
fresh SOB medium (see section 2.1.4.4.) supplemented with the appropriate antibiotic 
and 20 mM L-arabinose, to induce expression of the λ-Red system from the PBAD 
Figure 2.1 – λ-red mutagenesis. In the procedure described by Datsenko and Wanner (2000), 
an antibiotic resistance cassette is amplified by PCR with primers that will allow the synthesis 
of extremities homologous to the regions flanking the gene of interest in the genome (1). The 
PCR product is then used to transform cells expressing the λ-red recombinase system, which 
will allow homologous recombination between the PCR product and the genome (2), thus 
creating a knockout mutant (3). 
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promoter. Cells were incubated at 28°C and 180 rpm until OD600nm was between 0.4-0.8, 
at which point the cells were transferred to a chilled 50 mL falcon tube and spun at 3000 
xg, 4°C, for 10 min. Supernatant was discarded and the cell pellet was gently re-
suspended in 5 mL of ice-cold 10% (v/v) glycerol. This step was repeated a total of three 
times prior to the cell pellet being re-suspended in a final volume of 200 µL of ice-cold 
10% (v/v) glycerol. 40 µL of the now electro-competent cells were used per 
transformation by electroporation (see section 2.2.7.3.). 
 
2.2.7.3. Transformation by electroporation 
 DNA was placed into a chilled 2-mm electroporation cuvette prior to 40 µL of 
electro-competent cells being added. Adequate mixing and placement of the sample at 
the bottom was achieved by tapping the cuvette. The cuvette was then placed into the 
chamber of the electroporator (Bio-Rad) and pulsed at 2.45 kV, 200 Ω resistance, and 25 
µF capacitance. To aid cell recovery, 1 mL of SOC (see section 2.1.4.5.) was added to 
the cuvette and then transferred into a 1.5 mL Eppendorf for incubation at 37°C and 180 
rpm for 1 h. To select for incorporation of resistance gene onto the chromosome, cells 
were plated onto LB-agar supplemented with the appropriate antibiotic, and colony PCR 
was carried out to identify mutant colonies.  
 
2.2.8. Sequencing of DNA 
 To confirm successful knockout of the gene or successful cloning of fragment into 
plasmid, DNA samples were sequenced by GeneWiz and data was analysed using BioEdit 
v7.2.5 (Hall, 1999). For whole genome sequencing, library preparation was performed 
using Nextera® XT DNA Library Prep Kit from Illumina® following manufacturers’ 
instructions. Library preps were then sequenced on an Illumina® MiSeq benchtop 
sequencer using a MiSeq reagent kit v3. 
 
2.3. Biochemical Methods 
 
2.3.1. Beta-galactosidase assay 
 For NO detection using a beta-galactosidase assay, RKP2176 was transformed 
with pSU2718 and pSU2718-bNOS.  RKP2176 is an E. coli strain similar to RKP2178 
used by Poole et al. (1996) in which the native lacZ gene was inactivated and a hmp-lacZ 
fusion (Φ hmp-lacZ) was engineered. 
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 Overnight starter cultures of both RKP2176 harbouring pSU2718 (MS546) and 
pSU2718-bNOS (MS491) were used for a 1% inoculation of 10 mL of fresh M9 minimal 
medium supplemented with 0.1% casamino acids and 25 µg/mL chloramphenicol. 
Cultures were incubated at 37°C and 180 rpm until OD600nm was approximately 0.15, at 
which point 0.4 mM of IPTG and 10 mM of L-arginine were added. Beta-galactosidase 
activity was measured every 30 min as follows: OD600nm of each culture was recorded at 
every time point, and 50 µL of cell culture directly removed from the cuvette was mixed 
with 450 µL of Z-buffer (see section 2.1.4.8.) in a glass test tube. 5 µL of a 0.1% (w/v) 
sodium dodecyl sulphate (SDS) solution and 10 µL of chloroform were added to each 
tube, and samples were vortexed for at least 10 s, to ensure disruption of the cell 
membrane, and placed in a water bath at 28°C for 5 min. The assay was started by adding 
100 µL of a 4 mg/mL ortho-Nitrophenyl-ȕ-galactoside (ONPG; dissolved in Z-buffer) 
solution, and the reaction was stopped when a yellow colour developed by adding 250 µL 
of a 1 M Na2CO3 solution. Both start and end times were recorded. Absorbance at 420 nm 
(A4420nm) and at 550 nm (A550nm) were measured for each sample in quartz cuvettes and 
using a “no cell” control sample (50 µL of fresh M9 minimal medium supplemented with 
0.1% casamino acid was used instead of cell culture) to blank the Shimadzu UV-1800 
spectrophotometer.  Miller units were calculated as follows: 
 �����ݎ ܷ��ݐݏ = ͳͲͲͲ × ሺ�ͶʹͲ − ሺͳ.͹ͷ × �ͷͷͲሻሻሺݐ ×  ሺʹ ×  ܸሻ  ×  ��͸ͲͲሻ 
 
in which ‘A4β0’ is absorbance at 4β0 nm, ‘A550’ is absorbance at 550 nm, ‘t’ is time of 
assay (in min), ‘V’ is volume of cell culture used (in mL), and ‘OD600’ is the optical 
density of culture at 600 nm.  
 
2.3.2. Griess assay 
Activation of macrophages was assessed by indirectly assessing NO production 
through quantification of one of the oxidation products, nitrite. This was achieved using 
the Griess assay (Griess, 1879). Briefly, nitrite standard solutions with concentrations 
ranging from 0 to 25 µM were prepared in DMEM complete medium and dispensed into 
a 96-well microtiter in triplicate (50 µL per well). 50 µL samples of culture supernatants 
(from activated macrophages) were also dispensed in triplicate. 50 µL of a sulphanilamide 
solution (1% sulphanilamide in 5% phosphoric acid) was added to both sample and nitrite 
standard wells. After a 10 min incubation at room temperature in the dark, 50 µL of a 
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0.1% (w/v) solution of N-(1-naphtyl) ethylenediamine dihydrochloride (NED) was added 
to each well, followed by a 10 min incubation at room temperature in the dark. 
Absorbance at 540nm (A540nm) was read using a SPECTROstar nano microplate reader 
(BMG Labtech). The data was averaged, and the average of the 0 µM standard was 
subtracted from all other averages obtained for the standards, as well as the samples, prior 
to plotting, and a line was fitted using linear regression. The concentration of nitrite from 
experimental samples was obtained using the equation of the line fitted for the standard 
samples. 
 
2.4. Bioinformatics Methods 
 
2.4.1. Whole genome sequencing data 
2.4.1.1. Assembly and annotation 
Prior to assembling the reads obtained with Illumina® MiSeq, their quality was 
assessed with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) and 
trimmed using Trimmomatic (Bolger et al., 2014), which improves the quality of the 
reads by removing sequencing adapters, trimming bases at beginning and end of reads if 
they fall below the stipulated quality threshold and eliminates reads that do not possess 
the necessary minimum read length (36 bp by default). A de novo assembly of the reads 
was carried out using SPAdes Genome Assembler (Bankevich et al., 2012), and Mauve 
(Darling et al., 2004) was used to order the resulting contigs to a reference genome. For 
this purpose, the genome sequence of E. coli MG1655 (NC_000913.3) was used followed 
by an automated annotation using Prokka (Seemann, 2014). With the exception of 
FastQC, trimmommatic, and Mauve, all other tools were accessed and used through the 
MRC CLIMB microbial informatics infrastructure funded under grant reference 
MR/L015080/1. 
 
2.4.1.2. Screening for antibiotic resistance genes, virulence genes, and replicons 
Genome sequences were mined for acquired antibiotic resistance genes, virulence 
genes, and replicon presence using ABRicate (https://github.com/tseemann/abricate) to 
search the ResFinder v2.1 database (Zankari et al., 2012) for hits above 98% identity and 
above 90% coverage, the VFDB database (Chen et al., 2005) also for hits above 98% 
identity and above 90% coverage, and the PlasmidFinder v1.3 database (Carattoli et al., 
2014) for hits above 80% identity and above 90% coverage, respectively. For detection 
of fluoroquinolone resistance, the protein sequence of gyrase subunit A was extracted 
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from all the genomes, and aligned with T-Coffee (Notredame et al., 2000). Shading was 
accomplished using BoxShade 3.21 server (https://embnet.vital-
it.ch/software/BOX_form.html). ABRicate was accessed and used through MRC CLIMB 
microbial informatics infrastructure funded under grant reference MR/L015080/1. 
 
2.4.1.3. Protein and DNA alignments  
 Protein sequences were aligned with T-Coffee (Notredame et al., 2000), and 
BioEdit v.7.2.5 (Hall, 1999) was used to calculate protein identity and similarity of each 
pairwise alignment. Where required, alignments were carried out with references 
MG1655 (NC_000913.3), EC958 wild-type (NZ_HG941718.1), and CFT073 
(NC_004431.1). Structural analyses were performed using RaptorX (Källberg et al., 
2012) and CCP4MG software (McNicholas et al., 2011). Whole-genome sequence 
alignments were achieved using the online tool GVIEW server (https://server.gview.ca/). 
In brief, the genbank file of E. coli MG1655 (NC_000913.3) genome was uploaded as 
the reference genome, and FASTA files of each of the isolates of the Kent collection were 
uploaded as query files and organized accordingly to their sequence-type. The default 
settings were applied for comparison (i.e. 100% sequence coverage; 80% sequence 
identity). 
 
2.4.1.4. Phylogenetic analysis 
The core genome of the isolates in the Kent collection was determined with Roary 
(Page et al., 2015) using MG1655 genome sequence as a reference (NC_000913.3) and 
default settings for percentage sequence identity (95%). The core genome gene alignment 
output by Roary was then used as input in FastTree v2.1.9 (Price et al., 2009; Price et al., 
2010), and phylogenetic relationships between the isolates determined. The resulting file 
was upload into the online tool iTOL v3 (Letunic and Bork, 2016) for editing. For 
phylogenetic group determination, the Clermont method was used (Clermont et al., 2011; 
Clermont et al., 2013). In brief, the genomic sequence of each isolate was concatenated 
in FASTA format and used for in silico PCR using Unipro UGENE platform 
(Okonechnikov et al., 2012) with the primer sequences used by Clermont et al. (2013). 
Both Roary and FastTree were used through MRC CLIMB microbial informatics 










Exploring the use of NO as an 




























Urinary tract infections (UTI) are amongst the most common infections in 
humans, with E. coli being the etiological agent responsible for many UTIs worldwide. 
As the antibiotic resistance problem worsens, treatment of UTIs becomes increasingly 
more problematic. Hence, the development of new drugs and alternative therapies is 
imperative. Nitric oxide is endogenously produced by the mammalian immune system in 
response to invading pathogens and, as such, the use of NO as a stand-alone alternative 
therapeutic or in combination with conventional antibiotics is an attractive option. This 
chapter explores the potential for engineering a NO-producing asymptomatic UTI strain 
of E. coli to out-compete disease-causing strains in the bladder. 
An attempt to engineer NO-production into E. coli UTI strain 83972 was carried 
out by expression of the NO synthase enzyme (bNOS) from S. aureus, and the efficacy 
of this system (i.e. NO production) was assessed using a Φhmp-lacZ fusion E. coli strain. 
In addition, it was of interest to engineer NO tolerance in the same strain: various NO-
tolerance mechanisms present in E. coli were tested for their importance in uropathogenic 
strains under different oxygen conditions, and it is shown that under microaerobic 
conditions (i.e. the conditions encountered by E. coli during urinary tract infection), 
flavohaemoglobin Hmp-mediated protection has a predominant role. Simultaneous 
overexpression of Hmp and bNOS in E. coli 83972 under microaerobic conditions and 
endogenous production of NO by E. coli, which naturally outcompetes other 
uropathogenic strains of E. coli, could provide an alternative to conventional antibiotics. 
Overexpression of flavohaemoglobin Hmp resulted in increased sensitivity to GSNO in 
both the presence (low aeration) and absence of oxygen, leading us to speculate that the 
overexpression of Hmp is toxic to bacterial cells beyond the formation of superoxide. 
While insertion of the bNOS gene into the chromosome of E. coli 83972 was unsuccessful 
despite the many attempts, it was possible to clone a functional bNOS gene from S. aureus 












 For the most part, E. coli is a harmless bacterium and part of the intestinal flora 
of many mammals. However, some strains have acquired virulence traits that allows them 
to colonize different niches and establish infection. Urinary tract infections (UTI) are the 
most common infections in humans, and E. coli (i.e. uropathogenic E. coli – UPEC) is 
responsible for more than 80% of UTIs (Totsika et al., 2012; Bien et al., 2012). 
Conventional antibiotics such as amoxicillin were used for the treatment of 
uncomplicated UTI for a long time, but emergence of antibiotic resistance has forced a 
switch to other antibiotics. Currently nitrofurantoin is the antibiotic of choice, however it 
shows decreased efficacy in the treatment of acute kidney infection (pyelonephritis) due 
to its poor tissue penetration (Totsika et al., 2012).  
 
3.2.1. Asymptomatic bacteriuria (ABU) 83972 
Urinary tract infections can be symptomatic or asymptomatic. Symptomatic UTI 
are caused by uropathogenic strains of E. coli actively expressing a plethora of virulence 
factors, while asymptomatic UTIs are caused by asymptomatic bacteriuria (ABU) E. coli 
strains. The reasons why patients infected with ABU strains do not develop symptoms 
are still poorly understood, although transcriptomic and comparative genomic studies of 
ABU prototype strain 83972 revealed that this may not be due to a lack of virulence 
potential (i.e. potential to cause disease due to presence of virulence genes). 96% of the 
genes expressed by 83972 are also found in CFT073 (Welch et al., 2002), a well-known 
UPEC strain that is highly virulent (Hancock and Klemm, 2007). Interestingly, 
microarray studies from the urine of infected patients have revealed that most of the 
virulence genes of E. coli 83972 were down-regulated (Roos et al., 2006; Roos and 
Klemm, 2006), leading to the hypothesis that the down-regulation of virulence genes was 
necessary for long-term colonization, since some virulence genes, such as fimbriae, are 
responsible for activation of the immune system (Roos et al., 2006). Interestingly, E. coli 
83972 does not express functional type I fimbriae due to a truncation in the fim operon, 
and also possesses a non-functional pap operon, both of which have previously been 
shown to be important for ascending UTI (Klemm et al., 2006). Nevertheless, the growth 
rate of E. coli 83972 in urine is higher than other more virulent UPEC strains, and it has 
been shown by Roos et al. (2006) that E. coli 83972 is capable of outcompeting other 
UPEC strains. These characteristics of E. coli 83972 make this strain useful as a 
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prophylactic treatment in spinal injury patients that are susceptible to recurring UTI (Hull 
et al., 2000). 
In this work, it was hypothesized that engineering of an E. coli 83972 NO 
tolerant/NO producing strain by overexpression of its flavohaemoglobin Hmp and 
insertion of a functional bNOS gene onto its chromosome, combined with its natural 
ability to outcompete other UPEC strains, would result in an alternative and more 










Figure 3.1 – NO-tolerant/NO-producing E. coli 83972 as an alternative treatment for UTIs. 
It was hypothesized that overexpression of flavohaemoglobin Hmp and insertion and expression 
of bNOS in E. coli 83972, an asymptomatic strain of E. coli capable of long-term colonization of 
the bladder and of naturally outcompeting UPEC strains, would result in an aggressive alternative 
treatment for hard-to-treat UTIs. Colour scheme: light-orange - NO-tolerant/NO-producing E. 





3.3.1. Assessment of the role of bacterial NO protective mechanisms in pathogenic 
E. coli  
E. coli possesses several mechanisms that allow it to cope with the toxic effects 
of NO and other RNS (Figure 1.3). These mechanisms have been intensely studied in E. 
coli K-12 strains, although studies of their importance in pathogenic strains are scarce. 
To investigate the importance of each known mechanism that participates in NO-
tolerance, several single knockouts mutations were engineered into E. coli EC958, a well-
characterized ST131 multidrug resistant UPEC (Totsika et al., 2011; Forde et al., 2014). 
The role of the hybrid cluster Hcp-Hcr system in NO tolerance was exhibited and 
published by Wang et al. (2016) at a later date, and as such this system was not tested in 
the present studies.  
 
3.3.1.1. Well-diffusion assays 
In several previous studies, a disc-diffusion assay has been used to test the 
sensitivity of E. coli to different NO-donors. In Flatley et al. (2005), discs were saturated 
with a 100 mM solution of the NO-donor (and nitrosating agent) GSNO and placed on 
bacterial lawns to assess tolerance to GSNO. In this work, a similar protocol was followed 
to assess sensitivity to GSNO of the different EC958 knockout mutants. However, the 
protocol proved ineffective as no zones of inhibition were observed for any of the mutants 
in either M9 minimal agar or LB agar. It was hypothesized that the reactive nature of 
GSNO combined with poor agar diffusion could be limiting its potency. Hence, a well-
diffusion assay was combined with a ‘pour plate’ technique for generating bacterial 
lawns. In this assay, mid-exponential growing cultures were mixed with M9 minimal agar 
before pouring into petri plates; 6-mm wells were cut into the agar and a freshly prepared 
80 mM solution of GSNO was used to fill each well. This method allowed us to not only 
use more GSNO solution (80 µL per well) but also to improve the exposure of bacteria to 
GSNO (Figure 3.2), thus increasing the overall efficacy. 
Under aerobic conditions, both cydAB and cydDC mutants show higher sensitivity 
for GSNO compared to the isogenic wild-type strain (Figure 3.3), with the cydAB strain 
also exhibiting sensitivity under microaerobic conditions (Student’s unpaired t-test; p-
value < 0.05). Loss of hmp also impairs growth in the presence of GSNO under both 






conditions, only the loss of flavorubredoxin NorV and the partner reductase NorW 
induces GSNO sensitivity (Student’s unpaired t-test; p-value < 0.05) (Figure 3.3). 
 
 
3.3.1.2. NOC-12 growth curves and complementation 
To determine if the growth inhibition observed in the well diffusion assay is NO 
specific and not merely due to other by-products of GSNO decomposition, the wild-type, 
hmp and cydAB strains (hmp- and cydAB- respectively) were grown in M9 minimal 
medium supplemented with 0.1 % casamino acids in the presence and absence of an 
alternative NO-donor, NOC-12. In addition, to determine if the growth impairment was 
solely due to the loss of hmp or cydAB, and not a result of polar effects caused by 
Figure 3.2 – Diagram of GSNO diffusion. A) In a disc diffusion assay, a filter paper disc 
saturated with GSNO solution is placed on top of a growing lawn of bacteria. The diffusion of 
GSNO occurs in two directions (arrows). However, downward diffusion will have minimal 
impact on the lawn of bacteria at the surface of the agar. B) In a well diffusion assay, bacteria 
are imbedded in the agar and GSNO diffusion from the well occurs only sideways, enhancing 
exposure of bacteria to GSNO. 
Figure 3.3 – GSNO sensitivity of EC958 knockout mutants. GSNO sensitivity of each mutant 
was tested in different oxygen conditions and compared to wild-type isogenic strain. Each data 
point reflects the mean of six replicates from three independent cultures. Error bars represent 
standard deviation. (*: Student’s unpaired t-test p-value < 0.05). 
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insertional mutagenesis, the knockout strains were transformed with a plasmid encoding 
hmp or cydAB (hmp+ and cydAB+ respectively) cloned downstream of the inducible lac 
promoter. In the presence of 0.1 mM NOC-12 both hmp- and cydAB- exhibited growth 
impairment (Figure 3.4C and 3.4E), with doubling times (Figure 3.4A) being significantly  
 
Figure 3.4 – Complementation of the NOC-12-sensitive growth phenotype of hmp and cydAB 
mutants. EC958 knockout hmp and cydAB mutants were transformed with pSU2718-G-hmp and 
pSU2718-G-cydABX expression plasmids, respectively. Cultures were grown in M9 minimal 
media supplemented with 0.1% casamino acids and with glucose as the carbon source. 96-well 
plates were incubated at 37°C and 100 rpm, the latter providing low aeration and better mimicking 
the microaerobic conditions encountered in the human urinary tract (B to F). Doubling times (A) 
were measured for 1.5h following addition of NOC-12 (0 or 0.1 mM) for all strains. Each data 
point reflects the mean of five replicates. Error bars represent standard deviation. (*: Student’s 




different (Student’s unpaired t-test p-value < 0.05) than the no treatment control (0 mM 
NOC-12); complemented strains show no significant difference to the ‘no treatment’ 
control (Student’s unpaired t-test p-value > 0.05). No NOC-12 growth sensitive 
phenotype was observed for the EC958 wild-type isogenic strains (Figure 3.4A-B). 
GSNO sensitivity for the complemented mutant strains was also assessed using the well-
diffusion assay (Figure 3.5). While the diffuse nature of zones of inhibition for the cydAB- 
strain precluded a quantitative measure of sensitivity, restoration of growth was 




3.3.2. Engineering NO-tolerance in E. coli 
3.3.2.1. Overexpression of hmp 
The loss of hmp and cydAB resulted in a significant increase in GSNO 
susceptibility under microaerobic conditions (Figure 3.3). Thus, we hypothesized that 
overexpression of hmp could increase tolerance to NO. To test this hypothesis, a strategy 
Figure 3.5 – Complementation of GSNO-sensitive growth phenotype of hmp and cydAB 
mutants. Well-diffusion assay was used for a qualitative observation of the complementation of
the GSNO-sensitive growth phenotype. EC958 cydAB and hmp mutants (hmp- and cydAB-, panels 
A and C respectively) and their respective complemented strains (hmp+  and cydAB+ , panels B 
and D respectively) were grown in M9 minimal media to OD600nm~0.5, at which point 1 mL of 
culture was mixed with 19 mL of M9 minimal agar and plated. Wells were cut into the agar and 










Figure 3.6 – Desired locus of the hmp gene following replacement of the native promoter with Pbla. Substitution of the native hmp promoter with the constitutive 
ampicillin resistance gene promoter (Pbla). A chloramphenicol cassette and Pbla were amplified from pKD3 – with primers Hmp_Pbla_F and Hmp_Pbla_R – and 
introduced onto the E. coli chromosome via lambda-red insertional mutagenesis.  To achieve this, the primers contained 50 bp regions that were homologous to regions 
of the hmp locus (as indicated on the diagram by the grey areas identified as “Homology_region”). Primers Hmp_Sc_fw and Hmp_Sc_rev were the screening primers 
used for the colony PCR. 
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was devised to constitutively express the chromosomal copy of hmp in E. coli 83972, 
which involved substitution of the native hmp promoter with the constitutive promoter of 
the ampicillin resistance gene (Pbla). Primers were designed to amplify the Pbla promoter 
from the pKD3 plasmid (Datsenko and Wanner, 2000) to generate a fragment that also 
included the chloramphenicol resistance cassette to be used as a selective marker (Figure 
3.6). The primers also included a 50 bp overhang each, homologous to the desired 
recombination sites on the E. coli chromosome. The resulting PCR fragment was inserted 
into 83972 and MG1655 strains of E. coli (via electroporation), both harbouring pKD46 
that encodes the lambda-red recombinase (Datsenko and Wanner, 2000). Several attempts 
to produce a Hmp-overexpressing (Pbla-hmp) E. coli 83972 strain proved unsuccessful. 
However, insertion of the ampicillin resistance gene promoter upstream of hmp was 
achieved for E. coli MG1655: colony PCR revealed two colonies with a band between 
1500-2000 bp (expected molecular size for positive colonies: 1859 bp). E. coli MG1655 




3.3.2.2. Assessment of hmp-overexpressing E. coli MG1655 sensitivity to GSNO 
Figure 3.7 – Colony PCR confirming insertion of fragment. Insertion of Pbla promoter-
containing fragment into chromosome of E. coli MG1655 was confirmed in two transformants 
(‘Colony 1’ and ‘Colony β’ lanes) by colony PCR using screening primers Hmp_Sc_fw and 
Hmp_Sc_rev. For the negative control (‘Negative’ lane), DNA template was omitted from the 
reaction. For the positive control (‘Positive’ lane), one colony from E. coli MG1655 wild-type 
strain was used for DNA template (expected molecular size: 387 bp). 
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To determine whether constitutive expression of hmp afforded additional 
protection to GSNO, wild type and Pbla-hmp MG1655 strains were grown under low 
aeration/microaerobic conditions (Figure 3.8A-B) in M9 minimal medium in the presence 
of different concentrations of GSNO (0 mM, 1 mM, or 5 mM). Under low 
aeration/microaerobic conditions the Pbla-hmp strain exhibited a longer lag phase both in 
the presence and absence of GSNO. Despite reaching similar final cell densities, in the 
presence of 5 mM GSNO the lag phase is much longer in Pbla-hmp, suggesting a higher 
sensitivity to this compound. For growth under anoxic conditions, cells were growth 
statically at 37°C in sealed serum bottles filled to the top with M9 minimal media. As 
expected, the overall growth for both strains is lower under anaerobic conditions 
compared to microaerobic conditions. Moreover, Pbla-hmp (Figure 3.8D) exhibits higher 
sensitivity to GSNO than the wild-type strain (Figure 3.8C) under these conditions, with 
growth in the presence of 5 mM GSNO being almost abolished. 
  
  
Figure 3.8 – Sensitivity of hmp-overexpressing strain to GSNO. Cells were grown in M9 
minimal media at 37°C in 96-well plates at 100 rpm (for low aeration/microaerobic growth; panels 
A and B) or at 37°C, statically in filled serum bottles (for anaerobic growth; panels C and D). A 
fresh solution of GSNO was added for a final concentration of 0, 1, or 5 mM. Each data point 
reflects the mean of at least three different replicates from three independent cultures. Error bars 
represent standard deviation. 
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3.3.3. Engineering a NO-producing E. coli strain 
An initial aim was to insert the bNOS-encoding gene from S. aureus into the non-
functional fim locus of E. coli 83972. This, along with overexpression of the chromosomal 
copy of hmp, would then be used to generate a NO-tolerant/NO-producing strain which 
could potentially be used as an alternative to conventional antibiotics to combat UTIs. 
Despite the unsuccessful attempts to generate a NO-tolerant strain, engineering of an E. 
coli NO-producing strain was carried out by cloning of bNOS into a plasmid expression 
vector. 
 
3.3.3.1. Cloning of bNOS 
 bNOS was amplified from the genomic DNA of S. aureus MRSA USA300, a 
Gram-positive bacteria known to possess a chromosomal copy of bNOS (Van Sorge et 
al., 2013). The gene was amplified by PCR, cloned onto pSU2718 downstream of the  
IPTG-inducible Plac promoter (Figure 3.9A) and introduced into chemically competent E. 
coli BW25113 via transformation. Transformants were screened by colony PCR 
(expected molecular size for plasmid containing bNOS: 1197 bp) (Figure 3.9B), and E. 
coli BW25113 cells containing the pSU2718-hmp plasmid were used as a positive control 
for the PCR reaction (expected size: 1415 bp) (Figure 3.9B). Further confirmation of 
recombinant colonies (Figure 3.9B; Colony 5) was obtained by extraction of the plasmid 
and preparation of single (BamHI) and double (BamHI and FspI) restriction reactions, 
and subsequent DNA sequencing. 
 
3.3.3.2 Detection of NO production in bNOS-expressing E. coli cells 
After confirming the correct pSU2718-bNOS construct had been constructed, this 
plasmid was introduced into E. coli RKPβ176 Φhmp-lacZ (MS486), an identical strain to 
RKP2178 described in Membrillo-Hernández et al., (1996). This strain was also 
transformed with the empty pSU2718 vector as a control. Since it is well-known that the 
hmp promotor repression by NsrR is alleviated in response to NO (Filenko et al., 2007; 
Tucker et al., 2008), this hmp-lacZ fusion strain would allow for detection of NO by 
measuring beta-galactosidase activity. Beta-galactosidase assays were conducted in M9 
minimal media under aerobic conditions. Cells were grown to early exponential phase, at 
which point IPTG was added to induce bNOS expression, followed by addition of L-
arginine to ensure substrate availability (for the bNOS enzyme). Beta-galactosidase 
activity was measured every 30 min for a total of 2.5 h. After addition of IPTG and L-





Figure 3.9 – Cloning of bNOS. A) Genetic map of the plasmid containing cloned bNOS gene 
from S. aureus USAγ00. B) Colony PCR of eight transformants (‘Colony 1-8’ lanes) was 
performed using the primers pSU2718nssR_seqF and pSU2718nssR_seqR to identify colonies 
with the correct recombinant plasmid (i.e. Colony 5; expected molecular size: 1197 bp). For the 
‘Negative control’, DNA template was omitted from the PCR reaction. For the ‘Positive control’, 
E. coli BW25113 harbouring pSU2718-hmp plasmid was used for DNA template (expected 
molecular size: 1415 bp). 
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control (pSU2718) (Figure 3.10). Furthermore, beta-galactosidase activity remained 
higher than that observed for the control throughout the course of the assay (Figure 3.10), 


















Figure 3.10 – Assessment of NO production by bNOS. A beta-galactosidase assay was used to 
determine NO production by monitoring the expression of hmp in an E. coli Φhmp-lacZ strain 
harbouring pSU2718-bNOS or the empty pSU2718 vector (control). Assay was performed in M9 
minimal medium under aerobic conditions. Each data point reflects the mean of three different 





3.4.1. Flavohaemoglobin Hmp, cytochrome bd-I, and flavorubredoxin NorVW 
confer tolerance to nitric oxide in a multidrug resistant E. coli strain 
Nitric oxide tolerance mechanisms have been identified and studied in E. coli K-
12 strains. However, studies of the importance of these systems in pathogenic E. coli are 
limited. To determine the importance of these systems in the multidrug resistant E. coli 
EC958 strain, a well diffusion assay was developed and found to be a more useful tool to 
measure GSNO sensitivity compared to disc diffusion assays. In the well-diffusion 
assays, two halos were often observed (Figure 3.5): one closer to the well in which no 
bacterial growth was observed, and a second in which bacterial growth is observed but 
slightly distinct from the growth observed in the rest of the plate. It was hypothesized this 
second halo could be due to lower GSNO concentrations further from the well causing 
intermediate bacteriostatic effects. Hence, for this reason only the inner zones of 
inhibition were evaluated where possible. The well-diffusion data confirmed that the 
flavohaemoglobin Hmp and cytochrome bd-I respiratory oxidase as the two main systems 
that confer protection against GSNO under both aerobic and microaerobic conditions 
(Figure 3.3). This was confirmed with complementation studies by expressing hmp or 
cydABX from a plasmid in the presence and absence of NOC-12 (Figure 3.4) or GSNO 
(Figure 3.5). Interestingly, the final cell density achieved by the complemented cydAB+  
was lower than that achieved by the wild-type or complemented hmp+  strains in the 
absence of NOC-12. It is important to note that complementation of cydAB relied solely 
on the basal expression provided by leaky Plac promoter, as it was observed that induction 
with IPTG concentrations as low as 0.1 mM caused severe growth impairment in both 
absence and presence of NOC-12. Aerobic bacterial respiration generates ROS (Kohanski 
et al., 2007; Dwyer et al., 2014; Lobritz et al., 2015) thus a tight regulation of respiratory 
oxidases is necessary to maintain bacterial viability. Hence, we suggest that even basal 
expression of cydABX from pSU2718-G-cydABX is enough for an increase in endogenous 
ROS production to levels that can still be slightly toxic to cells, and in the presence of the 
NO-donor NOC-12 this effect is more pronounced due to formation of toxic radicals such 
as peroxynitrite. This growth impairment also made it impossible to accurately measure 
the zones of inhibition of cydAB- when the well-diffusion assay was performed, hence 
only a qualitative approach was carried out using this assay to determine if the 
complementation was successful (Figure 3.5).  
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The loss of cydDC causes a significant increase in GSNO susceptibility under 
aerobic conditions compared to wild-type. This glutathione/L-cysteine ABC exporter is 
necessary for the assembly of cytochrome bd-I (Georgiou et al., 1987; Poole et al., 1994; 
Goldman et al., 1996), a role which explains the phenotype observed. However, contrary 
to expected, no significant susceptibility to GSNO was observed for the cydDC mutant 
under microaerobic conditions, conditions in which cytochrome bd-I expression is known 
to be maximal (Fu et al., 1991). Flavorubredoxin NorV and its partner reductase, NorW, 
were shown to have a prominent protective role against GSNO in the absence of oxygen. 
Because the main aim was to engineer a NO-tolerant/NO-producing strain that could be 
used to combat infections in the urinary tract, which is a microaerobic environment 
(Hagan et al., 2010), a complementation experiment was not attempted for this system. 
Moreover, the growth impairment exhibited by cydAB+ , along with the well-documented 
NO-detoxifying capability of Hmp, are the reasons why overexpression of hmp was 
chosen as a strategy to engineer a NO-tolerant strain. 
 
3.4.2. Constitutive expression of Hmp does not confer additional protection to NO 
Substitution of the native Phmp promoter for the constitutive Pbla promoter was 
unsuccessful in E. coli 83972 but successful in an E. coli MG1655 background. Under 
low aeration/microaerobic conditions, the MG1655 Pbla-hmp strain exhibited a longer lag 
phase than its isogenic counterpart. While Anjum et al. (1998) and Wu et al. (2004) have 
previously shown that overexpression of Hmp under aerobic conditions exacerbates 
intracellular oxidative stress through the generation of superoxide radicals, it was 
hypothesised that lowering the oxygen would diminish this effect and permit the 
generation of an NO tolerant strain without a severe growth phenotype. However, the 
Pbla-hmp strain exhibited a longer lag phase compared to the wild type, and also displayed 
higher sensitivity to GSNO. This could be explained by the levels of oxygen still being 
too high, and the resultant superoxide generated by Hmp reacting with NO released by 
GSNO to form highly toxic peroxynitrite. In McLean et al. (2010), anaerobic growth of 
a nsrR mutant strain of Salmonella Typhimurium, which overexpresses Hmp due to loss 
of its negative regulator, exhibited higher tolerance to peroxynitrite than when grown 
under aerobic conditions. Due to the unwanted toxicity problems, even under low aeration 
conditions, the sensitivity to GSNO of the Pbla-hmp strain was tested in the absence of 
oxygen. Interestingly, in the presence of 5 mM GSNO, anaerobic growth of the Hmp-
overexpressing strain was severely impaired. Constitutive expression of Hmp will result 
in very high levels of this flavohaemoglobin regardless of oxygen concentration, whereas 
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under anaerobic conditions the Salmonella nsrR mutant did not overexpress Hmp, 
presumably due to activity of FNR. One might postulate that these very high levels of 
Hmp might place additional demands upon the cell that could render the cell sensitive to 
GSNO, although it is premature to speculate what the underpinning mechanism may be.   
 
3.4.3. NO-production by bNOS in E. coli 
Despite the unsuccessful attempt at engineering a NO-tolerant E. coli 83972 
strain, the cloning of bNOS was carried out. S. aureus bNOS was cloned into pSU2718 
vector, and assessment of bNOS functionality was undertaken by measuring beta-
galactosidase activity in a Φhmp-lacZ strain (Figure 3.10). A higher beta-galactosidase 
activity, i.e. higher hmp expression, was observed for the strain harbouring pSU2718-
bNOS, thus suggesting that the bNOS construct is producing active bNOS. Quantification 
of both nitrate and nitrite, products of NO oxidation, from supernatants of bacterial cells 
expressing bNOS was attempted with a modified Griess assay. This proved to be an 
unreliable approach to study NO production in these engineered strains, perhaps due to 
slow NO production by bNOS resulting from poor cofactor insertion or availability of 
arginine in the cytoplas or resulting from a rapid turnover of nitrate and nitrite by E. coli 
cells. Alternatively, since the bNOS enzyme only comprises the haem-containing oxidase 
domain and therefore requires a redox partner (or endogenous reductants such as GSH) 
to supply reducing power for the reaction to take place, perhaps the availability of 
reductants is the limiting factor for the modest NO production observed herein.  
 
3.4.4. NO-producing/NO-tolerant E. coli as an alternative therapy: is it possible? 
Due to the involvement of NO in critical biological functions, its use in the 
treatment of diseases is not a new concept. In fact, inhalation of nitric oxide is used to 
treat neonatal pulmonary hypertension (Wessel et al., 1997; Hunt et al., 2016). Due to its 
antimicrobial properties, a strategy was devised to engineer a NO-producing/NO-tolerant 
strain that could potentially be used to fight multidrug resistant UTIs. 
In this project a NO-producing E. coli strain was engineered by expressing bNOS 
(from S. aureus) from a plasmid. However, NO production was only achieved using an 
indirect method, i.e. a beta-galactosidase assay that quantified hmp promoter activity, and 
thus NO levels cannot be accurately inferred in this instance. Ideally, a more direct 
method of NO quantification, such as using a NO electrode, should have been used. The 
levels of NO being produced by bNOS are not the only limitation arising in this project. 
The very reactive nature of NO, combined with the cytoplasmic localization of bNOS in 
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our engineered E. coli strain, will limit the diffusion of NO to the point of very little to 
no NO diffusing to the outside of the cell and reach the intended target. Targeting bNOS 
to the periplasmic space could potentially circumvent this issue: NO would have less 
cellular targets to react with (compared to cytoplasm) which would result in a better 
diffusion and, potentially, higher levels of NO reaching the invading pathogen. 
Furthermore, the main NO detoxification mechanism of E. coli in the presence of oxygen 
(i.e. flavohaemoglobin Hmp) is localized in the cytoplasm, thus the periplasmic location 
of bNOS, and hence periplasmic production of NO, reduces the chance of 
flavohaemoglobin Hmp to completely interfere with NO levels. 
Despite the absence of bacteria in urine in healthy individuals, it is becoming 
increasingly accepted that the bladder itself is not a sterile environment and, in fact, 
possesses a microbiome with a protective role (Brubaker and Wolfe, 2016; Thomas-
White et al., 2016). In view of this information, one must consider the effects that NO 
will have on the natural microbiome; affecting the microbiome of the bladder in any way 
may, in fact, be more harmful to the host. 
To engineer a NO-tolerant strain of E. coli, the wild-type hmp promoter was 
replaced by the constitutive Pbla promoter, and NO susceptibility was determined. Whilst 
increased sensitivity to GSNO in the presence of oxygen (Figure 3.8, panel A and B) 
could be explained by formation of superoxide (Membrillo-Hernández et al., 1996; Mills 
et al., 2001; Wu et al., 2004), the sensitivity exhibited under anaerobic conditions was 
surprising. It is possible that this sensitivity could be due to toxicity caused by high levels 
of flavohaemoglobin protein expression. However, this hypothesis would have to be 
tested by assessing the levels of flavohaemoglobin Hmp with a western blot, using the 



















Phenotypic and genotypic 


























The emergence of antibiotic resistance has become a cause for concern as it is 
leading to an increase in mortality and morbidity associated with bacterial infections. 
Hence, not only is it necessary to find alternative therapies to combat resistant and multi-
drug-resistant bacteria but to also monitor the appearance and dissemination of antibiotic 
resistance and antibiotic-resistant clones to better understand the problem and also to 
administer the most suitable treatment to patients and prevent patient relapse. 
In this chapter, 50 bacteraemia E. coli isolates (i.e. collected from the blood of 
patients), were characterized phenotypically and genotypically for clonal lineage, 
antibiotic resistance, virulence, and presence of plasmids. Whilst most of the collection 
remained sensitive to all antibiotics experimentally tested, resistance to commonly used 
antibiotics such as amoxicillin and trimethoprim was highly prevalent. 14% of the clinical 
isolates showed a multidrug-resistant phenotype, with this number increasing to 30% 
when antibiotic resistance was detected by mining the genome sequences of the isolates 
for acquired resistance genes. However, in silico detection of antibiotic resistance resulted 
in many false negatives, mainly for ciprofloxacin resistance. In addition, in silico 
detection produced false positives for antibiotic resistance, mainly for chloramphenicol. 
Thus, whilst a convenient tool to detect antibiotic resistance, caution needs to be taken 
when interpreting in silico results and the data should always be complemented with a 
phenotypic assay.  
Despite observing that ST73 isolates were, on average, more virulent and less 
resistant, and ST131 isolates were, on average, less virulent and more resistant, no 
correlation between both variables was detected in the isolate collection as a whole. 
However, an association between resistance and specific virulence factors cannot be 
discounted. 
 Evidence of an association between CTX-M-15 and aac(3)-IIa, aac(6')Ib-cr, and 
blaOXA-1 is shown, and could explain why ESBL-producing isolates often exhibit a 
multidrug-resistant phenotype. Moreover, an association between certain virulence genes 
and phylogenetic group B2, which comprises sequence-types known to be associated with 









E. coli is usually a commensal bacterium and part of the normal human intestinal 
flora, where it promotes normal intestinal function and rarely causes disease. Some strains 
of E. coli, however, acquired certain genes (e.g. virulence genes) and took on a more 
pathogenic nature towards the host, and are thus capable of causing a broad spectrum of 
diseases. Pathogenic E. coli can be further subdivided according to their site of infection: 
enteropathogenic E. coli (EPEC) are responsible for many intestinal infections, 
particularly in infants, and extraintestinal pathogenic E. coli (ExPEC) are responsible for 
extraintestinal infections such as neonatal meningitis and UTIs. ExPEC are the most 
common cause of infection in humans and E. coli is the etiological agent responsible for 
80% of UTIs (Totsika et al., 2012; Bien et al., 2012).  
The ability of pathogenic E. coli to adapt and colonize new niches, combined with 
the emergence of antibiotic resistance, has led to a serious worldwide threat. One 
particular clonal type of E. coli, ST131, is the predominant lineage among ExPEC 
isolates. ST131-type strains, often associated with UTIs, are widespread and commonly 
reported to have an ESBL phenotype and exhibit fluoroquinolone resistance. 
Furthermore, it has been suggested that ST131 are responsible, at least in part, for the 
current increase of antibiotic-resistant E. coli, particularly ESBL-producing and 
fluoroquinolone-resistant E. coli (Johnson et al., 2010). This clonal group also contains a 
large virulence repertoire, and it was proposed that the combination of high antibiotic 
resistance levels and virulence genes confers an advantage to ST131 over other E. coli 
clonal groups, facilitating its dissemination (Johnson et al., 2010; Peirano et al., 2013). 
This combination contradicts the belief that increased levels of antibiotic resistance has a 
negative impact on fitness, thus resulting in less pathogenic strains (Johnson, Gajewski, 
et al., 2003; Houdouin et al., 2006; Moreno et al., 2006; Johnson et al., 2010).  
The emergence of E. coli ST131 highlights the need to better understand the molecular 
mechanisms behind pathogenicity and how this might affect antibiotic resistance. 
Furthermore, a deeper understanding of the magnitude of the problem is also of the utmost 
importance. Whole genome sequencing is a powerful tool which could be used for these 
purposes. It would allow collection of important information, such as antibiotic resistance 
and virulence genes, in one single step, as well as the identification of novel targets for 
antibiotics or vaccines. In fact, whole genome sequencing  was successfully used to screen 
the genome of serogroup B meningococcus and identify several conserved, surface-
exposed antigens, which were then experimentally tested and used to develop a vaccine 
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against Neisseria meningitidis (Pizza et al., 2000; Savino et al., 2006). The use of whole 
genome sequencing for molecular diagnostics is not currently well established in clinical 
settings, but its application is predicted to assist with epidemiological typing, support 
clinicians during outbreaks, and improve patient treatment (Ellington et al., 2012; Köser 



































4.3.1. General genome features 
In this work, the 50 E. coli bacteraemia isolates, collected from East Kent Hospitals 
University NHS Foundation, that comprise the designated Kent collection, were 
phenotypically and genotypically characterized. For the latter, whole genome sequencing 
was performed by preparing a library containing the genomic DNA of the clinical isolates 
using the Nextera® XT DNA Library Prep Kit, which is optimized for small genomes. 
This kit uses a transposome complex to simultaneously fragment genomic DNA and 
insert adapter sequences. The following PCR step uses the adapter to amplify the DNA 
fragments and add specific index sequences to each genomic DNA sample, thus allowing 
sequencing of pooled libraries. Following library preparation, samples were sequenced 
using an Illumina MiSeq benchtop sequencer. Key advantages of this sequencer include 
a fast run time and low-cost per run and per base pair, making it the ideal sequencer for 
small sequencing projects such as the one carried out in this work. The resulting short 
paired-end reads were assessed for quality with FastQC before and after trimming of the 
reads using Trimmomatic (Bolger et al., 2014), which removes the adapter sequences 
inserted during genomic DNA library preparation, as well as low quality bases and reads 
from the data. The trimmed reads were used as input in SPAdes Genome Assembler 
(Bankevich et al., 2012) for a de novo assembly of the bacterial genome. The resulting 
contigs were subsequently re-ordered using the genome of E. coli MG1655 as reference 
(NC_000913.3) with Mauve (Darling et al., 2004) and annotated with Prokka (Seemann, 
2014). 
The general features of all 50 E. coli genomes following assembly and annotation 
are shown in table 4.1. The smallest genome belonged to KC20 (4.66 Mb) and the largest 
to KC27 (5.52 Mb), and there is a clear linear relationship between the size of a genome 
and the number of CDS present (Figure 4.1) despite a relatively constant CDS density 
(0.93 ± 0.01 genes per kb) in all isolates of the collection.  
 







(Mb) No. contigs No. CDS 
CDS density (CDS 
per kb) 
188 KC1 5.18 134 4812 0.93 
189 KC2 5.18 120 4861 0.94 
190 KC3 4.85 90 4476 0.92 
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191 KC4 5.13 117 4716 0.92 
192 KC5 5.08 109 4691 0.92 
193 KC6 5.01 137 4697 0.94 
194 KC7 5.14 134 4780 0.93 
195 KC8 5.33 166 4959 0.93 
196 KC9 5.27 195 4953 0.94 
197 KC10 5.00 127 4687 0.94 
198 KC11 5.21 229 4945 0.95 
199 KC12 4.73 83 4402 0.93 
200 KC13 5.41 187 5124 0.95 
201 KC14 4.88 408 4611 0.94 
202 KC15 5.18 106 4813 0.93 
203 KC16 5.16 149 4767 0.92 
204 KC17 4.79 104 4440 0.93 
205 KC18 5.31 181 5059 0.95 
206 KC19 4.96 135 4588 0.92 
207 KC20 4.66 183 4278 0.92 
208* KC21 5.27 81 4965 0.94 
209 KC22 4.91 118 4577 0.93 
210 KC23 5.30 218 4922 0.93 
211 KC24 4.90 403 4553 0.93 
212 KC25 4.94 351 4554 0.92 
213 KC26 4.78 1016 4434 0.93 
214* KC27 5.52 385 5145 0.93 
215 KC28 4.88 408 4613 0.94 
216 KC29 5.21 184 4826 0.93 
217 KC30 5.26 154 4857 0.92 
218 KC31 5.22 851 4997 0.96 
219 KC32 5.04 233 4692 0.93 
220 KC33 5.33 270 5052 0.95 
221 KC51 5.10 216 4703 0.92 
222 KC35 5.03 250 4677 0.93 
223 KC36 4.66 721 4380 0.94 
224 KC37 4.95 339 4556 0.92 
225 KC38 4.93 56 4584 0.93 
226 KC39 5.23 236 4871 0.93 
227 KC40 5.23 265 4842 0.93 
228 KC41 5.10 146 4802 0.94 
229 KC42 5.28 148 4956 0.94 
230 KC43 5.10 73 4765 0.94 
231 KC44 5.08 144 4674 0.92 
232 KC45 5.31 188 4899 0.92 
233 KC46 5.28 246 4929 0.93 
234 KC47 5.34 162 4979 0.93 
235 KC48 5.22 207 4818 0.92 
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236 KC49 5.03 174 4676 0.93 
237 KC50 5.13 135 4762 0.93 
* Sequencing of these isolates was initially unsuccessful. As such, whole genome sequencing of these 
isolates was performed by MicrobesNG (Birmingham). 
 
 
4.3.2. Clonal and phylogenetic analyses 
4.3.2.1. Multi-locus sequence typing  
Multi-locus sequence typing (MLST) was performed according to the Achtman 
typing scheme (Wirth et al., 2006), which uses the internal sequence of seven 
housekeeping genes (adk, fumC, gyrB, icd, mdh, purA, and recA) to assign each E. coli 
strain to a specific sequence type (ST). Each sequence is searched against a database and 
assigned an allelic profile number, and each ST is determined based on the combination 
of the seven alleles. 
In total, 23 different STs were identified in the collection. The most prevalent STs 
in the Kent collection was ST73 (n=9; 18%), followed by ST69 (n=7; 14%) and ST131 
(n=6; 12%). Sixteen isolates (32%) represented their own ST, with four of the isolates in 
the collection not assigned to any known ST, and thus represent four novel STs. A 
minimum spanning tree (Figure 4.2) was constructed based on the MLST profile 
(Appendix A-1) to illustrate the clonal relationship based solely on the allelic profile of 
the seven housekeeping genes. Two of the four novel STs (?2 – KC33; ?3 – KC51) differ 
from ST131 and ST73, respectively, by one single allele, and singletons ST685, ST421, 
ST1618 also share six identical alleles (out of seven) with ST10, ST95, and ST73, 
respectively. All other STs identified differ from other STs by three or more alleles. 





4.3.2.2. Whole genome alignment 
A whole genome sequence comparison circular map was generated using the 
BLAST atlas setting of the GView server (https://server.gview.ca/) (Figure 4.3). While 
there is some degree of genetic variation between STs, within the isolates of a particular 
ST very little variation is observed. The backbone of ST404 and ST640 genomes exhibit 
less variability among themselves, in comparison with the higher variability observed in 
isolates within ST73, ST131, ST69, ST10, and ST95. In ST69, most of the genetic 
variability appears to originate from KC28 (represented by the fourth lane, from the 
inside, of the ST69 set in figure 4.3). 
 
4.3.2.3. Pan- and core-genome 
Described for the first time by Medini et al. (2005), the term pan-genome refers 
to the complete collection of genes present in a bacterial species (Figure 4.4) and 
Figure 4.2 – Minimum spanning tree of E. coli STs from the Kent collection. Partitions 
indicate the proportion of isolates in the collection belonging to the indicated ST. Strains within 
the same ST possess seven identical alleles; a single locus variant possesses one different allele 
to the other ST; a triple locus variant differs by three alleles; and a more than triple locus variant
differs by more than three alleles. The four unassigned STs are identified as ‘?1’ (KC17), ‘?β’ 





comprises the core genome (i.e. the set of genes shared by all strains of a bacterial species 
and involved in fundamental physiological functions and phenotypic traits of the bacterial 
species), the dispensable genome (i.e. the set of genes present in only a small subset of 
strains), and unique genome (i.e. a set of genes present in only one strain) (Figure 4.4). 
Both the ‘dispensable’ and ‘unique’ genome encode proteins not essential for bacterial 
growth and instead possess genes that confer a selective advantage (e.g. antimicrobial 
resistance genes or virulence genes) (Medini et al., 2005). 
The tool Roary (Page et al., 2015) was used to determine the distribution of core 
and dispensable genes in the Kent collection and in E. coli MG1655. Briefly, the general 
feature format (GFF) file of each genome generated by Prokka (Seemann, 2014) was used 
in Roary as input, which converted complete CDS nucleotide sequences to protein 
sequences, followed by a protein BLAST comparison of all sets of protein sequences (one  
Figure 4.3 – Whole genome comparison of E. coli MG1655 with the 50 clinical isolates of 
the Kent collection. The inner black ring corresponds to E. coli MG1655 and with each lane 
thereafter corresponding to a genome. Isolates were coloured according to their ST (colour-key 
legend is on the right). The four outermost lanes correspond to the isolates of unknown ST. Blank 
spaces indicate that the gene at that position in the reference genome is not found in the genome 





per genome). The pan-genome of the Kent collection, including E. coli MG1655, is made 
up of 13,172 genes in total (Figure 4.5A). Only approximately 19.6% of the genes 
(n=2,580) are a part of the core genome (i.e. present in all isolates), while accessory genes 
make up the remaining 80.4% (n=10,592) of the entire pan-genome (Figure 4.5A). The 
pan-genome of E. coli is an open pan-genome (Figure 4.5B) meaning the number of total 
genes increases with every new genome added. 
The multi-FASTA alignment file of the core genes created by Roary was used as 
input in FastTree (Price et al., 2009; Price et al., 2010) to deduce the approximately-
maximum-likelihood phylogenetic relationship of the isolates of the Kent collection 
based on single nucleotide polymorphisms (SNPs) present in the core genome (Figure 
4.6), and in silico PCR was used to determine the phylogenetic group of each E. coli 
isolate according to the Clermont quadruplex method (Clermont et al., 2013). 
Phylogenetic group B2 forms the basal group, with all other phylogenetic groups 
diverging later, and phylogenetic group A diverging last (Figure 4.6). Interestingly, 
KC20, also assigned to phylogenetic group B2, is shown to diverge much later than the 
remaining members of phylogenetic group B2, and is more closely related to members of  
phylogenetic group A. Over half of the entire collection (n=33; 65%) was assigned to 
phylogenetic group B2, including the isolates of sequence-type ST131, ST73, ST95, 
ST404, and three of the four isolates with novel STs.  Interestingly, KC28, also belonging 
to ST69, was assigned to phylogenetic group A, along with KC14 and KC36 (both ST10),  
Figure 4.4 – Venn diagram of the pan-genome. The pan-genome is described as the pool of 





and commensal E. coli MG1655. Apart from KC28 (ST69) and KC10 (ST131) that are 
assigned to phylogenetic group A and unknown phylogenetic group, respectively, STs 
with more than one isolate were assigned to the same phylogenetic group (Figure 4.6). 
Isolates from the same ST often cluster together, sharing a recent common ancestor. 
 
4.3.3. Antibiotic resistance analysis  
The phenotypic antibiotic resistance profile of the Kent collection was determined  
Figure 4.5 – The pan-genome of the Kent collection. A) The pan-genome of the Kent collection, 
including E. coli MG1655, comprises a total of 13,172 genes, with only 19% of these genes 
forming the core genome. B) The Kent collection exhibits an open pan-genome, with the number 





using disc diffusion assays (see Appendix B-1 and Appendix C-1 for full characterization 
of the Kent collection). Resistance to nine antibiotics was experimentally tested: 
penicillins (amoxicillin – AMX), cephalosporins (cefotaxime – CTX), phenicols 
(chloramphenicol – CAP), fluoroquinolones (ciprofloxacin – CIP), aminoglycosides 
(gentamicin – GEN), carbapenems (meropenem – MEM), nitrofurans (nitrofurantoin – 
NIT), trimethoprim (TMP), and polypeptides (polymyxin E/colistin – PME). More than 
half of the collection – 56% (n=28) of the isolates remained sensitive to all antibiotics 
tested, while the remaining isolates (n=22) exhibited resistance to at least one of the 
antibiotics tested, with seven of these isolates (14%) exhibiting a multidrug-resistant 
phenotype (i.e. resistant to three or more antibiotic classes) (Magiorakos et al., 2012) 
(Figure 4.7A). Three of the isolates (6%) exhibited resistance to cefotaxime (Figure 
Figure 4.6 – Dendrogram for the genetic relationships of E. coli isolates in the Kent 
collection. Phylogenetic relationship of the E. coli isolates of the Kent collection was inferred 
based on SNPs present in the core genome. For all isolates, the ST is indicated besides their KC 
number. Apart from KC10 (highlighted in white), all isolates were assigned to a phylogenetic 
group: phylogenetic group A in yellow; phylogenetic group B1 in orange; phylogenetic group B2
in blue; phylogenetic group D in green; and phylogenetic group F in red. 
94 
 
4.7A), and further analysis of their genome revealed the presence of the highly 
disseminated ESBL CTX-M-15 (Nicolas-Chanoine et al., 2008; Lau et al., 2008). The 
highest level of resistance was observed for amoxicillin (n=21; 42%), followed by 
trimethoprim (n=14: 28%) and ciprofloxacin (n=9; 18%) (Figure 4.7B). No isolate in the 
collection exhibited resistance to either meropenem or colistin (Figure 4.7B). 
 
 
The experimental phenotypic data obtained for antibiotic susceptibility was 
compared with the in silico data obtained by mining the genome sequences of all isolates 
for antibiotic resistance genes (Figure 4.8). For this purpose, the tool ABRicate was used 
to search the ResFinder 2.1 database (Zankari et al., 2012) and detect known acquired 
Figure 4.7 – Antibiotic susceptibility of the Kent collection. A) 14% of the isolates in the 
collection (n=7) exhibited a multidrug-resistant (MDR) phenotype, with 6% (n=3) displaying 
resistance to cephalosporins (cefotaxime) and shown to possess the ESBL CTX-M-15. B) The 
highest level of resistance is observed for amoxicillin (AMX), with 42% of the isolates (n=21) 
exhibiting resistance; no resistance was observed towards meropenem (MEM) and colistin 
(PME). Antibiotics tested are as follows: amoxicillin (AMX), cefotaxime (CTX), 
chloramphenicol (CAP), ciprofloxacin (CIP), gentamicin (GEN), meropenem (MEM), 
nitrofurantoin (NIT), trimethoprim (TMP), and colistin (PME). 
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resistance genes displaying ≥ 98% sequence identity over a minimum of 90% coverage 
of the gene. In silico detection of antibiotic resistance genes allowed for the detection of 
resistance to three extra classes of antibiotics that were not experimentally tested: 
macrolide-lincosamide-streptograminB (MLS), sulphonamides (SUL), and tetracycline 
(TET) (Figure 4.8). This revealed a total of 15 isolates (30%) with multidrug resistance, 
approximately twice as many as the ones revealed with the phenotypic assay. 
Analysis of both in silico and experimental data revealed that ST131 strains 
exhibit higher levels of antibiotic resistance than the other sequence-types, and ST73 
strain exhibit lower levels of antibiotic resistance. In silico analysis also confirmed a 
higher prevalence of resistance to amoxicillin (beta-lactams) and trimethoprim 
(sulphonamides) in the collection. However, it is important to note that the distribution of 
antibiotic resistance is not in complete agreement between both sets of data (in silico vs. 
experimental data).  
 Fisher’s exact test (two-tailed) was used to test the significance of the association 
between resistance/sensitivity and phylogenetic group (B2 vs. non-B2), although no 
significant relationship was found between both variables (p-value > 0.05). 
 
 
4.3.4. Virulence repertoire 
Virulence factors (VFs) were detected by mining the genome of each isolate with 
ABRicate. A total of 151 different genes encoding known VFs were detected among all 
the 50 isolates and used to predict the virulence potential of each isolate. Isolates with the 
Figure 4.8 – Antibiotic resistance prevalence for the most common sequence types of the 
Kent collection. In silico analysis of genomic sequences identified resistance to two more classes 
of antibiotics (MLS and TET). In both data sets, ST131 isolates exhibit higher levels of antibiotic 
resistance, while ST73 exhibit the lowest levels of resistance. 
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highest number of virulence genes theoretically possess a higher potential for virulence. 
The virulence potential (i.e. the % of the 151 VFs identified in a given isolate) of the 
collection ranged from a minimum of 21.9% (n=33) for KC20 (ST685), to a maximum 
of 69.5% (n=105) for KC16 (ST73), and an average of 49.1% observed for the entire 
collection. On average, ST73 strains exhibited a higher virulence potential (62%) than the 
other two main sequence-types identified in this study, ST69 (50%) and ST131 (43.9%) 
(Figure 4.9). Virulence genes entA, fepA, fyuA, fimH, and ompA show a high prevalence 
(> 80%) in all sequence-types (Figure 4.9). 
 
 
The statistical significance of the association of virulence genes and phylogenetic 
groups (B2 vs. non-Bβ) was tested with Fisher’s exact test (two-tailed) (Table 4.2). The 
genes set1A, set1B, hlyA, pic, papB, papE, chuA, and kpsM were significantly more 
prevalent (p-value < 0.05) in phylogenetic group B2 (Table 4.2), with an overall higher 
prevalence in ST73 isolates (Figure 4.9). Furthermore, no significant correlation was 
found between antibiotic resistance and virulence potential (Pearson r = - 0.0097, p-value 
= 0.95) (Appendix D-1). 
 
4.3.5. Plasmid typing 
The use of whole genome sequencing allows for the capture of sequencing data 
derived from both the bacterial chromosome and from any plasmids that might be present. 
While the assembly of plasmids from WGS short-read sequencing data is extremely 
difficult, some bioinformatic predictive tools have been developed to allow for plasmid 
Figure 4.9 – Prevalence of selected virulence genes in predominant STs. The prevalence of a 
small selection of virulence genes in the three main STs identified in the collection was assessed. 
ST73 exhibits a higher virulence potential than other the STs identified in the collection. 
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Table 4.2 – Presence of virulence genes in each phylogenetic group 
 
  No. of isolates (%) 
Trait Gene1 Total Phylogenetic group   
A (n = 3) B1 (n = 4) B2 (n = 33) D (n = 7) F (n = 2) Unknown (n = 1) p-value2 
Adherence afaA 6 (12) 0 (0) 0 (0) 6 (18.2) 0 (0) 0 (0) 0 (0) - 
 draD 4 (8) 0 (0) 0 (0) 4 (12.1) 0 (0) 0 (0) 0 (0) - 
 draP 6 (12) 0 (0) 0 (0) 6 (18.2) 0 (0) 0 (0) 0 (0) - 
 fimH 49 (98) 3 (100) 4 (100) 32 (97.0) 7 (100) 2 (100) 1 (100) - 
 focA 7 (14) 0 (0) 0 (0) 7 (21.2) 0 (0) 0 (0) 0 (0) - 
 papA 1 (2) 0 (0) 0 (0) 1 (3.0) 0 (0) 0 (0) 0 (0) - 
 papB 31 (62) 0 (0) 0 (0) 24 (72.7) 5 (71.4) 1 (50) 1 (100) 0.0254 
 papC 20 (40) 0 (0) 0 (0) 16 (48.5) 4 (57.1) 0 (0) 0 (0) - 
 papD 21 (42) 0 (0) 0 (0) 16 (48.5) 4 (57.1) 1 (50) 0 (0) - 
 papE 9 (18) 0 (0) 0 (0) 9 (27.3) 0 (0) 0 (0) 0 (0) 0.0198 
 papF 21 (42) 0 (0) 0 (0) 16 (48.5) 4 (57.1) 1 (50) 0 (0) - 
 papG 20 (40) 0 (0) 0 (0) 15 (45.5) 4 (57.1) 1 (50) 0 (0) - 
 sfaS 3 (6) 0 (0) 0 (0) 3 (9.1) 0 (0) 0 (0) 0 (0) - 
Iron uptake chuA 33 (66) 0 (0) 0 (0) 32 (97.0) 0 (0) 1 (50) 0 (0) < 0.0001 
 
entA  48 (96) 2 (66.7) 4 (100) 32 (97.0) 7 (100) 2 (100) 1 (100) - 
 
fepA 50 (100) 3 (100) 4 (100) 33 (100) 7 (100) 2 (100) 1 (100) - 
 
fyuA 45 (90) 3 (100) 2 (50) 31 (93.9) 6 (85.7) 2 (100) 1 (100) - 
 
iroN 19 (38) 1 (33.3) 2 (50) 16 (48.5) 0 (0) 0 (0) 0 (0) - 
 
iutA 12 (24) 2 (66.7) 0 (0) 5 (15.2) 4 (57.1) 1 (50) 0 (0) - 




ibeA 6 (12) 0 (0) 0 (0) 6 (18.2) 0 (0) 0 (0) 0 (0) - 
 
kpsM 38 (76) 0 (0) 0 (0) 31 (93.9) 5 (71.4) 2 (100) 0 (0) < 0.0001 
 
kpsT 9 (18) 0 (0) 0 (0) 8 (24.2) 0 (0) 1 (50) 0 (0) - 
Toxin astA 4 (8) 0 (0) 0 (0) 3 (9.1) 1 (14.3) 0 (0) 0 (0) - 
 
cnf1 6 (12.5) 0 (0) 0 (0) 6 (18.2) 0 (0) 0 (0) 0 (0) - 
 
gtrA 2 (4) 0 (0) 0 (0) 2 (6.1) 0 (0) 0 (0) 0 (0) - 
 
hlyA 11 (22) 0 (0) 0 (0) 11 (33.3) 0 (0) 0 (0) 0 (0) 0.0091 
 
pic 9 (18) 0 (0) 0 (0) 9 (27.3) 0 (0) 0 (0) 0 (0) 0.0198 
 
sat 28 (56) 2 (66.7) 0 (0) 19 (57.6) 5 (71.4) 1 (50) 1 (100) - 
 
senB 16 (32) 0 (0) 0 (0) 13 (39.4) 3 (42.9) 0 (0) 0 (0) - 
 
set1A 11 (22) 0 (0) 0 (0) 11 (33.3) 0 (0) 0 (0) 0 (0) 0.0091 
  set1B 11 (22) 0 (0) 0 (0) 11 (33.3) 0 (0) 0 (0) 0 (0) 0.0091 
          
1) Not all VF detected are present in this table 
      











prediction and typing from WGS data sets. In this work, the ABRicate tool was used to 
mine the assembled and re-ordered genome of the isolates of the Kent collection against 
the PlasmidFinder database (Carattoli et al., 2014), to identify replicon sequences (i.e. 
plasmid origins of replication). Each replicon is assigned to an incompatibility group, 
with the premise that plasmids within the same incompatibility group cannot co-exist 
within the same bacterial cell.  
IncFIB replicons were highly prevalent in the collection (74%), followed by 
Col(156) (66%), and IncFII (54%) replicons. In contrast, IncI2, IncN, IncX1, IncX4, 
IncY, and p0111 replicons were the least prevalent (2%). Except for five isolates (KC5, 
KC17, KC25, KC26, and KC44), at least one replicon was identified in all remaining 
isolates of the collection, including in isolates which exhibited a pan-susceptible 
phenotype (Table 4.3). Interestingly, the four main IncF incompatibility groups identified 
in the collection (IncFIA, IncFIB, Inc FIC, and IncFII) are all present in the three isolates 
(KC18, KC33, and KC45) that exhibit multidrug resistance, ciprofloxacin resistance 
arising from the presence of aac(6')Ib-cr, and identified as CTX-M-15 ESBL (Table 4.3). 
 





number Replicons Notes 
MS188 KC1 Col(156); IncFII Pan-susceptible 
MS189 KC2 Col(MG828); Col(RNAI) Pan-susceptible 
MS190 KC3 IncFIB; IncFIC; IncFII; IncQ1 MDR; Ciprofloxacin resistance 
MS191 KC4 Col(MG828); Col(RNAI); IncFIA; IncFIB; IncFII 
 
MS192 KC5 - Pan-susceptible 
MS193 KC6 Col(156); Col(pVC); IncFIB; IncFII; IncI2 
 
MS194 KC7 IncFIB; IncFII; IncI1; IncN Ciprofloxacin resistant 
MS195 KC8 
Col(MG828); Col(156); 
IncB/O/K/Z; IncFIB; IncFIC; 
IncFII 
 












MS199 KC12 Col(RNAI) Pan-susceptible 






Col(156); Col(RNAI); IncFIB; 
IncFIC; IncFII 
Pan-susceptible 
MS202 KC15 Col(156); IncFIB; IncFIC; IncFII 
 
MS203 KC16 IncFIB; IncFIC; IncFII Pan-susceptible 
MS204 KC17 - Pan-susceptible 
MS205 KC18 IncFIA; IncFIB; IncFIC; IncFII MDR; Posesses CTX-M-15; Ciprofloxacin resistant 
MS206 KC19 IncFIA; IncFIB; IncFII MDR; Ciprofloxacin resistant 
MS207 KC20 Col(RNAI) Pan-susceptible 
MS208 KC21 Col(BS512); Col(MG828); IncB/O/K/Z; IncFIB; IncFII Pan-susceptible 
MS209 KC22 Col(RNAI); IncI1 Pan-susceptible 
MS210 KC23 
Col(MG828); Col(156); 
Col(8282); IncFIB; IncFIC; 
IncFII 
Pan-susceptible 
MS211 KC24 Col(MG828); Col1(56); Col(8282); IncFIB; IncFII Pan-susceptible 
MS212 KC25 - Pan-susceptible 
MS213 KC26 - Pan-susceptible 
MS214 KC27 Col(156); IncFIB; IncFII Pan-susceptible 
MS215 KC28 
Col(MG828); Col(MP18); 
Col(156); Col(RNAI); IncFIB; 
IncFIC; IncFII 
 
MS216 KC29 Col(156); IncFIB; IncFIC; IncFII 
 
MS217 KC30 Col(MG828); IncFIA; IncFIB; IncFII; IncQ1 
 
MS218 KC31 Col(MG828); Col(156); IncFIB; IncFII Pan-susceptible 
MS219 KC32 Col(RNAI); IncFIB; IncFIC; IncFII Pan-susceptible 
MS220 KC33 IncFIA; IncFIB; IncFIC; IncFII MDR; Posesses CTX-M-15; Ciprofloxacin resistant 
MS221 KC51 Col(MG828); Col(156); Col(RNAI); IncFIB; IncFII Pan-susceptible 
MS222 KC35 Col(RNAI); IncFIB; IncFIC; IncFII Pan-susceptible 
MS223 KC36 Col(MG828); Col(pVC); Col(RNAI); IncFIB; IncFII Pan-susceptible 
MS224 KC37 Col(MG828); IncFIB; IncFIC; IncFII Pan-susceptible 
MS225 KC38 
Col(MG828); Col(8282); 
Col(RNAI); IncFIB; IncFIC; 
IncFII 
Pan-susceptible 
MS226 KC39 Col(156); IncFIB; IncFIC; IncFII 
 
MS227 KC40 Col(156); IncFIB; IncFII Pan-susceptible 
MS228 KC41 Col(MG828); Col(156); Col(RNAI); IncFIB; IncFII Pan-susceptible 
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MS229 KC42 Col(156); Col(RNAI); IncFIB; IncFII Pan-susceptible 
MS230 KC43 Col(156); Col(RNAI); IncFIB; IncFII Pan-susceptible 
MS231 KC44 - Pan-susceptible 
MS232 KC45 Col(156); IncFIA; IncFIB; IncFIC; IncFII; p0111 
MDR; Posesses CTX-M-15; 
Ciprofloxacin resistant 
MS233 KC46 Col(156); IncFIB; IncFII; IncI1  
MS234 KC47 Col(156); Col(8282); IncFIB; IncFII; IncQ1 MDR; Ciprofloxacin resistant 
MS235 KC48 IncB/O/K/Z  
MS236 KC49 Col(156); IncFIA; IncFIB; IncX1 MDR; Ciprofloxacin resistant 
MS237 KC50 
Col(156); Col(8282); 






























4.4.1. The E. coli genome 
Following genome assembly and annotation, general genome information for each 
isolate was gathered, including total genome size and number of genes in each genome. 
Unsurprisingly, comparison of genome size and number of genes showed a linear 
relationship between the two (Figure 4.1). Acquisition of mobile genetic elements, such 
as plasmids and pathogenicity islands, contribute to the genetic variability of E. coli. In 
fact, out of 13,172 unique genes present in the Kent collection, only 19% belong to the 
core genome, while the remaining 91% of genes vary among isolates, a testament to the 
variability encountered among E. coli clinical isolates.  
Interestingly, isolates belonging to phylogenetic groups F, D and B2 had, on 
average, larger genomes (5.26, 5.19, and 5.13 Mb respectively) than isolates belonging 
to phylogenetic groups A and B1 (4.81 and 4.84 Mb respectively). Assigning a 
phylogenetic group to an isolate can provide further information on the nature of the 
isolate, including phenotypic and genotypic traits, ecological niche, and pathogenicity 
(Clermont et al., 2013). Commensal strains of E. coli are routinely assigned to 
phylogenetic group A, while pathogenic strains are assigned to the remaining 
phylogenetic groups (Johnson and Stell, 2000). As such, phylogenetic group A, as well 
as phylogenetic group B1, a sister group of A (Gordon et al., 2008), contain isolates of 
low pathogenic potential. In contrast, phylogenetic groups B2, D, and F, with the latter 
comprising strains that are closely related to strains of group B2 (Clermont et al., 2011), 
contain more pathogenic strains. The results obtained above suggest the presence of extra 
genes that confer a greater ability to cause disease in strains belonging to phylogenetic 
groups B2, D, and F.  
 
4.4.2. E. coli isolates from the Kent collection are an epidemiologically 
heterogeneous population 
The Kent collection consisted of 23 different STs, including four novel ones. ST73 
was the most prevalent ST in the collection (Figure 4.2), contrasting with previous reports 
by Croxall et al. (2011) and Johnson et al. (2010) that reported a higher prevalence of 
ST131 in the UK and USA, respectively. However, the presence of E. coli ST131 in the 
collection further emphasises the widespread dissemination of this clonal group (Nicolas-
Chanoine et al., 2008). 
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Predictably, whole genome sequence alignment (Figure 4.3) revealed greater 
similarity between genomes of the same ST than between genomes of different STs. In 
ST69 isolates, the KC28 genome seems to differ greatly from the other six ST69 genomes. 
Further analysis revealed that KC28 was assigned to phylogenetic group A, while all other 
isolates belonging to ST69 were assigned to phylogenetic group D (Figure 4.6), and 
revealed a closer phylogenetic relationship with both ST10 in the collection (KC14 and 
KC36) and E. coli MG1655, all of which were assigned to phylogenetic group A. A 
similar scenario was observed for KC20 (ST685): while assigned to phylogenetic group 
B2, this strain exhibited a closer phylogentic relationship with isolates belonging to 
phylogroup A than the remaining members of phylogenetic group B2 (Figure 4.6). 
Overall, E. coli isolates cluster together according to phylogenetic group and also by ST, 
with phylogenetic group B2, which is associated with ExPEC virulence, forming the 
ancestral group from which all others diverged until the most recent phylogenetic group 
A, which comprises commensal strains. This is in accord with a study conducted by Le 
Gall and colleagues (Le Gall et al., 2007) which suggests that the E. coli ancestor was 
likely to be a facultative or opportunistic pathogen. Furthermore, the virulence potential 
observed between phylogenetic groups of the Kent collection was, on average, highest 
for phylogenetic group B2 (52.4%), of which ST73 isolates had the highest virulence 
potential, followed closely by phylogenetic groups D and F (52.1% and 47.7%, 
respectively), and finally sister phylogenetic groups B1 and A (36.4% and 28.9% 
respectively). Also, phylogenetic group B2 is known to comprise many asymptomatic 
strains of E. coli (Nicolas-Chanoine et al., 2014), of which E. coli 83972 is the archetypal 
strain. It was previously suggested that the ability of E. coli 83972 to colonize the urinary 
tract for long periods of time without evoking a host response is not due to the absence of 
virulence genes in its genome, but rather due to its ability to down-regulate the expression 
of the virulence genes that will activate host responses (Wullt et al., 2000; Roos et al., 
2006). These observations lead us to speculate on the advantage of virulence genes for 
the maintenance and dissemination of E. coli and propose that instead of acquisition of 
virulence genes, the opposite could have occurred during the evolutionary process of E. 
coli, giving rise to well-adapted commensal strains with smaller genomes and fewer 
genes, and thus avoiding the evolutionary pitfalls often found by pathogens that cause 




4.4.3. Relationships between CTX-M-15 and aac(3)-IIa, aac(6')Ib-cr, and blaOXA-1 
Despite over 50% of the Kent collection remaining sensitive to all nine antibiotics 
experimentally tested, a very high level of resistance was still observed, especially for 
amoxicillin, trimethoprim, and ciprofloxacin. This was unsurprising as these are three of 
the most commonly used antibiotics, hence there is a significant selective pressure driving 
the emergence of resistance to these antibiotics. Overall, 14% of the isolates exhibited 
multidrug resistance to antibiotics experimentally tested (Figure 4.7A). This number 
increased to 30% when analysing in silico data. It is important to note that the tool used 
to detect resistance genes in the genomic data of each isolate detected resistance genes 
belonging to three classes of antibiotics not tested experimentally, and it is very likely 
that the discrepancy between experimental and in silico datasets arises due to this 
phenomenon. Furthermore, in silico data obtained from ABRicate only contains known 
acquired resistance genes, while resistance to some antibiotics such as ciprofloxacin 
arises from mutations in the cellular target (e.g. DNA gyrase). As such, while three of the 
isolates carried the aac(6')Ib-cr  (Appendix C-1) resistance gene which confers resistance 
to some aminoglycosides but also resistance to low-levels of ciprofloxacin, the remaining 
isolates exhibiting a ciprofloxacin-resistant phenotype were not detected with ABRicate. 
Hence, a multiple sequence alignment of gyrase subunit A (GyrA) was performed 
(Appendix E-1), which is the main target for ciprofloxacin in E. coli. This was carried out 
to identify mutations known to confer ciprofloxacin resistance (Weigel et al., 1998), and 
enabled in silico confirmation for all experimentally-tested ciprofloxacin-resistant 
isolates. The inability of ABRicate (and the ResFinder v2.1 database) to identify 
resistance arising from mutations in the target protein could also explain why the 
nitrofurantoin resistance experimentally detected in KC3 was not identified in silico. 
Thus, while genome sequencing is a good tool to detect antibiotic resistance genes in 
genome sequences, phenotypic assays to detect resistance are preferable as they can detect 
resistance arising from both acquision of resistance genes and mutation on the antibiotic 
target, as well as detecting resistance which arises from currently unknown mechanisms. 
Interestingly, the three isolates carrying the aac(6')Ib-cr resistance gene also 
possessed codon changes that would result in amino acid substitutions in the GyrA protein 
(Appendix E-1). Analysis of the acquired resistance genes identified in silico (Appendix 
C-1) further showed that these three isolates (KC18, KC33, and KC45) were also the only 
isolates carrying ESBL CTX-M-15, aac(6')Ib-cr, aac(3)-IIa, and blaOXA-1, all of which 
confer resistance to antibiotics of different classes (Alekshun and Levy, 2007). CTX-M-
15 with blaOXA-1 and aac(6')Ib-cr are known to be located on IncF-type plasmids 
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(Carattoli, 2009), and four IncF-type replicon sequences were identified in the three 
isolates (Table 4.3). However, it was observed that the presence of an IncF-type plasmid, 
or the presence of any putative plasmid or number of plasmids, does not necessarily 
coincide with antibiotic resistance. In fact, many replicon sequences were identified in  
isolates that exhibited a pan-susceptible phenotype to all antibiotics tested (Table 4.3). 
Furthermore, carriage of CTX-M-15  and both of aac(3)-IIa and aac(6’)Ib-cr has been 
previously observed in K. pneumoniae isolates (Peerayeh et al., 2014). An association 
between these different resistance genes could explain the high levels of multidrug 
resistance often observed in CTX-M-15 ESBL-producing isolates (Nicolas-Chanoine et 
al., 2008; Hoban et al., 2010). 
 
4.4.4. No evidence for a correlation between antibiotic resistance and virulence 
For a long time, it was thought that antibiotic resistance and virulence were 
mutually exclusive in E. coli, with the former having a negative impact on fitness which 
would result in less pathogenic strains. However, the emergence and dissemination of 
ST131 isolates exhibiting significantly higher levels of antibiotic resistance and virulence 
(Johnson et al., 2010; Peirano et al., 2013) is not consistent with this model. Furthermore, 
it has been suggested that this correlation is the reason for the success of ST131 isolates 
(Nicolas-Chanoine et al., 2008; Johnson et al., 2010; Peirano et al., 2013). In this study, 
however, while ST131 was more resistant, on average, than the other two most prevalent 
STs (ST69 and ST73), ST131 did not exhibit higher levels of virulence. In fact, ST73 
isolates, which exhibit the lowest antibiotic resistance levels, exhibited, on average, the 
highest virulence potential. To determine whether a correlation exists between levels of 
antibiotic resistance (reflected by the number of antibiotics to which phenotypic 
resistance was detected) and virulence potential, the Pearson correlation coefficient was 
calculated (Appendix D-1) but no significant correlation was found between the two 
variables. 
A high prevalence of iron uptake genes (entA, fepA, and fyuA) was found in the 
collection. While colonizing the host, pathogenic strains encounter environments with 
low concentrations of free iron. Since iron is essential for bacterial growth and is 
sequestered in the body by the process of nutritional immunity, it is unsurprising that 
many pathogenic strains encode siderophores such as enterobactin (entA), 
ferrienterobactin (fepA), and yersiniabactin (fyuA). The high prevalence of fimH (type I 
fimbriae adhesin) and ompA (outer membrane protein A) was also found in a high number 
of both pathogenic and commensal E. coli strains (Salmon et al., 2003; Dhakal et al., 
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2008; Hagan et al., 2010). Overall, these results suggest that these genes might be broadly 
conserved among different sequence-types. 
Virulence genes set1A, set1B, hlyA, pic, papB, papE, chuA, and kpsM were 
significantly more prevalent in phylogenetic group B2, potentially  a reflection of the high 
prevalence of UPEC strains (e.g. ST131, ST73, and ST95) in this phylogenetic group, 
where  the virulence genes above are frequently encountered (Mobley et al., 1990; Wullt 
et al., 2000; Hagan and Mobley, 2007; Wiles et al., 2008; Bien et al., 2012; Nicolas-
































































Nitric oxide is a small molecule with important biological roles. In mammals, NO 
is produced by a specialized family of enzymes (mNOS family) and is involved in 
vasoregulation, platelet aggregation, and neurotransmission (Snyder and Bredt, 1992; 
Vallance, 2003). One member of the NOS family of enzymes (iNOS) is expressed in cells 
of the immune system, such as macrophages, and is involved in the response against 
invading pathogens during infection. In bacteria, the role of NO is not fully understood 
beyond its toxic effects, however it is known to be important for the life cycle of bacterial 
biofilms (Barraud et al., 2006; Barraud et al., 2015). Some Gram-positive bacteria possess 
mNOS homologues (bNOS), which provide an endogenous source of NO that has been 
shown to have an important role in the protection of these bacteria against oxidative stress 
associated with exposure to antimicrobials (Gusarov and Nudler, 2005; Shatalin et al., 
2008; Gusarov et al., 2009).  
The antimicrobial capabilities of NO and its natural occurrence in mammals, have 
made it a good candidate to be used as an alternative to antibiotics or co-administered 
with antibiotics to increase their efficacy (Reffuveille et al., 2015). However, several 
studies have demonstrated that ROS generation by the aerobic respiratory chain is 
inextricably linked to the lethality of various classes of antibiotics. Hence, herein we 
hypothesised inhibition of aerobic respiration by nitric oxide might abrogate the toxic 
effects of antibiotics. As such, experiments were designed to test the effects of nitric oxide 
on the lethality of gentamicin, a bactericidal antibiotic, against a well-characterized 
multidrug-resistant UPEC strain. Bacterial survival to gentamicin in the presence or 
absence of exogenously administered NO-donors (NOC-12 or GSNO) was determined 
for both planktonic cells and biofilms of E. coli EC958 wild-type, with both showing an 
increase in bacterial tolerance to gentamicin when NO is present. Furthermore, the effects 
of macrophage-derived NO combined with gentamicin treatment on bacterial intra-
macrophage survival was assessed, and although no significant differences in survival 
was observed for gentamicin, we cannot discard an effect for other bactericidal 
antibiotics.  
Recent work showed that exposure to bactericidal antibiotics increases bacterial 
respiration and leads to the accumulation of toxic ROS (Kohanski et al., 2007; Dwyer et 
al., 2014; Lobritz et al., 2015). Aerobic bacterial respiration is carried out by cytochrome 
oxidases, one of the main bacterial targets of NO. As such, we tested the susceptibility of 
E. coli EC958 strains lacking cytochrome bo’ (cyoA-) and cytochrome bd-I (cydAB-) to 
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gentamicin in the presence and absence of a NO-donor. The presence of GSNO increased 
bacterial survival in all the three strains tested. However, higher gentamicin tolerance was 
achieved in the strain of E. coli EC958 lacking cytochrome bd-I (cydAB-), suggesting that 
this respiratory oxidase is involved in antibiotic-mediated ROS generation, even in the 
presence of NO. This work has important implications for our understanding of antibiotic 


































5.2.1. Overview of bacterial energy generation 
 E. coli is a facultative anaerobic bacterium which can obtain energy in two ways: 
i) via substrate-level phosphorylation (e.g. glycolysis), or ii) via oxidative 
phosphorylation, where an electron transport chain is responsible for generating a proton 
motive force (PMF) that is then used to drive ATP synthesis by the ATP synthase. 
Alternative routes for ATP production in E. coli confer a certain degree of metabolic 
flexibility that can respond to environmental changes and energetic needs. For example, 
under anoxic conditions, E. coli can either perform substrate-level phosphorylation if a 
fermentable carbon source is present (e.g. glucose) or perform oxidative phosphorylation 
in the presence of alternative electron acceptors (e.g. nitrate). There is, however, a 
hierarchy, with aerobic respiration, i.e. oxygen as the final electron acceptor, taking 
precedence over anaerobic respiration, which in turn takes precedence over fermentation. 
Fermentation is an anaerobic process that does not result in the formation of a PMF to 
drive the ATP synthase, and thus exhibits the lowest energy yield out of the three 
processes. Aerobic and anaerobic respiration both generate a PMF, which is an efficient 
route for the conservation of energy that is used in the generation of ATP. 
 Inhibition of the electron transport chain can severely impair antibiotic lethality 
by decreasing metabolism, thus reducing toxic by-products generated by the bacterial cell 
during antibiotic exposure (Dwyer et al., 2014), or due to decreased expression of the 
antibiotic cellular target expression; or by disruption of PMF, in which case antibiotics 
whose uptake is PMF-dependent are unable to reach their cellular target (e.g. 
aminoglycosides) (Hancock, 1981; Allison et al., 2011). 
The main E. coli pathogen used in the current work is the urosepsis-causing 
EC958 strain (Totsika et al., 2011; Forde et al., 2014), and during infection of the urinary 
tract E. coli encounters a predominantly microaerobic environment (Hagan et al., 2010). 
Hence, the aerobic respiratory chain of E. coli will be discussed in detail below. 
 
5.2.2. Aerobic respiration in E. coli 
E. coli possesses a branched aerobic respiratory chain and can express different 
respiratory complexes depending upon the environmental conditions. The aerobic 
respiratory chain in E. coli is comprised of two main classes of respiratory complexes: 
NADH dehydrogenases (NDH-1 or NDH-2) and cytochromes oxidases (cytochrome bo’ 
or cytochrome bd-I). E. coli also contains a third respiratory oxidase, Cytochrome bd-II, 
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that is expressed under phosphate and carbon limitation (Atlung and Brondsted, 1994; 
Vitaliy B. Borisov et al., 2011; Vitality B. Borisov et al., 2011): this complex is not a 
major focus of the current study. Both NADH dehydrogenases feed electrons into the 
system by transferring them from NADH onto the quinone pool on the cytoplasmic 
membrane (Figure 5.1). However, while NDH-1 has a stoichiometry of four protons 
translocated for every NADH oxidised (i.e. two electrons), NDH-2 does not translocate 
protons to the periplasmic space (Matsushita et al., 1987) and, as such, does not contribute 
to generation of the PMF. The cytochrome oxidases perform the terminal step in the 
electron transport chain, the reduction of oxygen to water, a reaction linked to the re-
oxidation of the quinone pool and re-setting of the system (Figure 5.1). 
 
 
5.2.2.1. Cytochrome bo’ 
Cytochrome bo’ is a transmembrane enzyme that catalyses the reduction of 
oxygen to water, during which it also functions as a proton pump and translocates protons 
from the cytoplasm into the periplasmic space, contributing to the generation of a PMF 
(Puustinen et al., 1989) (Figure 5.1). The reduction of molecular oxygen occurs in the 
binuclear haem-copper site, making it a member of the haem-copper superfamily of 
terminal oxidases (Abramson et al., 2000; Stenberg et al., 2007). 
Figure 5.1 – Aerobic respiratory chain of E. coli. NADH dehydrogenase I catalyses the 
oxidation of NADH and transfers two electrons (e-) into the quinone pool. In a well-aerated
environment, cytochrome bo’ oxidase is expressed and catalyses the reduction of oxygen to water, 
coupled with the translocation 4 protons (H+) per 2e- via both scalar and vectorial proton 
translocation. In a microaerobic environment, E. coli maximally expresses cytochrome bd-I. This
cytochrome oxidase reduces oxygen to water and has a ratio of 1H+ per e- that is supported solely
by vectorial proton translocation. Unlike NDH-1, NDH-2 does not translocate protons. 
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In E. coli, cytochrome bo’ is encoded by the cyoABCDE operon, with cyoABCD 
encoding subunits II, I, III and IV of the cytochrome respectively, and cyoE encoding a 
proto-haem farnesyltransferase (haem o synthase) (Chepuri et al., 1990; Saiki et al., 
1993). Tseng and colleagues used a cyo-lacZ fusion to show that expression of 
cytochrome bo’ is maximal in highly aerated conditions (air saturation above 15%) 
(Tseng et al., 1996), with expression of cyoA-lacZ decreasing by 140-fold in 
anaerobically cultured cells (Cotter et al., 1990). Moreover, under low oxygen 
concentration, the expression of cytochrome bo’ was found to be higher in a fnr or arcA 
mutant, when compared to the wild-type isogenic strain, suggesting both FNR and ArcA 
act as transcriptional repressors of the cyo operon.  
 
5.2.2.2. Cytochrome bd-type oxidases 
Despite the functional equivalence of cytochrome bo’ and cytochrome bd-I in E. 
coli,  cytochrome bo’ is maximally expressed under aerobic conditions while cytochrome 
bd-I exhibits maximal expression under microaerobic conditions (Fu et al., 1991; Tseng 
et al., 1996). This differential expression of cytochrome oxidases confers a distinct 
advantage: cytochrome bd-I has higher affinity for oxygen (Km of 3-8 nM (D’mello et al., 
1996)) than cytochrome bo’ (Km of 0.016-0.085 µM (D’Mello et al., 1995)), and it is able 
to perform aerobic cellular respiration under microaerobic conditions. Moreover, 
cytochrome bd-I is less susceptible to NO-mediated inhibition compared to cytochrome 
bo’ (Mason et al., 2009), an advantage for pathogenic E. coli during infection (Shepherd 
et al., 2016). However, unlike cytochrome bo’, cytochrome bd-I does not directly 
translocate protons onto the periplasm (Figure 5.1) (D’Mello et al., 1995), and instead 
liberates protons into the periplasm via the oxidation of ubiquinol (Miller and Gennis, 
1985), also known as vectorial proton translocation. 
A third cytochrome oxidase, cytochrome bd-II, was identified by Dassa et al. 
(1991): the proteins encoded by appC and appB show 60% and 57% homology with 
subunit I and subunit II of E. coli cytochrome bd-I, respectively. The enhanced sensitivity 
to oxygen of the mutant lacking all respiratory oxidases (cyo- cyd- appB-) compared to the 
cyo- cyd- double mutant (Dassa et al., 1991), and in vitro quinol oxidase activity of AppCB 
(Jünemann, 1997) confirmed Dassa’s initial observations. While initially considered non-
electrogenic, i.e. no contribution to the PMF (Bekker et al., 2009), it was later shown that 
cytochrome bd-II generates a PMF in a manner identical to that of cytochrome bd-I 
(Vitality B. Borisov et al., 2011). In E. coli, expression of cytochrome bd-II is induced in 
response to phosphate starvation, entry into stationary phase, and microaerobic and 
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anaerobic conditions  (Atlung and Brondsted, 1994), and controlled by transcriptional 
activators AppY and ArcA, the latter also controlling expression of cytochrome bd-I and 
cytochrome bo’ as a transcriptional activator and transcriptional repressor, respectively. 
In contrast to both cydABX and cyoABCDE operons, induction of appCB is independent 
of FNR (Vitaliy B. Borisov et al., 2011). 
 
5.2.3. Cellular respiration and antibiotic efficacy 
Despite the wide array of targets, antibiotics are generally classified as 
bactericidal, i.e. cause bacterial cell death, or bacteriostatic, i.e. inhibit bacterial cell 
growth. Until recently, the lethal effects of bactericidal antibiotics were largely attributed 
to their primary mode of action. However, independent studies have led to the model that 
bactericidal antibiotics cause a metabolic shift which leads to the generation of toxic ROS 
that contributes to lethality (Kohanski et al., 2007; Wang and Zhao, 2009; Dwyer et al., 
2014) (Figure 5.2). Kohanski et al. (2007) observed that three different bactericidal 
antibiotics - ampicillin, norfloxacin, and kanamycin – belonging to three separate classes 
– beta-lactams, quinolones, and aminoglycosides, respectively -, thus different primary 
targets, all induced hydroxyl radical formation, while formation of this radical was not 
detected in E. coli cells treated with different bacteriostatic antibiotics.  Furthermore, 
addition of an iron chelator or thiourea, a hydroxyl radical scavenger, to drug-treated E. 
coli resulted in an increase in bacterial survival, further implicating the formation of 
hydroxyl radicals in bactericidal antibiotic lethality, and suggesting a critical role for the 
Fenton reaction (Kohanski et al., 2007; Wang and Zhao, 2009). This hypothesis was 
further supporter by Wang and Zhao (2009). In their work, a mutant strain lacking 
superoxide dismutase exhibited increased survival to different bactericidal antibiotics 
when compared to the wild-type strain. This phenotype was attributed to decreased 
hydroxyl radical production via the Fenton reaction due to low levels of its substrate, 
hydrogen peroxide, which is produced by superoxide dismutase (Wang and Zhao, 2009). 
Furthermore, testing bactericidal antibiotic efficacy in tonB, a protein required for iron 
transport, and iscS, involved in [Fe-S] cluster synthesis, single mutants revealed that 
intracellular iron originating from [Fe-S] clusters is the main driver for Fenton-mediated 
hydroxyl radical formation during exposure to bactericidal antibiotics (Kohanski et al., 
2007). Hence, the involvement of the bacterial respiratory chain in bactericidal antibiotic 
lethality was proposed due to the established fact that destruction of [Fe-S] clusters occurs 
mainly via superoxide, which in turn is generated mainly through the respiratory electron 
transport chain (Kohanski et al., 2007). This is supported by observations of upregulation 
114 
 
of NADH dehydrogenase I in cells treated with different bactericidal antibiotics, an 
increase in NADH consumption (Kohanski et al., 2007), and an increase in oxygen 
consumption rates of E. coli or S. aureus cultures treated with bactericidal antibiotics, 
which is the opposite of what was observed in cultures treated with bacteriostatic 
antibiotics (Lobritz et al., 2015). Furthermore, a triple respiratory E. coli mutant (cyoA- 
cydB- appB-) has been shown to exhibit significant resistance to bactericidal antibiotics 
in comparison to wild-type (Lobritz et al., 2015). Together, these results suggest that 
presence of bactericidal antibiotics leads to superoxide generation via the bacterial 




Figure 5.2 – ROS-mediated antibiotic killing. Bactericidal antibiotics have different but well-
established primary targets, but they all appear to have a common ROS-mediated killing pathway.
The current model involves both the tricarboxylic acid (TCA) cycle and the electron transport
chain. The presence of bactericidal antibiotics leads to hyperactivation of the electron transport 
chain and thus rapid depletion of NADH, whose regeneration is dependent upon the TCA cycle.
Hyperactivation of the respiratory chain leads to formation of superoxide which damages 
intracellular iron-sulphur clusters, releasing ferrous iron, which in turn exacerbates the Fenton 




5.2.3.1. The ROS-antibiotic controversy 
Despite the growing evidence suggesting a role for ROS in antibiotic lethality, 
there is still some debate over this subject.  
Part of the criticism against ROS involvement in bactericidal antibiotic-mediated 
killing lies with the use of hydroxyphenyl fluorescein (HPF) to detect ROS. This non-
fluorescent probe reacts with hydroxyl radicals with high specificity, giving rise to the 
fluorescent product fluorescein. However, data has shown that E.coli cells treated with 
bactericidal antibiotics exhibit an increase in autofluorescence, possibly due to 
filamentation and, as such, the increase in fluorescence observed in cells treated with both 
antibiotic and HPF, attributed to an increase in the level of ROS, could be an artefact (Van 
Acker and Coenye, 2017). Another main point of discussion is the difficulty to separate 
the effects caused by the metabolic shift and the generation of ROS, since both are 
intrinsically connected: generation of ROS occurs due to hyperactivation of cellular 
metabolism. Hence, it is possible that the shift in metabolism observed after exposure to 
bactericidal antibiotics is itself the contributor to antibiotic lethality and ROS may play 
only a minor role, if at all (Van Acker and Coenye, 2017; Yang, Bhargava, et al., 2017). 
Previous studies have also shown that lethality of several bactericidal antibiotics is not 
affected under anaerobic conditions compared to aerobic conditions (Liu and Imlay, 
2013), thus showing that the presence of oxygen, a requisite for ROS formation, is not 
required for antibiotic lethality. However, it is important to note that the data obtained by 
Liu and Imlay (2013) was not obtained under strict anaerobic conditions, i.e. exposure to 
antibiotics was performed in an anoxic chamber, but all subsequent experimental work 
(dilutions, plating, and incubation) was carried out under aerobic conditions. In contrast, 
experiments performed by Dwyer et al. (2014) under strict anaerobic conditions have 
shown that antibiotic lethality is significantly diminished in the absence of oxygen, but 
restored when nitrate, an alternative electron acceptor in bacterial respiration, is added, 
thus supporting the notion that bacterial cellular respiration plays a role in antibiotic 
lethality, but not necessarily involvement of ROS since no oxygen was present under the 
experimental conditions employed by Dwyer and colleagues (Dwyer et al., 2014). 
In light of these studies, it is still premature to assume that ROS are involved in 
antibiotic lethality. However, the involvement of bacterial respiration in antibiotic 





5.2.3.2. Implications for the treatment of bacterial infections 
 For many years, the lethality of antibiotics was attributed to its interaction with 
the bacterial target. However it has now become clear that downstream effects contribute 
to antibiotic lethality, and these effects are sensitive to environmental cues (Yang, Bening, 
et al., 2017). Reduced metabolic activity is linked to lower antibiotic efficacy (Rowan et 
al., 2016; Yang, Bening, et al., 2017), a state that is often observed in bacterial biofilms 
(Mah and O’Toole, β001) or when in a nutrient-limited environment. In support of this is 
the work of  Lobritz et al. (2015), in which they observed that treatment of E. coli cultures 
with a bacteriostatic antibiotic, which decreases bacterial metabolism usually by targeting 
protein synthesis, prior to or after exposure to a bactericidal antibiotic, which accelerates 
bacterial respiration and metabolism (Kohanski et al., 2007; Wang and Zhao, 2009; 
Dwyer et al., 2014), inhibited the bactericidal activity of the latter (Lobritz et al., 2015).  
As presented in section 5.2.3., the lethality of bactericidal antibiotics is linked to 
a downstream cascade of events that result in hyperactivity of the bacterial respiratory 
chain which can lead to over-production of ROS. Bacteria possess a plethora of defence 
mechanisms against ROS (e.g. catalase and superoxide dismutase), enzymes that repair 
ROS-induced damage, and systems that help to maintain the redox poise of the cell. It is 
therefore possible that activation of ROS-defence mechanisms could attenuate the 
lethality of bactericidal antibiotics. This is supported by observation that loss of 
superoxide dismutase function results in elevated resistance to the bactericidal antibiotics 
norfloxacin, ampicillin, and kanamycin (Wang and Zhao, 2009). Additionally, expression 
of the transcriptional regulator OxyR, one of the main regulators of the oxidative stress 
response, was up-regulated in Burkholderia cenocepacia  after exposure to a bactericidal 
antibiotic (Van Acker and Coenye, 2017). 
 Further studies on the lethality of antibiotics are crucial in other to maximise the 
potential of the few drugs currently available. Combinatorial antibiotic treatments are 
often used to treat bacterial infections, but as shown by the work of Lobritz et al. (2015) 
this may not always be the best approach as bacteriostatic antibiotics can decrease the 
efficacy of bactericidal antibiotics. The discovery that bactericidal antibiotics increase 
ROS production may potentially lead to new treatments: inhibition of specific 
components of the bacterial oxidative stress response may increase the efficacy of 
bactericidal antibiotics. In support of this is the increased susceptibility to quinolones 







5.3.1. Antibiotic resistance and nitric oxide susceptibility 
The antimicrobial effects of NO are well-known, targeting many bacterial 
components such as haem cofactors, thiols, and [Fe-S] clusters (Fang, 1997; Keszler et 
al., 2010), as well as being effective in the dispersal of E. coli and P. aeruginosa biofilms 
(de la Fuente-Núñez, Reffuveille, Fairfull-Smith, et al., 2013). NO exposure has long 
been considered as a potential alternative to antibiotics or for use in combination with 
antibiotics as a way of potentiating their effect, which has been shown to be effective 
against bacterial biofilms (Reffuveille et al., 2015). Thus, it is important to understand 
the relationship between NO tolerance and antibiotic resistance. To investigate this, a 
subset of isolates from the Kent collection (KC3, KC4, KC6, KC13, KC30; KC33; KC45, 
KC46, and KC47) exhibiting different degrees of antibiotic resistance and of different 
sequence-types (Figure 5.3A) was tested for GSNO susceptibility using the well-diffusion 
assay. Pan-susceptible E. coli MG1655, multidrug-resistant ST131 E. coli strain EC958 
(Totsika et al., 2011; Forde et al., 2014), pan-susceptible and highly invasive 
pyelonephritis-causing ST73 E. coli strain CFT073 (Kao et al., 1997), and pan-
susceptible ABU E. coli strain 83972 (Klemm et al., 2006; Roos and Klemm, 2006) were 
also tested due to their clinical relevance and as control samples. Apart from isolate 
KC45, no significant difference was found in GSNO susceptibility for the remaining 
isolates compared to the controls (Student’s unpaired t-test p-value > 0.05) (Figure 5.3B). 
Isolate KC45 exhibited significantly higher susceptibility to GSNO (Student’s unpaired 
t-test p-value < 0.05) under both aerobic and microaerobic conditions (Figure 5.3B). 
Further investigation of this isolate using the alternative NO-donor NOC-12 revealed no 
sensitivity of KC45 to this compound (Appendix F-1). It is possible that the higher 
sensitivity observed to GSNO is due to the much broader nitrosative nature of GSNO or 
one of its breakdown products (possibly glutathione), rather than NO itself. As such, when 
assessing the correlation between antibiotic resistance and GSNO susceptibility for the 
different oxygen conditions, KC45 was omitted from the analysis (Figure 5.3C). Analysis 
of the data obtained for the remaining 12 strains revealed no correlation between 
antibiotic resistance and GSNO susceptibility (Pearson r = 0.08, 0.04 and 0.19 for aerobic, 
microaerobic, and anaerobic conditions respectively; p-values of 0.79, 0.91, and 0.56 






Figure 5.3 – Antibiotic resistance does not correlate with increase/decrease in GSNO 
susceptibility. (A) Antibiotic resistance profiles of the subset of strains used to determine the 
relationship between antibiotic resistance and GSNO susceptibility. (B) GSNO susceptibility of 
the isolates in the presence (aerobic and microaerobic) and absence (anaerobic) of oxygen. Values 
represent the mean ± SD from 6 replicates of two independent cultures. (*: Student’s unpaired t-
test; p-value < 0.05). (C) Linear regression (R2 values of 0.007, 0.001, and 0.035 for aerobic, 
microaerobic, and anaerobic conditions, respectively) and correlation (Pearson r=0.08, 0.04 and 
0.19 for aerobic, microaerobic, and anaerobic conditions respectively. p-values=0.79, 0.91, and
0.56 for aerobic, microaerobic, and anaerobic conditions, respectively) between GSNO 
susceptibility and antibiotic resistance (reflected by the number of antibiotics to which each 
isolate was experimentally resistant to) was calculated with all strains in panels A and B except 
KC45. Abbreviations: AMX, Amoxicillin; CTX, Cefotaxime; CAP, Chloramphenicol; CIP, 
Ciprofloxacin; MEM, Meropenem; NIT, Nitrofurantoin; TMP, Trimethoprim; PME, Polymyxin 
E/Colistin; (-), Sensitive; (+), Resistant. N/A – Not Applicable. 
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5.3.2. Nitric oxide affects gentamicin lethality 
In light of recent evidence showing that deletion of respiratory oxidases increases 
bacterial tolerance to bactericidal antibiotics (Lobritz et al., 2015), an experiment was 
devised to determine the effects the respiratory inhibitor NO upon the lethality of a 
bactericidal antibiotic. Due to the clinical implications of such a study, a well-known 
multidrug-resistant E. coli strain (EC958) was chosen for the assay.  
For this assay, an early exponential culture of E. coli EC958 grown in M9 minimal 
medium was exposed to 1 mM of NOC-12 for 30 min, prior to exposure to different 
concentrations of gentamicin. Serial dilutions and colony counts were carried out to 
determine CFU/mL and calculate % survival. In the absence of NOC-12 pre-treatment 
(i.e. 30 min exposure to sodium phosphate buffer, used to prepare the NOC-12 solution), 
the IC50 of gentamicin was measured as 12.3 µg/mL (Figure 5.4). In contrast, pre-
exposure to 1 mM NOC-1β significantly diminished (Student’s unpaired t-test p-value < 




5.3.3. Endogenous NO production does not diminish gentamicin lethality 
To complement the observations above with exogenously added NO, a NO-
producing strain of E. coli EC958 (see chapter 3) was used to investigate the effects of 
endogenously-produced NO upon the sensitivity gentamicin. In Gram-positive bacteria, 
the endogenous production of NO by bNOS has been shown to provide protection against 
Figure 5.4 – NO decreases gentamicin lethality. A) Cell survival was determined for multidrug 
resistant E. coli EC958 following 90-min treatment with different concentrations of gentamicin. 
Pre-treatment with 1 mM NOC-12 was carried out for 30 min. B) IC50 of gentamicin in the absence 
or presence of NOC-12 pre-treatment. Each data point reflects the mean of three replicates from
three independent cultures. Error bars represent standard deviation. (*: Student’s unpaired t-test
p-value < 0.05). 
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bactericidal antibiotics (Gusarov et al., 2009; Van Sorge et al., 2013), and thus we 
hypothesized that endogenous NO-production through expression of a functional bNOS 
in E. coli would yield a similar result. Since the bNOS gene was cloned into the pSU2718 
vector, which requires selection with chloramphenicol, the empty pSU2718 vector 
backbone was also transformed into E. coli EC958 to be used as a ‘no nitric oxide’ control 
(E. coli EC958 pSU2718), with the added advantage of accounting for the effects of 
chloramphenicol on gentamicin lethality. Early exponential cultures of E. coli EC958 
pSU2718 and E. coli EC958 pSU2718-bNOS (henceforward designated by E. coli EC958 
bNOS) grown in M9 minimal media supplemented with chloramphenicol were exposed 
to IPTG and L-Arginine for 30 min, to ensure expression of bNOS and synthesis of NO. 
The cultures were then subjected to a 90-min exposure to different concentrations of 
gentamicin. Serial dilutions and colony counts were carried out to determine CFU/mL. 
Surprisingly, no significant change was observed in the survival of E. coli EC958 bNOS 
compared to the control strain (Figure 5.5A). In fact, the IC50 of gentamicin for the NO-
producing strain (9.5 µg/mL) is lower, albeit not statistically significant (Student’s 
unpaired t-test p-value > 0.05), than the IC50 observed for the empty vector control (14.3 
µg/mL) (Figure 5.5B). 
 
 
5.3.4. Macrophage-derived NO does not affect gentamicin lethality 
Nitric oxide is produced by phagocytic cells, such as macrophages, of the 
mammalian immune system in response to infection. Following our observation that 
exogenous NO disrupts gentamicin lethality, we hypothesized that macrophage-derived 
Figure 5.5 – Endogenously-produced NO does not affect gentamicin lethality. A) Bacterial
survival to gentamicin is not affected by the endogenous production of NO (bNOS) compared to 
control (pSU2718). B) The IC50 of gentamicin does not significantly change in response to the 
endogenous production of NO (Student’s unpaired t-test p-value > 0.05). 
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NO could affect the lethality of gentamicin in vivo (Figure 5.6). To test this hypothesis, 
the RAW-Blue™ macrophage cell line, derived from the RAW 264.7 cell line, was used 
 
 
for intra-macrophage bacterial infection assays, along with the iNOS inhibitor L-NAME, 
an arginine analogue that inhibits production of NO. 
In the first instance, macrophage activation conditions were assessed. To ensure 
expression of iNOS, and thus synthesis of NO, macrophages were activated with both 
LPS from E. coli and IFN-Ȗ. Furthermore, a β mM concentration of L-NAME was chosen 
to inhibit iNOS-derived NO production. Production of NO by the macrophages under 
these conditions was evaluated using the Griess assay, a colourimetric assay that detects 
nitrite, a product of the oxidation of NO. The medium used to propagate the macrophages 
was shown to contain low levels of nitrite (2.14 µM) (Figure 5.7), and a similar amount 
of nitrite (2.64 µM) was detected in the medium containing non-activated macrophages 
Figure 5.6 – Macrophage-derived NO could abrogate bactericidal antibiotic lethality. On
their own, both macrophage-derived NO and bactericidal antibiotics are toxic to invading bacteria
(in orange). However, NO and bactericidal antibiotics have antagonistic effects on bacterial
respiration. We hypothesize that in the presence of a bactericidal antibiotic (gentamicin), 
macrophage-derived NO (produced by iNOS upon macrophage activation) will promote intra-
macrophage bacterial survival. To test this hypothesis, NO-production with the iNOS inhibitor
L-NAME is used to control NO production. 
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(i.e. no addition of LPS or IFN-Ȗ) (Figure 5.7). In contrast, after an 18 h exposure of 
macrophages to LPS and IFN-Ȗ, a statistically significant increase (Student’s unpaired t-
test p-value < 0.05) in the concentration of nitrite was measured in the growth medium 
(14.89 µM of nitrite) (Figure 5.7). Moreover, an 18 h exposure of macrophages to LPS, 
IFN-Ȗ, and L-NAME resulted in low levels of nitrite present which exhibited a statistical 
significant difference to the levels observed for activated macrophage (Student’s unpaired 
t-test p-value < 0.05), but not to the other two conditions tested (Figure 5.7), showing that 




For the intra-macrophage bacterial survival assay, activated and L-NAME-treated 
activated macrophages were exposed to E. coli EC958 with a multiplicity of infection 
(MOI) of 10. After sufficient time for bacterial uptake (20 min), extracellular bacteria 
were removed with a combination of washes and incubation with a high concentration of 
gentamicin for 20 min. Following this step, the different concentrations of gentamicin 
were applied to each well. After a 90 min exposure to gentamicin, infected macrophage 
cells were lysed and CFU/mL was determined. No significant difference was observed 
Figure 5.7 – Griess assay reveals NO production in activated macrophages. Activated 
macrophages exhibit high levels of nitrite. In the presence of 2 mM L-NAME, the levels of nitrite
detected decreased, indicating that the inhibition of NO-production is successful under these 
conditions. Each data point reflects the mean of three replicates from three independent cultures.
Error bars represent standard deviation. (*: Student’s unpaired t-test p-value < 0.05). 
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for the bacterial load in the presence or absence of L-NAME at either 20 or 200 µg/mL 
of gentamicin (Figure 5.8). Interestingly, bacterial load increased after 90 min, with the 
‘β0 µg/mL without L-NAME’ condition exhibiting the highest increase in CFU/mL 




5.3.5. Cytochrome bd-I augments sensitivity to gentamicin 
The cytochrome oxidases of the bacterial respiratory chain are well-known to be 
inhibited by the respiratory inhibitor NO. In light of recent observations that the 
respiratory chain plays an important role in the lethality of bactericidal antibiotics 
(Kohanski et al., 2007; Lobritz et al., 2015), we hypothesized that inhibition of bacterial 
respiration by NO could be, at least in part, responsible for the disruption of gentamicin 
lethality observed when bacterial cells were pre-exposed to NOC-12 (Figure 5.4). The 
sensitivity of respiratory mutants of E. coli to gentamicin was measured in the presence 
and absence of a NO donor. For this assay the compound NOC-12 was replaced by 
GSNO, an alternative NO-donor with similar effect on gentamicin lethality. Wild-type 
EC958 cells that were pre-treated with 15 mM of GSNO for 30 min exhibited an 11-fold 
increase in IC50 for gentamicin (Figure 5.9A). The cydAB (lacks cytochrome bd-I) and 
cyoA (lacks cytochrome boˈ) (Appendix G.1) deletion mutants of E. coli EC958 were also 
tested. In the absence of GSNO, both cydAB (Figure 5.9B) and cyoA (Figure 5.9C) exhibit 
Figure 5.8 – Combination of macrophage-derived NO and gentamicin does not affect 
bacterial survival. After a 90-min exposure to 20 µg/mL or 200 µg/mL of gentamicin, in the
presence or absence of iNOS inhibitor L-NAME, no significant difference was observed in
bacterial survival. Each data point reflects the mean of three replicates from two independent 
cultures. Error bars represent standard deviation. 
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a similar survival pattern to the wild-type strain under the same conditions, with no 
significant difference to the IC50 of gentamycin (Student’s unpaired t-test p-value > 0.05). 
When pre-exposed to GSNO, all strains exhibit an increase in the resistance to gentamicin 
(Figure 5.9A-C), with an 11-, 15-, and 2-fold increase in the IC50 for gentamicin for wild-
type, cydAB mutant, and cyoA mutant strains, respectively (Figure 5.9). Interestingly, in 
the presence of pre-exposure to GSNO, no significant difference exists between the IC50 
of the wild-type strain and the IC50 of the cyoA mutant. However, the IC50 of gentamicin 
for the cydAB mutant after pre-exposure to GSNO is higher and statistically different than 
the IC50 observed for the wild-type isogenic strain (Student’s unpaired t-test p-value < 
0.05) (Figure 5.9D). 
 
 
5.3.6. Nitric oxide inhibits the effect of gentamicin of E. coli biofilms 
Bacterial biofilms are complex abiotic-associated structures that allow bacterial 
communities to withstand environmental stresses (Laverty et al., 2014), such as antibiotic 
Figure 5.9 – Nitric oxide effect on gentamicin lethality is linked to bacterial respiration. Cell
survival was measured in function of gentamicin concentration, in the presence or absence of pre-
exposure to NO-donor GSNO, for A) wild-type EC958; B) EC958 cydAB mutant; and C) EC958
cyoA mutant. D) IC50 of gentamicin in the absence or presence of GSNO, for each of the strains 
tested. Each data point reflects the mean of three replicates from at least two independent cultures.
Error bars represent standard deviation. (*: Student’s unpaired t-test p-value < 0.05). 
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therapy, and are often responsible for many persistent and chronic infections (de la 
Fuente-Núñez, Reffuveille, Fernández, et al., 2013). Biofilms are heterogeneous cellular 
structures containing bacterial cells in different growth and metabolic states (de la Fuente-
Núñez, Reffuveille, Fernández, et al., 2013). Nitric oxide has been shown to have an 
important role in the dispersal of biofilms of several bacterial species, including P. 
aeruginosa  and E. coli (Miranda et al., 2011; Barraud et al., 2015; Reffuveille et al., 
2015) and act synergistically with ciprofloxacin to eradicate biofilms (Reffuveille et al., 
2015). Given the dramatic effects of NO upon gentamicin sensitivity in planktonic cells, 
it was also of interest to investigate the effects of combinatorial treatments of GSNO and 
gentamicin upon E. coli biofilms. 
In the first instance, the biofilm-forming capability of E. coli EC958 wild-type 
strain in comparison to an E. coli K-12 strain, a well-known and pan-susceptible UPEC 
strain (E. coli CFT073), and a pan-susceptible ABU UTI strain (E. coli 83972) was 
determined. Biofilm formation was assessed by growing statically for 24 h in M9 
medium, followed by staining of the adherent bacteria with a solution of crystal violet. 
Under these experimental conditions, E. coli EC958 exhibited the lowest biofilm-forming 
capability of all four strains tested, with significant differences observed when compared 
to E. coli MG1655 and E. coli CFT07γ (Student’s unpaired t-test p-value < 0.05) but not 
to E. coli 8γ97β (Student’s unpaired t-test p-value > 0.05) (Figure 5.10). These 
observations can be attributed to an insertion in the fimB gene of E. coli EC958 (Totsika 
et al., 2011) and a non-functional fim operon in E. coli 83972 (Klemm et al., 2006). 
Interestingly, biofilm formation of the ABU E. coli strain 83972 is significantly lower 
than E. coli CFT073, contrasting results previously observed in human urine (Hancock et 
al., 2007). 
 
Figure 5.10 – Biofilm formation ability E. coli strains. E. coli EC958 exhibited the lowest 
biofilm-forming capability of all four strains tested. (*; Student’s unpaired t-test p-value < 0.05).
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GSNO has been previously shown to cause dispersal of P. aeruginosa  biofilms 
(Barraud et al., 2006), and a combinatorial treatment of the nitroxide Carboxy-TEMPO 
and ciprofloxacin led to an almost complete eradication of E. coli mature biofilm 
(Reffuveille et al., 2015). Thus, we assayed the effects of 15 mM GSNO on the biomass 
of the bacterial biofilm of E. coli EC958, in the presence of different concentration of 
gentamicin with the crystal violet assay (Figure 5.11). No significant decrease in biofilm 
biomass was observed at different gentamicin concentrations compared to the “no 
gentamicin” control in the absence of GSNO. In the presence of GSNO, biofilm biomass 
decreased but not in a statistically significant manner (Student’s unpaired t-test p-value > 
0.05), with an average decrease of 20%, and no correlation was found between the 
decrease in biofilm biomass and gentamicin concentration (Pearson r = 0.1907, p-value 
> 0.05).  
 
 
To determine the effects of GSNO upon gentamicin lethality against E. coli 
EC958 wild-type biofilms, biofilms were allowed to form in M9 medium for 24 h. 
Medium was replaced by fresh M9 medium containing different concentrations of 
gentamicin with or without 15 mM of GSNO. After a 90 min incubation, biofilms were 
disrupted by vortex and vigorous pipetting for CFU enumeration. Unsurprisingly, the IC50 
of gentamicin observed for E. coli EC958 wild-type biofilms (18.8 µg/mL) is higher than 
the one observed for planktonic cells (3.7 µg/mL). Similar to the results obtained for 
planktonic cells, the presence of GSNO also diminishes the susceptibility of bacterial 
Figure 5.11 – GSNO does not significantly affect biofilm biomass. Biofilms of E. coli EC958
wild-type were allowed to form in M9 medium for 24 h prior to a 90 min exposure to different 
concentrations of gentamicin with or without 15 mM of GSNO. Exposure to GSNO did not
significantly decrease biofilm biomass (Students’s unpaired t-test p-value > 0.05). 
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biofilms to gentamicin (Figure 5.12A), resulting in a significant 2.6-fold increase in the 
IC50 for this antibiotic (Student’s unpaired t-test p-value < 0.05) (Figure 5.12B).  
 
 
5.3.7. Cytochrome bd-I protein sequences 
In this work, it is shown that loss of NO-tolerant cytochrome bd-I leads to higher 
tolerance to gentamicin (see section 5.3.5). Given the prolonged use of antibiotics and the 
role of aerobic respiration in their mechanism of lethality, one might anticipate that loss-
of-function mutations in cytochrome bd-I may have arisen to de-sensitise clinical isolates 
to antibiotics. Hence, the degree of conservation of this protein complex was analysed in 
the Kent collection. In the first instance, protein sequences of the subunits of cytochrome 
bd-I (CydA, CydB, and CydX) of E. coli EC958, CFT073, and ABU 83972 were aligned 
using T-Coffee (Notredame et al., 2000; Di Tommaso et al., 2011), and pairwise 
alignments were performed with BioEdit v7.2.5 (Hall, 1999). CydA, CydB, and CydX of 
E. coli EC958 exhibited 100% sequence identity with CydA, CydB, and CydX of the 
three reference strains, suggesting a high degree of conservation. The CydA, CydB, and 
CydX protein sequences for each isolate of the Kent collection were extracted and aligned 
to the respective proteins in E. coli MG1655. Only four isolates possessed mutations in 
at least one subunit (Table 5.1). A total of five mutations were identified in the entire 
collection: three in CydA, and the remaining two in CydB. No mutations were found in 
the CydX subunit. Only one of the mutations identified resulted in a non-conservative 
mutation (Table 5.1), i.e. resulted in a change in the property of the amino acid. In this 
case, it resulted in a change from a non-polar amino acid (alanine) at position 521 of 
CydA, to a polar amino acid (threonine). 
Figure 5.12 – GSNO diminishes susceptibility of bacterial biofilms to gentamicin. A) In the
presence of NO-donor GSNO E. coli EC958 wild-type biofilms exhibit higher tolerance for the 
bactericidal antibiotic gentamicin. B) The IC50 of gentamicin for bacterial biofilms increases in 




Figure 5.13 – Structural modelling of E. coli cytochrome bd-I. A) Cytochrome bd-I comprises
three subunits: CydA (gold), CydB (blue), and CydX (red). The structure of E. coli CydABX was
modelled upon the crystal structure of CydABX from Geobacillus thermodenitrificans (PDB ID:
5DOQ) using RaptorX (Källberg et al., 2012). The cofactors haem b558, haem b595, and haem d, 
and their binding sites (M393, H186, W441, E445, H19 and E99) as well as the positions where 
amino acids substitutions were identified for the CydABX protein sequences of the Kent 
collection isolates (Table 5.1) were mapped onto the structure. B) Detailed zoom shows that none 
of the amino acid substitutions are located near the cofactors.   
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A structural model of E. coli cytochrome bd-I was generated using the RaptorX 
server (Källberg et al., 2012). Protein sequences of the three subunits of E. coli MG1655 
cytochrome bd-I (CydA, CydB, and CydX) were submitted to RaptorX (Källberg et al., 
2012) for structural prediction based on the recently characterized structure of the bd 
complex of Geobacillus thermodenitrificans (Safarian et al., 2016). To generate a model 
with haem cofactor, the E. coli modelled subunits were superposed onto the G. 
thermodenitrificans structure using CCP4MG software (McNicholas et al., 2011). The 
mutations identified by protein sequence alignment were mapped onto the structure and 
are displayed in figure 5.13. None of the amino acid substitutions identified in CydA 
(A521T, V461G, and T516S) are located near the haem cofactors in CydA. In the E. coli 
model, the haem b558, can be ligated by H186 and M393, the haem b595 can be ligated by 
H19 and E99, and the d–type haem is adjacent to a glutamic acid (E445) and tryptophan 
(W441) that are thought to be involved in proton and electron delivery, respectively 
(Safarian et al., 2016). 
 
Table 5.1 – Amino acid substitutions present cytochrome bd-I subunits 
 
Protein KC Mutation Classification 
CydA 
KC11 A521T Non-conservative 
KC31 V461G Conservative 
KC37 T516S Conservative 
CydB KC11 V206L Conservative 


















5.4.1. Exogenously administered NO affects gentamicin lethality 
The antimicrobial properties of NO and its use by the mammalian immune system 
in response to infection are well-known. With the emergence of antibiotic resistance, the 
use of exogenously supplied NO as an alternative treatment to antibiotics, or co-
administered with antibiotics, has been the focus of recent studies (Bang et al., 2014; 
Reffuveille et al., 2015). However, the recent observation that the effects of bactericidal 
antibiotics are not solely due to its primary interaction with the bacterial target, and have 
complex downstream metabolic effects partially involving the aerobic respiratory chain 
(Kohanski et al., 2007; Dwyer et al., 2014; Lobritz et al., 2015), leading us to question 
the strategy of combinatorial treatments of nitric oxide (a potent respiratory inhibitor) 
with bactericidal antibiotics.  
After ascertaining that the degree of antibiotic resistance does not correlate with 
a change in nitric oxide sensitivity (Figure 5.3), the effect of nitric oxide in antibiotic 
efficacy was tested on E. coli EC958, a well-characterized multidrug-resistant UPEC 
strain (Totsika et al., 2011; Forde et al., 2014). The multidrug-resistant phenotype of this 
strain posed an initial difficulty when choosing the bactericidal antibiotic to be tested, as 
this strain is only sensitive to a few of the antibiotics tested, not all of them bactericidal. 
Fortunately, E. coli EC958 exhibits sensitivity to gentamicin, a bactericidal antibiotic 
used in the treatment of several types of infection, including UTIs.  
To better mimic infection, planktonic cells were exposed to the NO-donor NOC-
12 prior to exposure to the antibiotic gentamicin. Pre-exposure to NOC-12 resulted in a 
14-fold increase of the IC50 for gentamicin (Figure 5.4), thus showing potent inhibition 
of gentamicin lethality by NO. In contrast, and contrary to what was observed in Gram-
positive bacteria, this was not observed for E. coli EC958 bNOS (Figure 5.5), a strain 
capable of producing NO endogenously. One possible explanation for these contrasting 
results is the rapid breakdown of NO in the bacterial cytoplasm by NO-detoxifying 
mechanisms, such as flavohaemoglobin Hmp. An effective NO-detoxification response 
would lead to low concentrations of NO, perhaps insufficient to elicit an effect. A way to 
test this hypothesis would be to transform pSU2718-bNOS into E. coli EC958 mutant for 
NO-detoxifying mechanisms, starting with flavohaemoglobin Hmp as it is an important 
NO detoxification mechanism under aerobic conditions, as determined in section 3.3.1. 
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5.4.2. Macrophage-derived NO does not abrogate gentamicin efficacy 
Due to the synthesis of NO by cells of the mammalian immune system, it was of 
interest to measure the effects of macrophage-derived NO upon antibiotic sensitivity. 
Hence, infection of murine macrophage by E. coli EC958 was carried out. Activation of 
macrophages with LPS and IFN-Ȗ is known to increase the expression of iNOS and thus 
synthesis of NO, and elevated nitrite levels under these conditions are consistent with this 
(Figure 5.7). Activation of macrophages in the presence of the iNOS inhibitor L-NAME 
was also shown to dramatically diminish nitrite accumulation (Figure 5.7), consistent 
with lower iNOS activity. For the infection assay, two different concentrations of 
gentamicin were chosen: 20 µg/mL gentamicin, equivalent to five times the minimum 
inhibitory concentration (MIC) for Enterobacteriaceae according to BSAC testing v13.0 
and an approximate concentration to the peak concentration in human serum (Cmax = 18 
µg/mL); and 200 µg/mL, to maximise the likelihood of antibiotic entry to the 
macrophage. The permeability of macrophage to this drug is low but intra-macrophage 
accumulation has been observed for high extracellular concentrations of gentamicin 
(Barcia-Macay et al., 2006). After infection with E. coli EC958, no significant difference 
was observed in the bacterial load in the presence of L-NAME compared to its absence. 
The intracellular environment of macrophages is complex and bacterial clearance during 
infection is achieved by the collective action of ROS, RNS, and lysosomal enzymes 
(Figure 5.14), and it is perhaps possible that this complex environment can interfere with 
the function of gentamicin. In fact, gentamicin is known to concentrate in lysosomes, 
which have a naturally acidic environment that interferes with gentamicin activity 
(Barcia-Macay et al., 2006). Despite the results observed for gentamicin, it remains 
possible that macrophage-derived NO may impact upon the lethality of other bactericidal 
antibiotics. 
 
5.4.3. Cytochrome bd-I confers sensitivity to gentamicin  
In the recent work of Lobritz et al. (2015), a link between bacterial respiration and 
lethality of bactericidal antibiotics was shown, with treatment of bacterial cells with 
bactericidal antibiotics resulting in a significant increase in cellular respiration. Nitric 
oxide targets many bacterial proteins, including the haem-containing cytochrome 
oxidases involved in bacterial aerobic respiration (Wink et al., 2011).  
The role of two cytochrome oxidases, cytochrome bo’ and the NO-tolerant 
cytochrome bd-I, was determined by assessing bacterial survival to gentamicin of E. coli 





the NO-releaser GSNO. While no significant differences were observed in the absence of 
GSNO, pre-exposure of both mutant and wild-type strains with GSNO resulted in an 
increase in gentamicin tolerance for all strains. However, the increase in the IC50 of 
gentamicin in the presence of GSNO was more pronounced for cydAB, with the IC50 of 
gentamicin increasing by 15-fold in the presence of GSNO compared to the 11-fold 
increase observed for the wild-type isogenic strain (Figure 5.9). In the cyoA null mutant, 
bacterial cells are still expressing the NO-tolerant cytochrome bd-I (Mason et al., 2009) 
allowing bacterial respiration to continue in the presence of nitric oxide and, possibly, the 
generation of ROS arising from the accelerated metabolism response that occurs in the 
presence of gentamicin. In contrast, in the cydAB mutant bacterial respiration is easily 
inhibited by NO due to the presence of NO-sensitive cytochrome bo’ (Mason et al., 2009), 
hence it is possible that gentamicin-mediated ROS production is abolished resulting in a 
higher tolerance for gentamicin. Alternatively, the abolishment of bacterial respiration is 
likely to result in a disruption of the PMF, which is necessary for the uptake of 
aminoglycosides such as gentamicin (Hancock, 1981; Allison et al., 2011). However, to 
determine whether ROS or decreased uptake of gentamicin are responsible for the 
decreased sensitivity to gentamicin, further investigation would be required. Despite this, 
Figure 5.14 – Bacterial clearance by macrophages. Invading bacteria are phagocytised by 
macrophages, forming a phagosome which then fuses with a lysosome, a vacuole containing 
enzymes that hydrolyse a plethora of bacterial constituents. In the resulting phagolysosome, the
hydrolytic enzymes, along with ROS and RNS kill and digest the invading bacteria. 
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based on the results presented here, we propose that cytochrome bd-I in the presence of 
NO increases bacterial sensitivity to bactericidal antibiotics and hypothesized that in the 
presence of NO bacterial species lacking the cytochrome bd-I complex, such as 
Campylobacter jejuni (Jackson et al., 2007), may be more tolerant to antibiotics. 
Given the sensitization of bacterial cells expressing cytochrome bd-I to 
gentamicin, loss-of-function mutations in cytochrome bd-I complex was hypothesised. 
However, sequence analysis of cytochrome bd-I subunits in the pathogenic E. coli isolates 
of the Kent collection shows a high level of conservation, which is consistent with the 
lack of NO-susceptibility observed in the Kent Collection (Figure 5.3B). These results 
suggest that maintaining respiration in the presence of NO (by cytochrome bd-I) is a 
stronger evolutionary driver than reducing sensitivity to antibiotics in the presence of NO 
(through loss of cytochrome bd-I activity). E. coli frequently encounters NO in the 
absence of antibiotics, in which case cytochrome bd-I will facilitate growth and survival 
by allowing continued aerobic respiration. Furthermore, it has also been shown in 
previous studies that cytochrome bd-I is important for bacterial survival during infection 
of the mammalian host (Shepherd et al., 2016). Hence, it is perhaps not surprising that 
mutations in cytochrome bd-I are rare. 
 
5.4.4. Exposure of biofilms to GSNO increases tolerance to gentamicin 
Bacterial biofilms are often formed in response to environmental stresses, and the 
sessile cells found in bacterial biofilms are both phenotypically and physiologically 
different from planktonic cells. Furthermore, nitric oxide has been implicated in the 
dispersal events of P. aeruginosa  and E. coli biofilms (Barraud et al., 2006; Barraud et 
al., 2015; Reffuveille et al., 2015). This led us to question whether exogenous nitric oxide 
would affect resistance to gentamicin in biofilms. Out of the four strains tested for 
biofilm-forming capabilities, E. coli EC958 and E. coli 83972 formed the lowest biofilm 
biomass (Figure 5.10), which can be explained by an insertion in the fimB gene of E. coli 
EC958 (Totsika et al., 2011), a gene which encodes a recombinase that switches on the 
expression of type I fimbriae. Also, there is no functional fim operon in E. coli 83972 
(Klemm et al., 2006). In both cases, expression of type I fimbriae, important in the initial 
stages of biofilm development, is not possible. We also observed a difference between 
biofilm biomass of E. coli CFT073 and E. coli 83972, with the former forming 
significantly more biofilm. However, this contrasts with what was observed by Hancock 
et al. (2007) in human urine, where E. coli 83972 formed significantly more biofilm.  
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E. coli EC958 24 h biofilms showed a 4-fold increase in the IC50 for gentamicin 
(Figure 5.12) compared to planktonic cells (Figure 5.9). This result was expected as 
increased resistance to antibiotics is a well-known phenotype of bacterial biofilms (Mah 
and O’Toole, β001). In the presence of GSNO, the resistance of biofilms to gentamicin 
further increases by 2.6-fold (Figure 5.12). Assessment of GSNO-induced biofilm 
dispersal (Figure 5.11) showed that GSNO does not elicit a significant change in biofilm 
biomass, so the increase in IC50 of gentamicin in the presence of GSNO cannot be 
explained by NO-induced alterations in biofilm dispersal. Biofilms are heterogenous 
structures, formed by cells in different metabolic states. For example, P. aeruginosa  
biofilms possess areas with low metabolic activity and areas with high metabolic activity 
(Pamp et al., 2008). Thus, one possible explanation is that this same heterogeneity is 
present in biofilms of E. coli EC958 and GSNO interference with its many targets, 
including respiratory cytochrome oxidases, slows down the metabolism of previously 
active cells and increases tolerance to gentamicin. However, further studies are required 
























































6.1. Background  
 
The emergence of antibiotic-resistant bacteria is an increasing concern worldwide. 
Of particular importance is the emergence of bacteria exhibiting a multidrug-resistant 
phenotype, i.e. resistant to three or more classes of antibiotics. This makes the treatment 
of bacterial infections more difficult, in some cases even impossible, with negative 
impacts upon morbidity, mortality and the cost of healthcare. As such, surveillance of 
antibiotic resistance among bacterial pathogens and the development of alternative 
therapies are of the utmost importance to help tackle this problem. 
Nitric oxide is a small molecule which can be toxic to both mammals and bacteria 
Nevertheless, NO is produced in mammals where it carries out important physiological 
roles, such as smooth muscle relaxation. Furthermore, NO is known for its antimicrobial 
properties and its produced by cells of the mammalian immune system as part of its 
response to invading pathogens. As such, the use of NO as a potential alternative therapy 
against resistant and multidrug resistant bacteria has been an appealing prospect for some 
time. Indeed, NO has been shown to be effective against bacterial biofilms (Barraud et 
al., 2006; de la Fuente-Núñez, Reffuveille, Fairfull-Smith, et al., 2013). However, 
bacteria often possess a plethora of mechanisms that allow detoxification of NO and other 
toxic RNS, as well as tolerance, thus allowing bacteria to survive and grow even in the 
presence of this toxic molecule. Herein, the antibiotic resistance of E. coli bacteraemia 
isolates was assessed with both phenotypic and genomic tools. Furthermore, the potential 
use of nitric oxide as a therapeutic was assessed on its own, but also in combination with 
conventional antibiotics, in both planktonic and biofilm structures of a multidrug-resistant 
















6.2.1. Insights into antibiotic resistance in E. coli 
E. coli bacteria are a normal part of the human gut flora where its commensal 
nature promotes normal intestinal function. However, E. coli can take on a more 
pathogenic nature and cause diseases such as UTI, intestinal infections, and neonatal 
meningitis. The rise of antibiotic resistance, particularly amongst E. coli clinical isolates, 
is thus a global concern, and it is vital to track the patterns and rise of antibiotic resistance 
in order to implement the best treatment. As part of this work, a collection of 50 E. coli 
bacteraemia clinical isolates from Kent (UK) was characterised using phenotypic and 
genomic tools.  
A resistant phenotype was observed in 44% of the isolates, with 14% exhibiting a 
multidrug resistant phenotype, with the highest level of resistance observed for 
amoxicillin, trimethroprim, and ciprofloxacin. This result was unsurprising and can easily 
be explained by the wide use of these antibiotics in the treatment of bacterial infections 
and in agricultural settings, which results in a higher selective pressure that drives the 
development of antibiotic resistance. Furthermore, these results are in agreement with the 
surveillance report carried out by the ECDC which shows high levels of resistance to 
fluoroquinolones (e.g. ciprofloxacin) and penicillins (e.g. amoxicillin) in E. coli in several 
European countries, including in the UK (ECDC, 2017). In silico detection of antibiotic 
resistance was also carried out in this work by performing whole genome sequencing of 
the 50 E. coli clinical isolates. This allowed not only the detection of acquired resistance 
genes, but also for a more comprehensive characterization of the entire collection (e.g. 
presence of virulence genes and phylogenetic analysis). In silico analysis identified 30% 
of the isolates as being multidrug-resistant (i.e. resistant to three or more classes of 
antibiotics (Magiorakos et al., 2012)), nearly twice as more isolates as those identified 
using the disc diffusion assay. However, this discrepancy can easily be explained by the 
identification of resistance to two extra classes of antibiotics using in silico analysis. 
Whilst in silico approaches can rapidly identify patterns of antibiotic resistance, these 
techniques require up-to-date and well curated databases with all known genes and/or 
mutations known to confer resistance to antibiotics (Ellington et al., 2012; Fricke and 
Rasko, 2014). Additionally, discrepancies between predicted resistance and 
experimentally verified resistance can occur: herein we encountered isolates that encode 
chloramphenicol resistance genes, but the phenotype was not observed during the disc 
diffusion assays.  As such, it remains necessary to verify resistance phenotypes 
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experimentally, particularly as it would allow detection of antibiotic resistance arising 
through novel and unidentified mechanisms (Ellington et al., 2012). Furthermore, no 
isolate in the collection exhibited resistance to meropenem nor colistin. The existence of 
beta-lactamases capable of hydrolysing carbapenems (e.g. meropenem) have been known 
quite some time (reviewed in Poole, 2004) and their spread among bacterial pathogens 
are of particular concern due to their ability to inactivate virtually all beta-lactam 
antibiotics, and their association with other antibiotic resistance determinants, thus 
leading to a multidrug-resistant phenotype (Yong et al., 2009; Walsh et al., 2011). In 
agreement with the data presented here, the ECDC surveillance report (ECDC, 2017) 
reveals that levels of resistance to carbapenems among E. coli remain low (0.1%) amongst 
European countries. The absence of colistin-resistance in the Kent collection can be 
explained by the very recent emergence of plasmid-borne colistin resistance in China (Liu 
et al., 2016), thus it is likely that dissemination of the plasmid-associated mcr-1 gene, 
which confers resistance to colistin, is still in its early stages. However, the absence of 
meropenem and colistin resistance in the Kent collection highlights the importance of 
implementing strict rules and control for the usage of these antibiotics in order to diminish 
the dissemination of resistance towards these antibiotics. 
The antibiotic resistance problem is aggravated with the development of 
multidrug resistance. E. coli ST131 is currently the most worrying clonal group of E. coli. 
E. coli ST131, an UPEC strain, is prevalent in most parts of the world and is frequently 
associated with fluoroquinolone resistance and the expression of CTX-M-15, an ESBL 
capable of inactivating penicillins (e.g. amoxicillin) and cephalosporins (e.g. cefotaxime) 
(Nicolas-Chanoine et al., 2014), and it has been hypothesized that the worldwide 
dissemination of E. coli ST131, success attributed to a combination of antibiotic 
resistance and high virulence (Johnson et al., 2010; Peirano et al., 2013; Nicolas-
Chanoine et al., 2014), has contributed to the increase in antibiotic resistance observed in 
E. coli (Johnson and Stell, 2000; Peirano et al., 2013). Contrary to previous 
epidemiological studies reporting E. coli ST131 as the most prevalent clonal lineage in 
the UK and USA (Johnson et al., 2010; Croxall et al., 2011), E. coli ST131 represented 
12% of the Kent collection, surpassed by both ST73 (18%) and ST69 (14%). Furthermore, 
despite exhibiting high levels of resistance, the ST131 isolates in this collection did not 
exhibit high virulence, contrasting the previous findings by Johnson et al., 2010 and 
Peirano et al., 2013, and further supporting the long standing hypothesis that high levels 




would affect fitness thus leading to decreased virulence (Johnson, Kuskowski, et al., 
2003). 
 
6.2.2. Flavohaemoglobin Hmp, cytochrome bd-I and flavorubredoxin NorVW are 
the main nitric oxide tolerance mechanisms in E. coli 
The emergence of multidrug resistance in poses a threat to public health. As such, 
alternative strategies to combat antibiotic resistance is urgently needed. Nitric oxide, a 
small radical molecule naturally produced by the mammalian immune system in response 
to infection, can potentially be used as an alternative antimicrobial. In fact, inhalation of 
nitric oxide is currently used to treat pulmonary hypertension (Wessel et al., 1997; Hunt 
et al., 2016), and studies have shown a potential use for nitric oxide in the eradication of 
bacterial biofilms (Barraud et al., 2006; Reffuveille et al., 2015; Ren et al., 2016). 
However, no strategies currently exist for the sustained delivery of NO at the site of 
infection. As such, one of the main aims of this project was to engineer a NO-
producing/NO-tolerant strain of asymptomatic strain of E. coli that could potentially be 
used to help treat UTIs caused by multidrug-resistant E. coli. The strategy employed in 
this work involved the overexpression of the chromosomal copy of flavohaemoglobin 
Hmp combined with expression of bNOS.  
 Due to the toxicity of nitric oxide, it comes as no surprise that E. coli possesses 
several mechanisms that help the cell cope with the toxic effects of NO (see section 1.2.3). 
To engineer NO-tolerance in a strain of E. coli, it was important to determine the 
importance of these mechanisms under different oxygen conditions in order to choose the 
appropriate mechanism for overexpression. A well diffusion assay showed that in the 
presence of oxygen flavohaemoglobin Hmp and NO-tolerant cytochrome bd-I respiratory 
oxidase played an important role in protecting E. coli EC958 from GSNO, whilst 
flavorubredoxin/flavorubredoxin reductase NorVW is important under anaerobic 
conditions. Congruent with the data present here is the work of Gardner and colleagues 
(Gardner et al., 1998; Gardner and Gardner, 2002) in a non-pathogenic E. coli, showing 
that the protection afforded by flavohaemoglobin Hmp was much greater when oxygen 
was present. Furthermore, NO-metabolizing NorVW activity was shown to be higher 
under anaerobic conditions (Gardner et al., 2002). Cytochrome bd-I has been previously 
shown to be a NO-tolerant respiratory oxidase (Mason et al., 2009) and crucial for the 
survival of E. coli during infection (Shepherd et al., 2016). The presence of a functional 
cytochrome bd-I during nitrosative stress and in the presence of oxygen allows for 
bacteria to carry out aerobic respiration (Mason et al., 2009), the most effective form of 
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ATP generation, a characteristic that explains the sensitivity of the E. coli EC958 cydAB 
mutant observed in this work. 
 Based on the microaerobic conditions of the bladder (Hagan et al., 2010), and the 
sensitivity of the cytochrome bd-I complementation strain (see section 3.3.2), possibly 
due to the generation of high levels of toxic ROS (Kohanski et al., 2007; Dwyer et al., 
2014; Lobritz et al., 2015) due to high expression levels of cytochrome bd-I, 
overexpression of flavohaemoglobin Hmp was chosen instead in an attempt to create a 
strain of E. coli highly tolerant to NO. Following the successful substitution of the native 
Hmp promoter with a constitutive promoter, GSNO susceptibility was assessed. Whilst 
the increased sensitivity of the Hmp-overexpressing strain in the presence of oxygen can 
be explained with formation of toxic superoxide (Membrillo-Hernández et al., 1996; 
Anjum et al., 1998; Wu et al., 2004) and, consequently, peroxynitrite in the presence of 
NO, the sensitivity to GSNO observed under anaerobic conditions is much more 
surprising. This could be due to 1) formation of superoxide from the remaining oxygen 
present in the media since the bacterial growth assay was not carried out under strict 
anaerobiosis or 2) the Hmp protein levels resulting from constitutive expression lead to 
toxicity.  
 NO-production was attempted with cloning of bNOS onto a plasmid. Induction of 
hmp promoter, whose activity increases in the presence of NO or nitrosative stress (Poole 
et al., 1996), in the strain of E. coli harbouring pSU2718-bNOS was observed. However, 
a more direct measurement of NO needs to be carried out to determine the levels of NO 
being produced with certainty (e.g. using a NO electrode for NO quantification). 
 
6.2.3. Nitric oxide diminishes lethality of gentamicin 
For many decades, the lethality of bactericidal antibiotics was thought to result 
directly from the primary mode of action of the antibiotic. However, studies have recently 
suggested that bacterial metabolic activity has an effect on the efficacy of the bactericidal 
antibiotic  (Rowan et al., 2016; Yang, Bening, et al., 2017). Recent work by Lobritz and 
colleagues (Lobritz et al., 2015) show that deletion of the three main respiratory oxidases, 
cytochrome bd-I, cytochrome bd-II, and cytochrome bo’, in a non-pathogenic E. coli 
strain resulted in a higher tolerance for a wide array of bactericidal antibiotics and led us 
to hypothesize that a potent respiratory inhibitor such as NO could lead to a reduction in 
antibiotic efficacy (Figure 6.1).  
In this work, the impact of the respiratory inhibitor NO upon the lethality of the 





strain in planktonic cultures and biofilms. Pre-exposure to either NOC-12 or GSNO 
greatly increased the IC50 for gentamicin, suggesting that NO offers significant protection 
against the effects of gentamicin, for both bacterial planktonic cells and biofilms, 
presumably due to inhibition of aerobic bacterial respiration. Bacterial aerobic respiration 
is carried out by cytochrome oxidases bo’ and cytochrome bd-I, both well-known NO 
targets. However, whilst cytochrome bo’ is rapidly inhibited by NO, cytochrome bd-I is 
a NO-tolerant respiratory oxidase (Mason et al., 2006). The work carried herein shows 
that the IC50 of gentamicin is significantly higher for the cydAB knockout mutant of E. 
coli EC958, compared to the cyoA knockout or wild-type isogenic strains, both of which 
share similar IC50, in the presence of GSNO. This suggests that the presence of 
cytochrome bd-I increases bacterial sensitivity to gentamicin when GSNO is present. The 
NO-tolerant nature of cytochrome bd-I (Mason et al., 2006) allows aerobic bacterial 
respiration to continue. As previously mentioned, it has been suggested that the lethality 
of bactericidal antibiotics is due, in part, to the synthesis of ROS (Kohanski et al., 2007; 
Wang and Zhao, 2009; Dwyer et al., 2014) generated by the bacterial respiratory chain. 
Thus, it is possible that the susceptibility to gentamicin observed in the presence of GSNO 
Figure 6.1 – Model for the roles of NO during bacterial exposure to antibiotics. Bactericidal
antibiotics cause downstream effects on bacterial metabolism that lead to the accumulation of 
ROS (red). Nitric oxide exposure (blue) can have deleterious and protective effects where 
nitrosylation of multiple cellular targets is toxic and respiratory inhibition can diminish the 
generation of ROS that results from antibiotic treatment. Abbreviations: Resp DHase, 
Respiratory Dehydrogenase; Resp Oxidases, Respiratory Oxidases. 
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in both the wild-type and cyoA knockout strain of E. coli EC958 is due to the 
hyperactivation of cytochrome bd-I, thus production of lethal ROS, which, in contrast, is 
completely abolished in the cydAB knockout mutant. However, it is also a well-
established fact that uptake of aminoglycosides, such as gentamicin, into the bacterial cell 
requires a PMF threshold (Hancock, 1981; Humbert and Altendorf, 1989), which 
maintained by the bacterial respiratory chain. Hence, it is also possible that the sensitivity 
to gentamicin herein observed in the presence of GSNO occurs because cytochrome bd-I 
is capable of maintaining the PMF threshold required for gentamicin uptake through 
vectorial translocation of protons (Miller and Gennis, 1985). Further studies are required 
to determine the underpinning mechanism.  
Despite increasing sensitivity of bacteria to antibiotics, the primary sequences of 
of cytochrome bd-I (CydA, CydB, and CydX) were found to be highly conserved in E. 
coli. Cytochrome bd-I has been shown to play an important role in bacterial survival 
during infection (Shepherd et al., 2016), and it is plausible that bacteria such as E. coli 
encounter NO in the absence of antibiotics more frequently than in the presence of 
antibiotics. Thus, it is possible that the importance of cytochrome bd-I in niches where 




















6.3. Further work 
 
In chapter 3, attempts at quantifying nitrate and nitrite as a measure of NO 
production by the bNOS gene were unsuccessful during this work. It was proposed that 
the fast consumption of nitrite and nitrate by E. coli wild-type cells could be partially 
responsible for the negative result. The assay could be repeated following transformation 
of pSU2718-bNOS into a strain of E. coli lacking nitrite reductases and/or nitrate 
reductases, thus increasing the amount of nitrite and nitrate for detection by the Griess 
assay. Alternatively, and preferably, NO levels could be measured directly with a NO 
electrode.  
Further in chapter 3, it was proposed that GSNO susceptibility exhibited by the 
Hmp-overexpressing strain under anaerobic conditions was a result of protein 
accumulation and consequent toxicity. Hence, Hmp protein levels need to be assessed 
with a western blot.  
In chapter 4, phylogenetic analysis showed that commensal strains of E. coli have 
diverged more recently, and it was hypothesised that the evolutionary process of E. coli 
has resulted in loss of virulence genes, aiming for a commensal relationship with the host 
that allows long-term colonization and survival. However, it is possible that the rapid 
emergence of antibiotic resistance could disrupt this pattern and a more detailed 
comprehensive analysis, perhaps even including a larger number of genome sequences 
belonging to E. coli (or even other bacterial species) is necessary to determine how 
antibiotic resistance may influence the evolution of virulent strains. 
 In chapter 5, one of the isolates of the Kent collection (KC45) exhibited a 
significantly higher susceptibility to GSNO in the presence of oxygen. Further work could 
focus on investigating the cause of this phenotype (e.g. glutathione susceptibility), as this 
isolate did not show increased sensitivity to NOC-12, a more specific NO-donor than 
GSNO. Also in chapter 5, the effects of NO upon the efficacy of gentamicin, a bactericidal 
antibiotic, were tested. It was shown that the presence cytochrome bd-I results in elevated 
susceptibility to gentamicin during NO exposure. For a more complete analysis, a mutant 
of cytochrome bd-II could be engineered and tested for susceptibility to gentamicin, and 
other bactericidal antibiotics, in the absence and presence of pre-exposure to NO. Given 
the similarity between bd-II and bd-I, one might predict that the bd-II terminal oxidase 
could also support ROS generation in the presence of NO, especially if the cells were 
grown under conditions where bd-II is maximally expressed. Additionally, to avoid the 
problems associated with bacterial uptake and elimination of extracellular bacteria, 
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neutrophils could provide an extracellular nitrosative burst to the bacteria as previously 
described (Shepherd et al., 2016). Finally, to confirm the general model for NO protecting 
bacteria against antibiotic-mediated ROS generation during NO exposure, similar 
experiments with a range of other bactericidal antibiotics and other bacterial species 
would be useful. These experiments could provide important insights into how different 
bacteria respond to different antibiotics during infection and pave the way for future 
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Appendix A-1. MLST details of all isolates of the Kent collection. 
Multilocus sequence typing (MLST) was performed in all isolates of the collection using the Achtman typing scheme (Maiden et al., 1998). 
  
Strain Number KC Number ST ST Complex Adk fumC gyrB icd mdh purA recA 
188 KC1 ST69 ST69cplx 21 35 27 6 5 5 4 
189 KC2 ST404 ST14cplx 14 14 10 14 17 7 74 
190 KC3 ST162 ST469 9 65 5 1 9 13 6 
191 KC4 ST1406 None 46 156 2 25 5 16 19 
192 KC5 ST69 ST69cplx 21 35 27 6 5 5 4 
193 KC6 ST58 ST155cplx 6 4 4 16 24 8 14 
194 KC7 ST131 None 53 40 47 13 36 28 29 
195 KC8 ST73 ST73cplx 36 24 9 13 17 11 25 
196 KC9 ST69 ST69cplx 21 35 27 6 5 5 4 
197 KC10 ST131 None 53 40 47 13 36 28 29 
198 KC11 ST59 ST59cplx 27 32 24 29 26 19 22 
199 KC12 ST1148 None 6 95 3 18 11 7 14 
200 KC13 ST95 ST95cplx 37 38 19 37 17 11 26 
201 KC14 ST10 ST10cplx 10 11 4 8 8 8 2 
202 KC15 ST73 ST73cplx 36 24 9 13 17 11 25 
203 KC16 ST73 ST73cplx 36 24 9 13 17 11 25 
204 KC17 unknown None 9 260 15 26 11 26 6 
205 KC18 ST131 None 53 40 47 13 36 28 29 
206 KC19 ST131 None 53 40 47 13 36 28 29 
207 KC20 ST685 None 8 11 4 8 8 8 2 
208 KC21 ST95 ST95cplx 37 38 19 37 17 11 26 
209 KC22 ST357 None 13 40 13 13 23 25 66 
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210 KC23 ST1618 None 36 24 9 13 17 11 159 
211 KC24 ST73 ST73cplx 36 24 9 13 17 11 25 
212 KC25 ST131 None 53 40 47 13 36 28 29 
213 KC26 ST421 ST95cplx 37 38 19 37 17 8 26 
214 KC27 ST404 ST14cplx 14 14 10 14 17 7 74 
215 KC28 ST69 ST69cplx 21 35 27 6 5 5 4 
216 KC29 ST73 ST73cplx 36 24 9 13 17 11 25 
217 KC30 ST73 ST73cplx 36 24 9 13 17 11 25 
218 KC31 ST404 ST14cplx 14 14 10 14 17 7 74 
219 KC32 ST640 None 13 147 93 13 17 28 30 
220 KC33 unknown None 53 40 47 13 36 28 25 
221 KC51 unknown None 36 24 9 13 17 11 30 
222 KC35 ST640 None 13 147 93 13 17 28 30 
223 KC36 ST10 ST10cplx 10 11 4 8 8 8 2 
224 KC37 ST141 None 13 52 10 14 17 25 17 
225 KC38 unknown None 13 167 19 13 36 28 30 
226 KC39 ST73 ST73cplx 36 24 9 13 17 11 25 
227 KC40 ST69 ST69cplx 21 35 27 6 5 5 4 
228 KC41 ST95 ST95cplx 37 38 19 37 17 11 26 
229 KC42 ST404 ST14cplx 14 14 10 14 17 7 74 
230 KC43 ST95 ST95cplx 37 38 19 37 17 11 26 
231 KC44 ST73 ST73cplx 36 24 9 13 17 11 25 
232 KC45 ST405 ST405cplx 35 37 29 25 4 5 73 
233 KC46 ST127 None 13 14 19 36 23 11 10 
234 KC47 ST69 ST69cplx 21 35 27 6 5 5 4 
235 KC48 ST73 ST73cplx 36 24 9 13 17 11 25 
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236 KC49 ST131 None 53 40 47 13 36 28 29 
237 KC50 ST69 ST69cplx 21 35 27 6 5 5 4 
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Appendix B-1. Characterisation of the isolates of the Kent collection. 
  Each isolate was characterized for sequence-type (ST), phylogenetic group, and antibiotic resistance profile based on the phenotype 
observed during the disc diffusion assay.  
 
        Antibiotics1 
Strain KC number ST 
Phylogenetic 
group AMX CTX CAP CIP GEN MEM NIT TMP PME 
MS188 KC1 ST69 D S S S S S S S S S 
MS189 KC2 ST404 B2 S S S S S S S S S 
MS190 KC3 ST162 B1 R S R R S S R R S 
MS191 KC4 ST1406 D R S S S S S S S S 
MS192 KC5 ST69 D S S S S S S S S S 
MS193 KC6 ST58 B1 R S S S S S S R S 
MS194 KC7 ST131 B2 R S S I S S S S S 
MS195 KC8 ST73 B2 R S S S S S S R S 
MS196 KC9 ST69 D R S S S S S S R S 
MS197 KC10 ST131 Unknown R S S R S S S S S 
MS198 KC11 ST59 F S S S S S S S S S 
MS199 KC12 ST1148 B1 S S S S S S S S S 
MS200 KC13 ST95 B2 S S S S S S S R S 
MS201 KC14 ST10 A S S S S S S S S S 
MS202 KC15 ST73 B2 R S S S S S S S S 
MS203 KC16 ST73 B2 S S S S S S S S S 
MS204 KC17 Unknown B1 S S S S S S S S S 
MS205 KC18 ST131 B2 R R S R R S S R S 
MS206 KC19 ST131 B2 R S S R R S S R S 
MS207 KC20 ST685 B2 S S S S S S S S S 
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MS208 KC21 ST95 B2 S S S S S S S S S 
MS209 KC22 ST357 B2 S S S S S S S S S 
MS210 KC23 ST1618 B2 S S S S S S S S S 
MS211 KC24 ST73 B2 S S S S S S S S S 
MS212 KC25 ST131 B2 S S S S S S S S S 
MS213 KC26 ST421 B2 S S S S S S S S S 
MS214 KC27 ST404 B2 S S S S S S S S S 
MS215 KC28 ST69 A R S S S S S S S S 
MS216 KC29 ST73 B2 R S S S S S S S S 
MS217 KC30 ST73 B2 R S S S S S S R S 
MS218 KC31 ST404 B2 S S S S S S S S S 
MS219 KC32 ST640 B2 S S S S S S S S S 
MS220 KC33 Unknown B2 R R S R R S S R S 
MS221 KC51 Unknown B2 S S S S S S S S S 
MS222 KC35 ST640 B2 S S S S S S S S S 
MS223 KC36 ST10 A S S S S S S S S S 
MS224 KC37 ST141 B2 S S S S S S S S S 
MS225 KC38 Unknown B2 S S S S S S S S S 
MS226 KC39 ST73 B2 R S S S S S S S S 
MS227 KC40 ST69 D S S S S S S S S S 
MS228 KC41 ST95 B2 S S S S S S S S S 
MS229 KC42 ST404 B2 S S S S S S S S S 
MS230 KC43 ST95 B2 S S S S S S S S S 
MS231 KC44 ST73 B2 S S S S S S S S S 
MS232 KC45 ST405 F R R S R R S S R S 
MS233 KC46 ST127 B2 R S S S S S S S S 
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MS234 KC47 ST69 D R S S R S S S R S 
MS235 KC48 ST73 B2 R S S S S S S R S 
MS236 KC49 ST131 B2 R S S R R S S R S 
MS237 KC50 ST69 D R S S S S S S R S 
   
  
1)
 AMX – amoxicillin; CTX – cefotaxime; CAP – chloramphenicol; CIP – ciprofloxacin; GEN – Gentamicin; MEM – meropenem; NIT – 














Appendix C-1. Acquired resistance genes. 









Aminoglycoside Beta-Lactam Fluoroquinolone1 MLS Phenicol  Sulfanilamide Tetracycline Trimethoprim 
MS188 KC1         
MS189 KC2         
MS190 KC3 aadA5; strA; strB blaTEM-1B   catA1 sul2 tet(B) dfrA17 
MS191 KC4         
MS192 KC5         
MS193 KC6 strA; strB blaTEM-1B    sul2  dfrA5 
MS194 KC7  blaTEM-1B    sul2   
MS195 KC8 strB; aadA1 blaTEM-1B; blaSHV-1 
   sul2; sul1 tet(D) dfrA14 
MS196 KC9 strB; strA; aadA5 blaTEM-1B  mph(A)  sul1; sul2 tet(B) dfrA17 
MS197 KC10  blaTEM-1B       
MS198 KC11         
MS199 KC12         
MS200 KC13        dfrA5 
MS201 KC14         
MS202 KC15 aadA1 blaTEM-1B    sul1   
MS203 KC16 aadA1     sul1   
MS204 KC17         
MS205 KC18 aac(3)-IIa; 
aac(6')lb-cr; aadA5 
blaOXA-1; 
blaCTX_M-15 aac(6')Ib-cr mph(A) 
 sul1  dfrA17 
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MS206 KC19 aac(3)-IId; aadA5 blaTEM-1B    sul1  dfrA17 
MS207 KC20         
MS208 KC21         
MS209 KC22         
MS210 KC23      sul2 tet(A)  
MS211 KC24         
MS212 KC25         
MS213 KC26         
MS214 KC27         
MS215 KC28         
MS216 KC29  blaSHV-1       
MS217 KC30 strB; strA blaTEM-1B    sul1; sul2 tet(B) dfrA1 
MS218 KC31         






blaOXA-1 aac(6')Ib-cr mph(A) 
 sul1 tet(A) dfrA17 
MS221 KC51         
MS222 KC35         
MS223 KC36         
MS224 KC37         
MS225 KC38         
MS226 KC39 aadA1 blaSHV-1    sul1   
MS227 KC40         
MS228 KC41         
MS229 KC42         
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MS230 KC43         
MS231 KC44         
MS232 KC45 aadA5; aac(3)-IIa; 
aac(6')lp-cr 
blaCTX-M-15; 
blaOXA-1 aac(6')Ib-cr mph(A) 
 sul1 tet(B) dfrA17 
MS233 KC46  blaTEM-1B       
MS234 KC47 aadA5 blaTEM-1B   catA1 sul1; sul2 tet(B) dfrA17 
MS235 KC48 strB blaTEM-1B    sul2  dfrA14 
MS236 KC49 strB; strA; aadA5; 
aac(3)-Iid blaTEM-1B 
 mph(A)  sul2; sul1 tet(A) dfrA17 
MS237 KC50 strA; strB blaTEM-1B       sul1; sul2   dfrA7 
 











Appendix D-1. Linear regression and correlation between antibiotic resistance and 
virulence.  
Correlation between the virulence potential and the degree of antibiotic resistance 
(reflected by the number of different antibiotics to which each isolate was experimentally 
resistant to) was analysed with the Pearson Correlation Coefficient (Pearson r = -0.0097; 
p-value = 0.95). Virulence potential was calculated as the percentage of the 151 virulence 
genes identified that are carried in a given isolate. The linear relation between the two 























Appendix E-1. Alignment of Gyrase subunit A. 
Alignment of the protein sequences of gyrase subunit A of all isolates of the Kent 
collection identifies isolates KC3, KC7, KC10, KC18, KC19, KC33, KC45, KC47, and 
KC49 as being ciprofloxacin resistant due to mutations at amino acid position 83 (Serine 





Appendix F-1. Susceptibility of KC45 to NO-donor NOC-12. 
Susceptibility of bacterial strains to NO was tested by growth in M9 minimal medium in 
the presence of different concentrations of the NO-donor NOC-12. Growth of MG1655 
(A), EC958 (B), and KC45 (C) was followed for 8 h. Error bars represent standard 
deviation. Each data point is the mean of three biological repeats, each one comprising 
three technical repeats. The doubling time (D) was calculated based on the readings that 
were taken during 1.5h of growth following the addition of NOC-12. Error bars represent 
















Appendix G.1 – Engineering of cyoA E. coli EC958 knockout mutant using λ-red 
mutagenesis. 
A) cyoA gene of E. coli EC958. The chloramphenicol resistance cassette from plasmid 
pKD3, amplified by PCR using the primers cyoA_Cm_fw and cyoA_Cm_rev2, was 
electroporated onto E. coli EC958 harbouring pKOBEG. B) Recombinant colonies 
(colonies 1-5) were screened by colony PCR with primers cyoA_Sc_fw and 
cyoA_Sc_revβ (Expected molecular size: 1γ90 bp). A positive control (‘Positive’) 
containing E. coli EC958 wild-type harbouring pKOBEG was also prepared (Expected 
molecular size: 1300 bp). Recombinant colonies were then grown in LB at 43°C for 
curing of the pKOBEG plasmid. Only colonies with a chloramphenicol resistant and 
gentamicin sensitive phenotype were stocked and used for the survival assays. 
 
 
 
 
 
 
 
 
 
